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Sommario 
 
Il diabete mellito rappresenta una delle patologie più diffuse nel mondo e si stima che la 
sua incidenza aumenterà del 50 % nell’arco di 15 anni, passando da 250 milioni a quasi 
400 milioni di malati nel 2025. La patologia comporta l’insorgenza di devastanti 
complicanze croniche, tra cui disturbi legati al danneggiamento dei vasi sanguigni sia a 
livello macro-vascolare – come coronopatia, infarto, insufficienza cardiaca, angina 
pectoris, ictus – che micro-vascolare, con conseguente danno a carico dei reni (nefropatia) 
e degli occhi (retinopatia). La patologia diabetica ha un’enorme impatto sia in termini di 
qualità di vita dei pazienti, sia a livello economico, in quanto si stima che più del 10 % 
dei costi dell’assistenza sanitaria di tutta l’Europa siano imputabili alla cura del diabete. 
Per questo motivo, nuovi mezzi che permettano di prevenire l’insorgere e il progredire 
della malattia e delle sue complicanze sono assolutamente necessari. 
L’obiettivo del seguente lavoro di tesi è quello di proporre nuovi metodi computazionali 
per lo studio delle complicanze del diabete in un ambito di modellistica multi-livello. 
Il diabete mellito è una malattia fortemente multifattoriale, nella quale molteplici fattori 
di rischio di diversa natura (genetica e ambientale) concorrono a provocarne l’insorgenza 
e lo sviluppo. I meccanismi fisiologici che sottendono allo scatenarsi e al progredire della 
patologia sono ancora per la maggior parte sconosciuti. 
Data la natura multifattoriale del diabete, lo studio delle complicanze si presta ad essere 
affrontato con un approccio multi-livello. Lo schema generale di una malattia 
multifattoriale, come il diabete, prevede l’azione combinata di 3 elementi chiave sullo 
stato patologico (l’outcome) del paziente: i) il fenotipo, ovvero l’insieme di tutte le 
variabili metaboliche, antropometriche e ambientali caratteristiche del paziente, ii) il 
genotipo, ovvero la sequenza DNA del paziente, iii) il trattamento, ovvero l’insieme di 
interventi esterni effettuati sul paziente, come terapie ed utilizzo di farmaci. Queste 3 
variabili sono interconnesse tramite interazioni e concorrono tutte insieme a determinare 
l’outcome del paziente. 
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L’approccio multi-livello consente di scomporre il problema completo in sottoproblemi, 
focalizzando l’attenzione di volta in volta solo su un sottoinsieme di variabili e di 
interazioni, a seconda del livello di informazione contenuto nei dati a disposizione. 
Nel seguente lavoro, vengono considerati 3 principali livelli di studio delle complicanze 
diabetiche, e, per ognuno dei 3 ambiti, vengono proposti nuovi metodi sviluppati durante 
il periodo di dottorato. 
I 3 livelli di studio trattati sono: i) modellizzazione dell’effetto del genotipo sull’outcome, 
ii) modellizzazione dell’effetto combinato di fenotipo e trattamento sulla progressione 
dell’outcome, iii) modellizzazione dell’azione del trattamento sul fenotipo. 
Il primo livello di studio si propone di studiare le complicanze diabetiche da un punto di 
vista statico, ovvero senza considerare l’evolversi e il progredire di tali complicanze nel 
tempo, ed ha come obiettivo quello di identificare i principali biomarcatori genetici che 
consentano di predire lo stato di malattia dei pazienti, e di stratificare i pazienti in base al 
rischio di sviluppare o meno la malattia. I Genome Wide Association Studies (GWAS), 
sono studi di associazione volti a identificare gli SNPs che, da soli o in combinazioni con 
altri SNPs, consentono di spiegare le differenze che si osservano in un determinato 
outcome (a presenza o meno di una patologia) tra casi (soggetti malati) e controlli 
(soggetti sani) in una popolazione di studio. Diversi metodi di selezione univariata e 
multivariata sono presenti in letteratura per l’identificazione di marcatori genetici da studi 
GWAS. In questo ambito, è stato sviluppato un nuovo metodo per la selezione 
multivariata di biomarcatori genetici e per la classificazione di soggetti a partire da dati di 
SNPs di studi GWAS, basato sui classificatori di Bayes e arricchito da 3 principali 
componenti: i) una predizione ottenuta da un insieme di classificatori di Bayes, 
utilizzando una strategia basata sul bootstrap, ii) un nuovo metodo per ordinare e 
selezionare gli attributi selezionati da ogni classificatore, iii) una procedura, bastata sulle 
permutazioni, per selezionare i biomarcatori significativi, sulla base della loro utilità 
marginale nel processo di classificazione. Il metodo è stato validato sui dati genome-wide 
del Wellcome Trust Case-Control Consortium, (WTCCC)  relativi a diabetici di tipo 1 e 
le sue performance confrontate con gli algoritmi rappresentanti lo stato dell’arte in 
letteratura per studi di associazione genetica, in particolare un classificatore di Bayes e un 
algoritmo di regressione logistica penalizzata (HyperLASSO). 
Il secondo livello di studio riguarda l’analisi dinamica delle complicanze, nella quale 
interviene anche la variabile tempo come fattore chiave. In quest’ottica, si vuole 
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modellizzare l’insorgere e la progressione temporale delle principali complicanze legate 
al diabete utilizzando l’informazione fenotipica e terapeutica, con l’obiettivo di stimare la 
probabilità che il paziente diabetico possa o meno sviluppare una certa complicanza, 
ottimizzando quindi i trial clinici ed evitando esami costosi e invasivi. In letteratura, sono 
presenti diversi modelli delle complicanze di diabete, ma nessuno è in grado di integrare 
in maniera flessibile le diverse conoscenze –omiche (proteomica, metabolomica, 
genomica) ad un livello clinico macroscopico. I principali modelli presenti in letteratura 
sono infatti basati sui modelli di Markov (detti anche modelli si transizione di stato) e 
utilizzano l’informazione fenotipica senza la possibilità di integrare facilmente 
informazioni aggiuntive. In questo ambito di studio, viene proposto un nuovo modello in-
silico delle complicanze cardiovascolari e renali del diabete, che propone come aspetto 
innovativo l’utilizzo delle reti dinamiche bayesiane (Dynamic Bayesian Networks, 
DBNs) per modellizzare le interazioni tra le variabili. Rispetto ai modelli di Markov, che 
richiedono tanti nodi quante sono le possibili combinazioni degli stati delle variabili, le 
DBN hanno il vantaggio di rappresentare ogni variabile tramite un singolo nodo e 
permettono quindi una maggiore facilità nella gestione della struttura e nell’integrazione 
di eventuale informazione aggiuntiva. Il modello è stato costruito utilizzando i dati del 
Diabetes Control and Complications Trial (DCCT), un trial clinico randomizzato 
condotto con lo scopo di confrontare gli effetti della terapia intensiva rispetto a quelli 
della terapia convenzionale sullo sviluppo delle complicanze vascolari e neurologiche a 
lungo termine. Il modello sviluppato, è in grado di predire la progressione delle 
complicanze diabetiche trattate con un’accuratezza superiore al 95% a livello di 
popolazione. Il modello si presta quindi ad essere utilizzato come tool di supporto nel 
processo di decisione terapeutica da parte dei clinici e, in quest’ottica, sta portando alla 
realizzazione di un’interfaccia web. La struttura flessibile del modello inoltre consentirà 
di integrare facilmente l’informazione genotipica, con l’obiettivo futuro di migliorare le 
prestazioni a livello di predizione. 
Il terzo ed ultimo livello di studio considerato è lo studio dell’azione di uno specifico 
farmaco su un particolare fenotipo, con l’obiettivo finale di sviluppare metodologie che 
consentano di personalizzare i farmaci, adattandoli alla specifica risposta dell’individuo. 
Nell’ambito specifico delle complicanze cardiovascolari del diabete, una delle terapie più 
diffuse è quella del trattamento con aspirina per la prevenzione di eventi avversi nei 
pazienti ad alto rischio. L’aspirina deve  la sua azione preventiva alla capacità di inibire 
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un enzima chiave (la prostaglandina-endoperossido sintase PTGS-1, conosciuta anche 
come cicloossigenasi COX-1) nella cascata che porta alla formazione di trombossano B2 
(TxB2), il principale responsabile dell’aggregazione piastrinica nel sangue e della 
conseguente formazioni di trombi. È noto, da letteratura, come i pazienti diabetici 
rispondano in maniera differente alla terapia con aspirina rispetto ai soggetti sani, 
evidenziando una risposta ridotta al farmaco, tanto da portare in ambito clinico alla 
coniazione del termine ‘aspirino-resistenza’. Data la mancanza di una trattazione 
matematica del fenomeno in letteratura, si è deciso di studiare il problema utilizzando un 
approccio modellistico di farmacodinamica, con un intento. Utilizzando informazioni 
biologiche ricavate da letteratura, si è sviluppato un modello, in parte compartimentale e 
in parte distribuito, che descrive: i) la cinetica dell’enzima COX-1 a partire dalla sua 
produzione all’interno dei megacariociti del midollo osseo fino a giungere nelle piastrine 
del sangue, ii) la farmacocinetica e la farmacodinamica dell’aspirina, ovvero la 
distribuzione del farmaco nel corpo e la sua interazione con l’enzima COX-1. Il modello 
è stato testato su dati sperimentali relativi al recupero di trombossano B2 sierico dopo la 
sospensione di aspirina in pazienti sani. Sono stati infine discussi meccanismi 
potenzialmente candidati a spiegare il fenomeno dell’aspirino-resistenza in pazienti 
diabetici. 
  
V 
 
 
 
Summary 
 
Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs. 
Worldwide prevalence figures estimate that there are 250 million diabetic patients today 
and that this number will increase by 50% by 2025. The disease is associated with 
devastating chronic complications including coronary heart disease, stroke and peripheral 
vascular disease (macrovascular disease) as well as microvascular disorders, leading to 
damage of kidneys (nephropathy) and eyes (retinopathy). These complications impose an 
immense burden on the quality of life of the patients and account for more than 10% of 
health care costs in Europe. Therefore, novel means to prevent the onset and the 
progression of  these devastating diabetic complications are needed. 
The aim of the work presented in this thesis is to propose novel computational methods to 
study diabetes complications with a multi-level approach. 
Diabetes mellitus is a strongly multifactorial disease, and several risks factors (such as 
genetic, and environmental factors) are combined together in a complex trait, leading to 
the onset of the disease. 
Physiological mechanisms that underlie the disease and the onset and progression of the 
different complications are still mostly unknown. 
Given the complex nature of diabetes, the study of the complications can be faced with a 
multi-level modeling approach. In the general scheme for complex disease, such as 
diabetes, 3 key elements act together to determine the disease status (outcome) of a 
patient: i) the phenotype, i.e. the set of all metabolic, anthropometric and clinical 
variables characterizing the patient, ii) the genotype, i.e. the DNA sequence of the patient, 
iii) the set of interventions on the patient, i.e. therapies and treatments with drugs. All 
these 3 variables are connected each other through interactions and have a joint effect on 
the final outcome of the patient. 
The multi-level approach allows to disjoint the full problem into sub-problems, focusing 
only on a set of variables and interaction (reflecting a specific level of information) 
according to available data. 
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In the present work, 3 main levels of study of diabetes complications are considered, and, 
for each approach, novel methodologies developed during my PhD are proposed. 
The 3 levels of study considered in the present work are: i) modeling the effect of 
genotype on the outcome, ii) modeling the effect of phenotype and treatment on the 
progression of the outcome, iii) modeling the effect of treatment on the phenotype. 
In the first level of study, diabetes complications are studied from a static point of view, 
i.e. without considering their progression over time, and the main objective is to identify 
the genetic biomarkers that allow to predict the disease state of the patients with the final 
goal to stratify patients according to the risk of developing the disease. Genome Wide 
Associations Studies (GWAs) are statistical studies aiming at identify those SNPs able to 
explain the differences observed for a certain outcome (the disease status) between cases 
(diseased subjects) and controls (healthy subjects) in a study population. Several methods 
performing univariate and/or multivariate selection have been used in literature for the 
identification of genetic markers from GWAs data. In this thesis, a novel algorithm for 
genetic biomarker selection and subjects classification from genome-wide SNP data has 
been developed. The algorithm is based on the Naïve Bayes classification framework, 
enriched by three main features: i) bootstrap aggregating of an ensemble of Naïve Bayes 
classifiers, ii) a novel strategy for ranking and selecting the attributes used by each 
classifier in the ensemble, iii) a permutation-based procedure for selecting significant 
biomarkers, based on their marginal utility in the classification process. The algorithm has 
been validated  on the Wellcome Trust Case-Control Consortium on Type 1 Diabetes and 
its performance compared with the ones of both a standard Naïve Bayes algorithm and 
HyperLASSO, a penalized logistic regression algorithm from the state-of-the-art in 
simultaneous genome-wide data analysis. 
The second level of study is represented by the dynamic analysis of diabetes 
complications, where the variable “time” plays a major role. In particular, the objective is 
to model the onset and the progression of diabetes complications over time, using 
phenotypic and therapeutic information, with the final goal to estimate a probability for 
the diabetic patient to develop a certain complication, thus optimizing clinical trials and 
avoiding invasive and expensive tests. So far, several models of diabetes complications 
are present in literature, but none is able to flexibly integrate accumulating –omics 
knowledge (i.e. proteomics, metabolomics, genomics) into a clinical macro-level. The 
most interesting complication models, in fact, are based on Markov Models (also called 
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state transition model) and use phenotypic information to describe the cohort of interest 
without the possibility to easily integrate additional information. A new in-silico model 
for simulating the progression of cardiovascular and kidney complications in diabetic 
patients is presented. The model proposes, as innovative feature, the use of Dynamic 
Bayesian Networks (DBNs) for modeling the interactions between variables. Compared 
to Markov Models, which require as many nodes as the number of combinations of 
variables’ values, DBNs are more advantageous in handling both the structure and 
possible additional information, since each variable is simply represented by a node in the 
network. The model was built relying on data from the Diabetes Control and 
Complications Trial, a multicenter randomized clinical trial designed to compare 
intensive with conventional therapy with regard to their effects on the development and 
progression of the early vascular and neurologic. The developed model is able to predict 
the progression of the main diabetes complications with an accuracy greater than 95% at a 
population level. The model is suitable to be used as a decision support tool to help 
clinicians in the therapy design through cost-effectiveness analysis: exploiting the 
simulations generated through the model, it is possible, for example, to choose the best 
strategy between two different therapies for treating a specific cohort of patients. To this 
aim, a user-interface based on the present model is currently under development. The 
flexible structure of the model will allow to easily add genotypic information in the next 
feature as a potential mean to improve predictions. 
The last level of study focuses on the action of a specific drug on a target phenotype,  
with the final aim to develop rational means to personalize drug therapy and to ensure 
maximum efficacy with minimal adverse effects. Focusing on cardiovascular diseases as 
a direct complication of diabetes, aspirin therapy is an important component of 
cardiovascular prevention  for high risk patients. Aspirin performs its preventive action 
by inhibiting a key enzyme (the prostaglandin-endoperoxide synthase PTGS-1, also 
known as cyclooxygenase COX-1) in the cascade leading to the production of 
thromboxane B2 (TxB2), the major factor involved in the platelets aggregation with 
consequent formation of thrombi. It is known, from literature, that diabetic patients 
exhibit a different response to aspirin therapy in comparison to healthy subjects, showing 
a reduced effectiveness of the drug, which is often referred to as ‘aspirin resistance’. 
Given the lack of a mathematical characterization of these phenomena, the problem was 
faced using a pharmacodynamics modeling approach, with an explorative intent. Relaying 
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on biological knowledge retrieved from literature, a partially lumped and partially 
distributed compartmental model was developed, able to describe: i) the kinetics of COX-
1 enzyme, from its production within megakaryocytes in bone-marrow to circulating 
platelets in blood, ii) the pharmacokinetics and pharmacodynamics of aspirin, i.e. its 
distribution in the body tissues and its interaction with COX-1. The model was tested 
using data of serum thromboxane TxB2 recovery levels after aspirin withdrawal in healthy 
subjects. Possible mechanisms to explain the so-called ‘aspirin resistance’ have been 
finally discussed. 
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Chapter 1 
 
1 Introduction 
Diabetes mellitus is a metabolic diseases in which a person’s blood sugar is too high, 
either because the pancreas does not produce enough insulin, or because cells do not 
respond to the insulin that is produced, or a combination of the above mechanisms. 
Different variables, such as genetic, metabolic and environmental factors, play together in 
the onset and the progression of the disease, thus classifying diabetes as a complex-trait 
disease. 
Diabetes is associated with severe long-term complications, mainly caused by the damage 
of blood vessels, both at micro and macro-level, because of the high glucose 
concentration in blood. As a result, the main organs involved are the heart and the 
cardiovascular system (diabetic cardiovascular complications), the kidney (diabetic 
nephropathy), the retina (diabetic retinopathy) and the nervous system (diabetic 
neuropathy). These complications heavily affect the quality of life of the patients and 
impose an immense impact on health care costs. 
Therefore, novel means to prevent and/or treat these devastating diabetic complications 
are needed. Since long-term clinical trials are costly, time-consuming, and difficult to 
conduct, the use of computer-simulated disease models has increased considerably in 
recent years to facilitate the simultaneous evaluation of long-term clinical and economic 
effects of treatment. It is now widely accepted that models can provide valuable 
information for clinical practice and are important tools in medical, regulatory, 
governmental, and public health decision-making. A requirement for diabetes simulation 
models has been identified in the medical and healthcare policy community, and, as a 
result, a number of models have been developed and reported in the literature. 
Given the complex nature of diabetes, the problem of investigating its long-term 
complications can be faced with a multi-level modeling approach. 
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In the present chapter, after a brief introduction on diabetes and its complications, the 
complex-trait nature of the disease will be described. Finally, the multi-level modeling 
approach, representing the general framework of this thesis, will be introduced. 
1.1 Diabetes and its complications 
Diabetes mellitus is a lifelong, incapacitating disease affecting multiple organs, that 
causes a person's blood sugar level to become too high. There are two main types of 
diabetes, referred to as type 1 (T1D) and type 2 (T2D). 
T1D is often referred to as insulin-dependent diabetes. It is also sometimes known as 
juvenile diabetes or early-onset diabetes because it often develops before the age of 40, 
usually during the teenage years. T1D is an autoimmune condition, where immune system 
attacks and destroy pancreatic cells, responsible for insulin secretion. Thus, in T1D, the 
pancreas does not produce any insulin. Insulin is a hormone that regulates blood glucose 
levels. If the amount of glucose in the blood is too high, it can seriously damage the 
body's organs [1]. 
T2D occurs when the body doesn't produce enough insulin to function properly, or the 
body’s cells don't react to insulin. This is known as insulin resistance. T2D is far more 
common than T1D and it usually affects people over the age of 40, although increasingly 
younger people are also being affected. It is more common in people of South Asian, 
African-Caribbean or Middle Eastern descent [1]. 
It is important that diabetes is diagnosed as early as possible so that treatment can be 
started. 
Diabetes cannot be cured, but treatment aims to keep blood glucose levels as normal as 
possible, and control symptoms to prevent health complications developing later. The 
therapy usually consists in a mixture of insulin infusions, diet and physical exercise [1]. 
Worldwide prevalence figures estimate that there are 250 million diabetic patients today 
and that this number will increase by 50% by 2025 [56]. The disease is associated with 
devastating chronic complications including coronary heart disease, stroke and peripheral 
vascular disease (macrovascular disease) as well as microvascular disorders leading to 
damage of kidneys (nephropathy) and eyes (retinopathy). These complications impose an 
immense burden on the quality of life of the patients and account for more than 10% of 
health care costs in Europe [27].  
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In the following, we will focus on the main vascular complications in T1D and T2D, i.e. 
diabetic nephropathy and retinopathy in both T1D and T2D and cardiovascular disease in 
T2D. 
1.1.1 Diabetic nephropathy (DN) 
Around 30% of patients with T1D and T2D develop DN [14]. Once manifest, DN is 
characterized by a progressive decline in kidney function, leading to end-stage renal 
disease (ESRD). DN represents the most common cause of ESRD (and hence the major 
precipitant of dialysis and transplantation therapy) in the Western world [23]. Metabolic 
control and elevated blood pressure are important risk factors, but these act in concert 
with genetic and other factors [23].  
1.1.2 Diabetic retinopathy (DR) 
Most patients with diabetes will develop some degree of DR and 2% will become blind. 
There is a strong correlation between duration of diabetes, glycemic control and 
development of DR. The prevalence of proliferative DR increases from 0% in those with 
less than 5 year duration to 26% after 15 years and to 56% after 20 years duration [36]. 
Both hypertension and dyslipidemia accelerate progression of DR. However, genetic 
factors clearly contribute to individual differences in the rate of progression and extent of 
DR. 
1.1.3 Cardiovascular disease (CVD) 
Up to 75% of all deaths in T2D are due to CVD. Also men and women with T1D have a 
fourfold and sevenfold risk of major CVD [48]. In addition to established risk factors 
such as smoking, dyslipidemia, hypertension and glycemic control [34], genetic factors 
are likely to be playing a substantial role in determining individual risk. Although there 
are no reliable heritability estimates for CVD in diabetic families, siblings of diabetic 
patients suffering from an early myocardial infarction have a 7-fold increased risk of 
CVD. The risk for development of a first myocardial infarction is increased 2-5 fold in 
subjects with diabetes, which makes the risk equivalent to that of a non-diabetic person 
with a previous myocardial infarction [25]. Moreover, the risk for recurrent acute cardiac 
events is more than 2-fold higher in diabetics than in non-diabetics. Patients with diabetes 
also have a 2 to 4-fold increased risk for development of stroke and peripheral arterial 
disease. Diabetes affects stroke outcome as well, with increased risk for subsequent 
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development of dementia, recurrence of a new stroke and death. It is also important to 
note that the relative protection from cardiovascular disease that characterizes pre-
menopausal women is diminished by diabetes. 
1.2 Diabetes as a complex-trait disease 
Although hyperglycemia represents one of the most important risk factors for 
development of diabetic vascular complications, not all hyperglycemic patients seem to 
be at equal risk: other factors clearly modify an individual’s susceptibility to develop 
complications, as reported in the previous section. It is thus clear that diabetes can be 
classified as a complex-trait disease, in which different factors such as genetic profile, 
metabolic and anthropometric phenotype and environmental risk factors, as well as 
individual response to treatments, concur to cause the onset of the disease and the 
development of different complications [51]. This complex nature is common both to 
T1D and T2D, even if a preponderant genetic cause characterizes T1D [42]. 
 
A general scheme of the main variables (and their interactions) involved in a complex 
disease such as diabetes is reported in Figure 1.1. 
 
 
Figure 1.1: General scheme of the multi-level model for diabetic complications. 
where, 
• Genotype represents the genotypic profile of the individual, i.e. the Single 
Nucleotide Polymorphisms (genotypic biomarkers). 
• Phenotype represents phenotypic biomarkers such as: 
PHENOTYPE
TREATMENT
GENOTYPE OUTCOME
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o metabolic and physiological biomarkers (lipids, glycosylated hemoglobin, 
blood, pressure, heart rate, etc.); 
o anthropometric measures (weight, body mass index, etc.); 
o environmental factors (smoke status, physical activity, etc.); 
• Outcome is the target of the study, i.e. diabetes or diabetic complications (Cardio 
Vascular Diseases, Nephropathy, Retinopathy, etc.); 
• Treatment is the intervention variable, representing the specific therapy for the 
individual. 
According to this general scheme, the genotype acts both on phenotype and on outcome, 
while the phenotype acts only on outcome. Treatment acts both on phenotype and 
outcome, but not on genotype. 
1.3 Multi-level approach 
Since diabetes is a complex-trait disease, the problem of investigating its long-term 
complications can be faced with a multi-level modeling approach: the scheme of Figure 
1.1, in fact, represents different kind of variables and interaction between them. 
According to the level of detail which available data allows to reach, the interconnected 
structure of a multi-level model can be decomposed in sub-schemes, each one potentially 
analyzable independently on the others. Of course, the final ambitious aim of such an 
approach is to integrate all the possible sub-models (or at least most of them) in order to 
finally obtain a macro-model able to offer a complete characterization of the studied 
phenomena. Unfortunately, this objective is very difficult to achieve for most of the 
biological problems, given both the paucity of available data and the intrinsic limitations 
in the modeling process. 
In this work, three main levels of study of diabetic complications will be considered, 
according to data availability: i) modeling the effect of genotype on the outcome (Figure 
1.2.A), ii) modeling the combined effect of phenotype and treatment on the progression of 
the outcome (Figure 1.2.B), iii) modeling the effect of treatment on the phenotype (Figure 
1.2.C). 
For each approach, novel investigation methodologies are proposed. 
The research presented in this thesis has been supported by the European Union's Seventh 
Framework Program (FP7/2007-2013) for the Innovative Medicine Initiative under grant 
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agreement n° IMI/ (the SUMMIT consortium), whose objective is to identify markers that 
predict the risks of developing diabetes chronic micro- and macro-vascular complications 
with focus on Diabetic Nephropathy, Diabetic Retinopathy and Cardiovascular disease. 
For a more detailed presentation of the concept and organization of the SUMMIT 
consortium, see public available information at http://www.imi-summit.eu/. 
 
Figure 1.2: Possible decompositions of the overall model for a multifactorial diseases: A) focus on the effect 
of the genotype on the outcome; B) focus on the combined effect of genotype, phenotype and treatment 
on the outcome; C) focus on the combined effect of treatment and genotype on the phenotype. 
PHENOTYPE
TREATMENT
GENOTYPE OUTCOME
PHENOTYPE
TREATMENT
GENOTYPE OUTCOME
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B)
C)
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1.4 Outline 
Chapter 2 will deal with the first level of study – modeling the effect of genotype on the 
outcome. Data exploited to this aim are SNPs data from Genome Wide Association 
Studies, whose objective is to detect correlation between one or more genetic 
polymorphisms and a discrete trait (the presence or absence of a disease condition). 
Chapter 3 will treat the second level of study – modeling the combined effect of 
phenotype and treatment on the progression of the outcome. To this aim, longitudinal data 
(coming from intervention clinical trials) regarding the main diabetes complications, as 
well as information on clinical variables (the phenotype) and on the treatment will be 
exploited. 
Chapter 4 will focus on the last level of study – modeling the effect of treatment on the 
phenotype – in which data regarding the effect of a drug on a specific target phenotype 
will be exploited. 
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Chapter 2 
 
2 Modeling the effect of genotype on 
diabetes: biomarker selection ad 
subject classification 
 
Referring to the multi-level scheme presented in Figure 1.1, this chapter will focus on the 
effect of the genetic variables on the outcome, as shown in Figure 2.1. 
 
Figure 2.1: Modeling the effect of genotype on the outcome. 
Genetic Association Studies and the objective of their study, i.e. SNPs, will be first 
introduced, with particular regard to Genome Wide Association Studies. Then, the most 
widely used approaches to analyze results coming from these studies will be briefly 
described to provide an exhaustive overview of the state of the art. Finally, a new 
algorithm for biomarker selection and subject classification from Genome Wide SNP data 
will be presented and its performance assessed by a comparison with a penalized logistic 
regression algorithm from the state of the art in simultaneous Genome Wide data analysis. 
PHENOTYPE
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2.1 Single Nucleotide Polymorphisms (SNPs) 
The DeoxyriboNucleic Acid (DNA) represents the hereditary material in humans and in 
most of all the other organisms. 
The biological information is stored into the DNA as a string composed by four chemical 
bases: adenine (A), cytosine (C), guanine (G) and thymine (T). The sequence of these 
bases determines the information available for building and maintaining the organisms. 
DNA bases pair with each other (A-T; C-G) and form structures called “base pairs” (bp). 
Each base is linked to a sugar molecule and a phosphate molecule, forming a nucleotide. 
Within the nucleus of each cell, the DNA macromolecules are packed into structures 
called chromosomes. In humans, each somatic cell contains 23 pairs of homologous 
chromosomes (46 chromosomes in total). In each pair of homologous chromosomes, one 
is inherited from the father,  and one from the mother. 
The genes represent the basic unit of heredity. A gene represents a segment of DNA 
(which physical location on the chromosome is called genic locus), and it contains the 
knowledge for coding proteins, macromolecules with either structural or functional 
biological roles [52]. 
In humans, as in other species, the length of the DNA sequence constituting a gene is 
extremely variable (from few hundreds of bp up to more than 2 millions bp). The Human 
Genome Project [http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml] 
estimated that human DNA sequence contains about 20,000 – 25,000 genes (~ 3% of the 
whole human DNA sequence, which is long ~ 3 billion base pairs). 
More than 99.9 % of DNA sequence is identical between any two individuals. Even 
though most of the DNA sequence is identical, since the human genome sequence is so 
long, there are still many genetic variations. 
Alleles are different versions of the same gene, carrying variations in terms of DNA 
sequence, which determinate the physical characteristics that differentiate individuals 
belonging to the same specie. 
The Single Nucleotide Polymorphism (SNP) is defined as a DNA segment showing 2 or 
more alleles in a population and represents the simplest and most common source of 
variability among individuals [52]. For example, a SNP may replace the nucleotide pair 
G-C on a chromosome with the nucleotide pair A-T on the homologous chromosome, in a 
certain position of the DNA (Figure 2.2). 
 The combination of allele
called genotype, while a set of 
[52]. 
For an SNP showing 2 alleles in a population, since chromosomes are in pairs, we can 
have 3 possible genotype
combination of the 2 alleles
frequent in the population), and with 
the population), the 3 possible genotypes are: 
respectively, common homozygou
 
Figure 2.2: Example of Single 
 
SNPs are not directly involved in causing a disease condition, but they modulate the 
probability of its occurrence, by interacting with other non
(e.g. smoke or alcohol intake for some classes of cancer) 
external interventions, such as treatments and drug assumption 
 
2.2 Genome Wide
The study of complex diseases
Association studies (GAS
association studies applied to the field of population genetics 
s in the same position on the two homologous chromosomes is 
alleles on the same chromosome represents an 
 for the single individual, each corresponding to a possible 
. Denoting with A the common  form of the allele (i.e. most 
a the rare form of the allele (i.e. the less frequent in 
AA, Aa and aa, which are referred to as, 
s, heterozygous and rare homozygous 
Nucleotide Polymorphism at a given locus
-genetic predisposing factors 
and modulating the effe
[5]. 
 Association Studies 
, such as diabetes, requires adequate tools. Genetic 
) are variants of the clinical and epidemiological case
[5]. The 
11 
haplotype 
[52]. 
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-control 
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is to detect correlation between one or more genetic polymorphisms and a discrete trait 
(the presence or absence of a disease condition), comparing the frequencies of SNP 
alleles in two well-defined groups of individuals: cases who have been diagnosed with the 
disease under study, and controls, who are either known to be unaffected, or who have 
been randomly selected from the population. An increased frequency  of a SNP allele or 
genotype in the cases class compared with the controls class indicates that presence of the 
SNP  allele may increase risk of disease. 
According to the a priori knowledge defined by the study design, GAS can be classified as 
follows, as the number of analyzed SNPs increases: 
- Candidate SNPs association studies. This kind of studies focus on a single SNP which 
is suspected to have a causal role in the disease of interest. 
- Candidate genes association studies. The object of the study is not a single SNP, but a 
set of markers (typically 5 - 10) located within the same potentially causative gene. 
- Fine mapping. This kind of studies involve typically up to hundreds of nucleotides; the 
aim is to have a better definition (coverage) of a genome region potentially involved in 
physiological/pathological processes and previously identified by linkage studies or 
genome-wide association studies. 
- Genome Wide Association Studies (GWAS). This approach consists in scanning markers 
across the complete sets of SNPs of many people to identify genetic variations associated 
with a particular disease. Such studies are particularly useful in finding genetic variations 
that contribute to common, complex diseases, such as asthma, cancer, diabetes, heart 
disease and mental illnesses. GWAS are essentially “hypotheses free approaches”, i.e. this 
kind of studies do not require a prior knowledge about the right gene to be analyzed, but 
represent hypotheses generating instruments. 
In the following sub-sections, a focus on GWAS will be presented. 
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2.2.1 Study design 
When planning to perform a GWAS on unrelated individuals based on a case-control 
design, cases are selected on the basis of the trait of interest (i.e. type 2 diabetes), while 
control individuals must be clinically proven to be free not only from the condition of 
interest, but also from other traits that are not common to cases, otherwise a second sub-
phenotype may be introduced in the analysis. The choice of the reference group may 
introduce confounding effects, and therefore an appropriate case-controls matching based 
on some phenotypic, exposure or environmental factors (gender, smoking history, 
ancestry) is required, in order to avoid spurious associations. Limiting factors when 
planning a GWAS are often represented by the difficulty of enrolling a sufficient number 
of cases and matched controls, and by the genotyping costs [5]. 
2.2.2 Genotyping 
The process of examining DNA sequence in order to determine individual’s 
polymorphisms is called genotyping. For the past decade, microarrays have grown in 
popularity as the primary tool for genotype analysis. Recently, however, next-generation 
sequencing (NGS) technologies has been introduced as a promising, new platform for 
genetic analysis, since they parallelize the sequencing process (i.e. s the process of 
determining the precise order of nucleotides within a DNA molecule), producing 
thousands or millions of sequences concurrently [26], thereby allowing to measure a huge 
amount of polymorphisms for each individual at the same time (up to > 1,000,000 SNPs). 
Nevertheless, for genotyping studies, microarrays are still widely adopted as they are 
substantially less expensive than NGS and much more conducive to processing thousands 
of samples required for typical genome-wide associations studies [26]. Illumina [Illumina, 
San Diego, CA] and Affymetrix [Affymetrix, Santa Clara, CA] represent the reference 
technologies for cost genotyping large amount of samples with high coverage in a cost 
effectively way (~ 200 $ for a 370 K SNPs chip). 
Genotyping workflow according to Illumina protocols is represented in Figure 2.3. 
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Figure 2.3: Genotyping process according to Illumina protocol. The schema represent the main steps of the 
Illumina Infinium genotyping workflow. Figure from 
[http://res.illumina.com/documents/products/workflows/workflow_infinium_ii.pdf]. 
Even if genotyping protocols differ between manufacturers, the main steps are common 
both to Illumina and Affymetrix protocols. A brief description of the genotyping 
processes is reported below. 
1. DNA extraction, purification and amplification. Peripheral blood is drawn from each 
enrolled individual and successively DNA is extracted, amplified and purified. 
2. Hybridization on the chip. DNA is labeled using fluorochromes and hybridized to the 
chips, each containing a redundant set of probes for each analyzed SNP. Mismatched and 
crosshybridization problems are avoided by different strategies, according to the 
manufacturer. 
3. Fluorescence intensities acquisition. Fluorescence intensity for each SNP is captured 
for each analyzed sample by a scanner or “arrayer” at a fixed wave-length specific for 
different fluorochrome. 
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4. Genotypes determination. Once fluorescence captures have been extracted, “ad-hoc” 
programs allow for the quantization of the fluorescence intensities and for the genotypes 
determination. These softwares have been specifically developed by Illumina (Bead 
Studio and Genome Studio) and by Affymetrix (BRLMM) and implement multivariate 
clustering strategies for genotypes assignment on the basis of fluorescence intensity 
signals corresponding to each of the two alleles. 
2.2.3 Quality Control 
A preliminary analysis step is represented by data Quality Control, which is necessary to 
filter out low quality data in order to reduce the probability of false positive findings. 
Experimental systems involving biological material are typically prone to errors, often 
non-randomly distributed [5]. This lack of randomness is both due to the very nature of 
the available experimental technologies and to the presence of several concurrent factors 
such as DNA quality and preparation, specific experimental conditions or different skills 
of the experimenters, errors during the phase of genotypes assignment. Non random 
distribution of errors can affect results and reduce the power of the study [5]. Since most 
GWAS aim to identify very slight variations in allele frequencies between cases and 
controls, even the presence of small experimental errors could dramatically affect the 
outcome [6], [16]. Therefore it is necessary to apply filtering procedures in order to 
identify specific SNPs yielding errors in multiple individuals (markers-affecting errors), 
or individuals in the sample with errors across multiple SNPs (problems with the DNA 
sample), and simply exclude them from the analysis. 
The basic Quality Control parameters that could help in identifying and removing low-
quality samples and markers are the following: 
- Samples genotyping rate: fraction of determined genotypes for each sample. This 
measure ranges from 0 (no genotype has been assigned) to 1 (all genotypes have been 
assigned). 
- SNPs genotyping rate: fraction of determined genotypes for each SNPs. This 
measure ranges from 0 (no genotype has been assigned) to 1 (all genotypes have been 
assigned). 
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- MAF value: SNPs showing an extremely low value for the Minor Allele Frequency 
(MAF <0.01/0.05), could represent low genotyping-quality markers or too rare 
polymorphisms [5]. 
- HWE p-value: neutral genetic variants in a large random-mating population are 
expected to display Hardy Weinberg Equilibrium (HWE), under which assumption 
expected genotype frequencies satisfy the rules: E[AA]=p2, E[Aa]=2pq, E[aa]=q2, 
where p and q are the frequency of A and a alleles in the population, respectively. 
Genotyping errors can shift the SNPs observed frequencies from the expected 
proportions, and therefore testing for deviations from the HWE in the control 
population defining a cut-off on the result of the test (the HWE p-value) represents a 
standard approach to detect genotyping errors [53]. Such test can be performed using 
a Pearson goodness-of-fit statistic with one degree of freedom (d.f), under the null 
hypothesis of HWE. 
 
2.3 Univariate Analysis 
Once the preliminary phase of data QC has been performed, the next step usually consists 
in analyzing the whole set of markers, one SNP at a time, by univariate association tests 
under the null hypothesis of no association in order to identify SNPs statistically 
associated with the outcome, once a significance threshold P has been fixed. 
The strength of the association between each single variable (SNP) and the outcome 
(disease/trait) is expressed in terms of p-value, which represents the probability of 
detecting an association that is stronger than that derived from data “by chance”, when 
there is no evidence of association (i.e. a false positive): a very low p-value indicates that 
the observed result would be highly unlikely under the null hypothesis, which will be then 
rejected when the p-value turns out to be less than the significance threshold P [46]. 
The common way to represent the results of such a test is the so-called Manhattan Plot, in 
which, for each SNP, the –log(p-value) is reported, thus placing the most significant 
SNPs in the top part of the plot. Figure 2.4 represents, as an example, the association 
results coming from univariate association tests on a GWAS dataset on myopia [31], 
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where the –log(thresholds) are very high (i.e. the significance thresholds are very low) 
since a correction for multiple test has been performed (see section 2.3.3). 
 
Figure 2.4: The statistical significance values across the 22 autosomes of each SNP's association with 
refractive error (measured as spherical equivalent) are plotted as −log10P values. X-axis represent the 
location of each SNP on the chromosomes, ordered according to their physical position. Y-axis represents 
the strength of association (-log10(p-value)) corresponding to each SNP. The blue horizontal line 
indicates P = 10
−5
 and the red line indicates P = 5 × 10
−8
. 
The way of testing for association depends on the genetic model assumed for the SNP 
[39]. 
By defining the minor allele as a, the common allele as A, and the risk of developing the 
disease given a certain allele or genotype configuration as R, the most commonly used 
genetic models can be defined as follows: 
- Genotypic model (aa vs aA vs AA). No a priori assumption is made about the 
association between genotype and phenotype, therefore the risk R is assumed to be 
equal for each genotype. 
- Dominant Model (aa/aA vs AA). The underlying assumption of this model is that 
having one (aA) or two copies (aa) of the risk allele a induces the same risk R of 
being affected with respect to AA genotypes. The genotypes aA and aa are 
therefore pooled into the same group (aa/aA) and their frequency compared with 
the estimated frequency of the AA genotyes. 
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- Recessive Model (aa vs aA/AA). The assumption is that the risk R linked to a 
certain allele a is manifest only if it occurs in double copy aa. The frequency of aa 
genotype is therefore compared with aA/AA genotypes frequency. 
- Allelic or multiplicative model (a vs A): the unity of the analysis is represented 
by alleles instead of genotypes. It assumes a multiplicative effect of the allele 
dosage (i.e. if heterozygote individuals aA risk R of developing the disease with 
respect to AA individuals, homozygote aa individuals risk R*R with respect to AA 
individuals). 
- Additive or trend model (aa > aA > AA). The unity of risk is represented by 
alleles and it assumes that the risk linked to a certain allele has an additive effect 
on the case/control outcome (i.e. if heterozygote individuals aA risk R of 
developing the disease with respect to AA individuals, homozygote aa individuals 
risk R+R with respect to AA individuals). 
The most widely employed association tests are based on the Pearson’s χ2 test and 
Cochran-Armitage test for trend. 
2.3.1 Pearson χ2 test.  
Considering a pool of ncase unrelated cases, affected by the disease of interest, and 
unaffected ncont controls for which a certain marker with alleles A and a has been 
genotyped, the sample genotype data can be represented by a 2 x 3 contingency table, as 
represented in Table 2.1.a, where the total number of subject is n = ncase + ncont. The 
contingency table can be analyzed directly using an  observed-expected test statistic, 
which has a χ2 distribution on two degrees of freedom.  
The χ2 statistic tests for departure from the expected values across cells in the table. Thus 
the observed value for AA genotype in cases (O1 = N11) is compared with its expected 
value (E1) given the total number of cases and the total number of AA genotypes, so E1 = 
nAA·ncase/n. The full test statistic is given by equation (2.1): 
 
  =   − 	


   ~  
 (2.1)   
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where the summation is over all six cells in the table, and Oi are the observed values N11, 
N12, N13, N21, N22, N23 in each cell. Notice that this test statistic compares the observed 
number of AA genotypes in cases with that expected assuming both cases and controls 
have the same frequency of AA genotypes. 
The Pearson’s χ2 test can be used for each genetic model, simply modifying the 
contingency table, as shown in Table 2.1. 
(a) Full genotype table for a generic genetic model 
  AA Aa aa 
Cases  N11 N12 N13 
Controls  N21 N22 N23 
 
(b) Dominant model: allele B increases risk 
  AA Aa + aa 
Cases  N11 N12 + N13 
Controls  N21 N22 + N23 
 
(c) Recessive model: two copies of allele B required for increased risk 
  AA + Aa aa 
Cases  N11 + N12 N13 
Controls  N21 + N22 N23 
 
(d) Multiplicative model: r-fold increased risk for AB, r2 increased risk for 
BB. Analyzed by allele, not by genotype 
  A a 
Cases  2N11 + N12 N12 + 2N13 
Controls  2N21 + N22 N22 + 2N23 
 
(e) Additive model: r-fold increased risk for AB, 2r increased risk for BB. 
Genotypes analyzed by Armitage’s test for trend 
  AA Aa aa 
Cases  N11 N12 N13 
Controls  N21 N22 N23 
 
Table 2.1: Contingency tables for case control analyses, by genetic model. Test 1 is a baseline analysis, and 
any  further analysis should be driven by prior hypothesis. a, b, c, d, e, f are genotype counts observed in 
cases and controls. Figure from [39]. 
 
2.3.2 Cochran-Armitage test for trend 
For complex traits, it is widely thought that contributions to disease risk from individual 
SNPs will be often roughly additive – that is, the heterozygote risk will be intermediate 
between the two homozygote risk. The Pearson’s χ2 test have reasonable power regardless 
of the underlying risks, but if the genotype risks are additive they will be not as powerful 
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as tests that are tailored to this scenario. In fact, when data consist of a series of 
proportions occurring in groups which fall into some natural order, the question asked is 
then not so much whether the proportions differ significantly, but whether they show a 
significant trend, upwards or downwards, with the ordering of the groups. In this case, the 
Cochran-Armitage test can be applied [3]. It modifies the Pearson’s χ2 test to incorporate 
a suspected ordering in the effects of the three categories of the SNP. The idea is to test 
the hypothesis of zero slope for a line that fits the three genotypic risk estimates best (see 
example in Figure 2.5). 
 
Figure 2.5: Example of Armitage test of single-SNP association with case–control outcome. The dots 
indicate the proportion of cases, among cases and controls combined, at each of three SNP genotypes 
(coded as 0, 1 and 2), together with their least-squares line. 
Referring to Table 2.1.e, the trend statistic is: 
  =  
 − 
	  (2.2)  
where R1 = N11 + N12 + N13 is the number of cases, R2 = N21 + N22 + N23 is the number of 
controls, and the ti are the weights selected according to the suspected mode of 
inheritance. For example, in order to test whether allele A is dominant over allele a, the 
choice t = (1, 1, 0) is locally optimal. To test whether allele A is recessive to allele a, the 
optimal choice is t = (0, 1, 1). To test whether alleles A and a are codominant, the 
choice t = (0, 1, 2) is locally optimal. For complex diseases, the underlying genetic model 
is often unknown. In GWAS, the additive (or codominant) version of the test is often 
used. The test has good power in this case but power is reduced by deviations from 
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additivity. In an extreme scenario, if the two homozygotes have the same risk but the 
heterozygote risk is different (overdominance), then the Armitage test will have no power 
for any sample size even though there is  true association. 
2.3.3 Correction for multiple tests 
Once a set of association tests have been performed, a significance threshold (usually a 
cut-off value on p-value) must be fixed in order to discriminate between statistically 
associated and null SNPs. The question of what strength of evidence should be considered 
significant has yet to be fully resolved in genetic association analysis [19]. On the one 
hand, multiple testing issues arise in most studies, whether based on candidate genes or 
genome wide scans, with attendant issues of how to quantify the multiplicity, what error 
rate to control and which method to use [40]. 
The following most commonly used approaches for dealing with the multiple testing issue 
are the following: 
- Bonferroni Correction. Bonferroni correction [9] is the simplest procedure for 
assessing the significance threshold when multiple tests have been performed. 
This approach consists in rescaling the significance threshold α by the number of 
tests that have been performed N, in order to obtain a new multiple testing-
adjusted significance threshold α’: 
  = 1 − 1 − 	 → ′ ≈  (2.3)   
 
- False Discovery Rate (FDR). Bonferroni correction is often considered an 
overconservative correction, with the deriving risk of losing biologically relevant 
associations [40]. A less conservative approach for facing the issue of multiple 
testing is represented by the calculation of the False Discovery Rate (FDR) as 
described by Benjamini and Hochberg [8]. For a family of hypothesis tests, let R 
denote the number of rejected null hypotheses, and V the number of falsely 
rejected null hypotheses. The FDR is then computed as follows: 
  =   ! " > 0% ∙ ' > 0	 (2.4)   
22 
 
Benjamini and Hochberg introduced a step-up procedure for the control of FDR: 
given m null hypotheses to test H1, …, Hm, and p1, …, pm their correspondent p-
values, chosen a significance level α, the control procedure works as follows: 
a. order the p-values in increasing order and denote them by p(1), …, p(m) 
b. find ( = max ,-	 ≤ / 0 
c. reject all H(i) for i = 1, …, k 
This procedure is valid when all the m hypotheses are independent, otherwise step 
b changes into: 
b. find ( = max 1-	 ≤ / 2∑ 456 78695 : 
 
2.3.4 Univariate Analysis: drawbacks 
The described approaches examine one SNP at the time in relation to a defined trait. This 
over-simplistic strategy is not able to capture the multi-factorial nature of complex 
diseases, leading to the identification of a large set of associated SNPs (correlated by 
Linkage Disequilibrium, i.e. the association between two alleles located near each other 
on a chromosome, such that they are inherited together more frequently than would be 
expected by chance) but missing potential informative interactions [44]. 
Hoh and Ott [30] described the case in which the simultaneous presence of three 
genotypes at different loci induces a disease. By analyzing them though univariate models 
they would not result associated with the trait, since they share a low penetrance (i.e. poor 
association). This example is known as the Simpson’s paradox and it explains also how 
the marginal independence of two variables (i.e. the evidence that knowledge of the first 
variable’s value doesn’t affect the belief in the second variable’s value) does not 
necessary require their independence when other variables are taken into account [44]. 
 
2.4 Multivariate Analysis 
The extremely large numbers involved in a GWAS (O(106) SNPs in O(103) individuals) 
have led the vast majority of studies to rely upon single SNP association tests, as already 
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described. Complex diseases, however, have an heterogeneous nature, arising from 
complex patterns of interaction between a set of genetic traits and the environment: to 
fully capture the optimal set of genetic biomarkers, thus, all SNPs in a GWAS should be 
analyzed simultaneously in a multivariate framework [29].  
Multivariate models aim to do this, thus overcoming the described limitations that 
characterize the standard approaches. Moreover, they allow also to learn a rule for 
classifying unknown subjects as cases or controls, given their genetic profile and, 
possibly, other environmental covariates. 
The most widely employed multivariate tests are based on Penalized Logistic Regression 
models.  
2.4.1 Penalized Logistic Regression 
Although the more usual way of modeling case and control data is in terms of probability 
distribution of genotype conditional upon disease status, reflecting the manner in which 
data are generated, Prentice and Pyke [43] demonstrated that comparable results could be 
obtained by applying a likelihood based approach in which case-control condition is 
considered a random outcome. 
Given the random binary outcome Y (assuming only 2 possible states: 0 = control, or 1 = 
case) and one or more independent variables X = X1, …, Xp (SNPs in this case) the 
relation between Y and X can be modeled as the probability P(Y|X). 
Denoting P(Y = 1| X = x1, …, xp) with π, that is the probability that an individual 
randomly drawn from the population is a case, equation (2.5) reports the logistic 
regression model 
 ln =1 − = = >? +  >A
B
  (2.5)   
 
Where >? + ∑ >AB  represents the linear relation between a function of π (named logit) 
and the independent variables xi, in this case the SNPs of interest for the individual. 
From equation (2.5) the probability π can be computed as: 
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 = = CDEF∑ D6G6H6951 + CDEF∑ D6G6H695  (2.6)   
Equation (2.6) states that the probability for the individual to be a case is a non linear 
function of his SNPs’ values x1, …, xp and it ranges between 0 and 1. Figure 2.6 reports 
an example of equation (2.6) with only one independent variable x and parameters value 
β0 = 0 and β1 = 1. 
 
Figure 2.6: Example of logistic regression model in the case of a single independent variable x. 
 
The probability for the observation Y = yi is given by: 
 'I = J|A	 = =	L6 ∙ 1 − =	ML6 (2.7)   
Given N independent observation (i.e. N different patients) the maximum likelihood 
estimation maximizes the log-likelihood for the N observations: 
 NO	 = PJ ∙ lnQ=∗S + 1 − J	 ∙ lnQ1 − =∗STU  (2.8)   
 OV = WXYmaxO PNO	T (2.9)   
In the case of GWAS, when the number of markers is larger than the number of test 
subjects, since only a very small set of SNPs (compared to the total number of SNPs) is 
π (x)
0
1
x
-5 5
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likely to have an effect on the outcome, a penalization term is introduced in the logistic 
regression model, in order to obtain sparse solution, i.e. select few predictive variable 
without information loss [54]. These methods operate by shrinking the size of the 
coefficients of markers with little or no apparent effect on a trait down to zero. 
The main penalization strategies are the following: 
1. LASSO regression (L1 penalization regression). The Least Absolute Shrinkage 
and Selection Operator (LASSO) penalized regression, proposed by Tibshirani 
[50], estimates the parameters of the logistic model adding to the likelihood 
the penalization term given by: 
 Z = |O| = |>|B  (2.10)   
The model parameters vector β is then estimated by: 
 OV = WXYmaxO PNO	 − [ ∙ |O|T (2.11)   
Where λ is the weight of the penalization term. 
In a Bayesian interpretation, Lasso Regression can be derived as Bayes posterior 
mode under independent double-exponential priors for the βi [50]. Lasso 
Regression shrinks coefficients β1, β2, …, βp setting most of them to 0 and thus 
selecting the most significant variables. However, for a problem with N 
observation, it can select no more than N variables. 
2. Ridge regression (L2 penalization regression). The L2 penalized regression, 
proposed by Hoerl and Kennad [28], estimates the parameters of the logistic 
model adding to the likelihood the penalization term given by: 
 Z
 = |O|
 =  >
B  (2.12)   
The model parameters vector β is then estimated by: 
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 OV = WXYmaxO PNO	 − [ ∙ |O|
T (2.13)   
Where λ is the weight of the penalization term. 
In a Bayesian interpretation, Ridge Regression can be derived as Bayes posterior 
mode under independent Gaussian priors for the βi [28]. 
Ridge regression shrinks coefficients β1, β2, …, βp but  does not set any one to 0, 
thus makes no real variable selection. 
3. Elastic Net regression (L1L2 penalization regression). The L1L2 penalized 
regression, proposed by Zou and Hastie [57], estimates the parameters of the 
logistic model adding to the likelihood the penalization term given by a 
convex combination of L1 and L2 penalties. The model parameters vector β is 
then estimated by: 
 OV = WXYmaxO PNO	 − [ ∙ Q1 − 	 ∙ |O| +  ∙ |O|
ST (2.14)   
Where λ is the weight of the global penalization and α determines the relative 
weight of L1 and L2 penalties. 
Elastic Net produces sparse models encouraging a grouping effect, where strongly 
correlated predictors tend to be in or out the model together. 
4. Minimax Concav Penalty (MCP regression). Zhang et al. [55] propose a 
penalization term give by: 
 \],_>	 = `[> − >

2W b\ > ≤ W[12 W[
 b\ > > W[
c
 (2.15)   
The effect of the penalty is determined by the gradient of equation (2.15): 
 
d\],_d> >	 = e[ − >W b\ > ≤ W[0 b\ > > W[c (2.16)   
 Where λ is determines the magnitude of the penalization and 
which the penalization is applied. MCP regression causes unimportant 
variables to be eliminated, leaving the important ones unpenalized.
5. HyperLASSO regression 
variant of the Bayesian interpretation of the LASSO regression, using
Normal Exponential Gamma (
on the weights 
distribution with 2 extra parameters regulating scale and sharpe of the curve
The sharper peak induces sparse solutions
being minimally shrunk once included in the model
In Figure 2.7, plots of the negative of the penalty fun
Considering that the effect of the penalty is determined by the derivative of the penalty 
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HyperLasso strive to relieve some of this bias introducing penalties with flatter tails, so 
that large coefficients are only minimally shrunk.
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trend ATT) and simple forward stepwise regression (FSTEP). The authors explored the 
performances of penalization in selecting SNPs as predictors in two simulated genetic 
association studies. In particular, the methods were first compared with respect to 
detection of effect, in which detection of an allele in linkage disequilibrium (r2 > 0.05) 
with a true causal variant counted as a success (and any other detection counted as a false 
positive), and second with respect to localization/differentiation, in which only counted 
detection of the true causal locus itself as a success. In the first simulation study, a GWAS 
was simulated by generating 500 replicate datasets, each composed of 1000 cases and 
1000 controls, 4000 SNPs and 6 causal loci. In the second simulation study, a Fine 
Mapping study was simulated by generating 500 replicate datasets, each composed of 
1000 cases and 1000 controls, 3 given gene regions (CYP2D6, CFTR and CTLA4, 
containing 110, 190 and 228 SNPs respectively) and 5 causal loci within each region. 
Since all penalized regression methods required input of one or more values for the 
penalization parameter/s (to which we can refer as λ), rather than finding the best value 
for λ, results were analyzed in terms of AUC (Area Under Curve) in the ROC (Receiver 
Operating Characteristic) space, as the penalty parameter λ was varied. In particular, with 
respect to the first simulation study,  Figure 2.8 shows the relationship between true and 
false-positive detection for each of the methods as λ is varied, while, with respect to the 
second simulation study, Figure 2.9 shows he relationship between true and false-positive 
detection for each of the methods as λ is varied in the three gene regions of interest. 
Figure 2.8 and Figure 2.9 show similar performances between the different multivariate 
methods, with NEG giving the overall best and ATT the overall worst performance. 
Although larger parameter estimates are always more heavily penalized, methods that 
apply larger relative penalties on small parameters estimates and relatively lower 
penalties to larger estimates performed better and more accurately estimate the effect size 
of the selected SNPs. The superior performance of the HyperLasso regression with 
respect to detection as well as with respect to differentiation/localization of effects makes 
it a gold standard for GWAS SNPs analysis [4].  
 
 Figure 2.8: Sensitivity (detection rates) versus 1
is
Figure 2.9: Sensitivity (detection rates) versus 1
is varied, for the three gene regions of 
 
2.4.2 The problem of robustness for multivariate approaches
The identification of robust lists of biomarkers 
greatly influence subsequent 
pharmaceutical applications, 
methods described in the previous section for the discovery of biomarkers 
diseases from high-throughput
statistical significance [21]
mainly imputable to: 
-specificity (false positive rates) as the penalty parameter λ 
 varied, for simulation study 1. Figure from [4]. 
 
-specificity (false positive rates) as the penalty parameter λ 
simulation study 2. Figure from 
represents a fundamental issu
steps, such as the definition of targets for clinical and 
as well as early diagnosis and treatment of diseases. 
 data often provide results with limited overlap or reduced 
, [10]. As summarized in [18], these difference in results are 
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1. heterogeneity of both experimental protocols and computational pipelines 
carried out for the analysis; 
2. dataset size, which often include few subjects (some hundreds) with respect to 
the number of features (up to O(106) SNPs); 
3. heterogeneity of the complex disease,  responsible for high correlation in the 
features, some of these being real causal loci, other being correlated by linkage 
disequilibrium. 
As a result, different features may thus be selected under different settings, even when 
good classification accuracy is reached (it is in principle possible to have a lack of 
stability due to the presence of many highly correlated features, even with accuracy equal 
to one). 
The stability issue in feature selection has received much attention recently, as well as the 
precision of biomarker identification, i.e. the ability to select true biomarkers, defined as 
features biologically related to the physiological or clinical condition under study as cause 
or effect of it [17], [58], [2]. 
In the next section, a new algorithm for biomarker selection and subject classification 
from genome-wide SNPs, developed to effectively handle the problem of robustness in 
the biomarker discovery will be presented. 
 
2.5 Bag of Naïve Bayes 
As described in the previous sections, the analysis of genome-wide SNP data for complex 
diseases mainly suffers from two, intertwined problems: on the one hand, multifactorial 
diseases are caused by complex patterns of interaction between multiple genetic traits and 
the environment, on the other hand, linkage disequilibrium confounds the search for 
genetic biomarkers, because of the non-random association between the true genetic 
causes and the SNPs in genomic regions close to them, thus resulting in a lack of 
precision and stability of the lists of biomarkers selected by different methods, as reported 
in section 2.4.2. 
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In this section a new algorithm, Bag of Naïve Bayes (BoNB), developed to effectively 
tackle both of these problems, is presented. 
As reported in section 2.4, the most widely used methods for the simultaneous SNP 
analysis on a genome wide scale relay on the penalized logistic regression framework, 
where SNPs are modeled as discrete variables from the domain {0,1,2} and a log-additive 
model of genetic effect on the disease is assumed. 
BoNB is based on Naïve Bayes (NB) classification [41], thus it relies on contingency 
table analysis without having to assume a pre-specified model of genetic effect and, 
differently from logistic regression methods, it can easily handle missing values in the 
data, without having to perform imputation. Three main strategies are exploited in BoNB 
to tailor the Naïve Bayes framework to Genome Wide SNP data analysis: (a) a bagging of 
Naïve Bayes classifiers, to improve the robustness of the predictions, (b) a novel strategy 
for ranking and selecting the attributes used by each bagged classifier, to enforce attribute 
independence, and (c) a permutation-based procedure for selecting significant biomarkers, 
based on their marginal utility in the classification process. 
Before describing the algorithm, a brief introduction on the Naïve Bayes Classifier is 
reported in the following. 
2.5.1 Naïve Bayes Classifier 
The Naïve Bayes classifier (NB) is one of the most efficient classification algorithms for 
machine learning and data mining [41]. NB has been widely used for classification 
purposes in the biomedical fields and, more recently, in the context of GWAS [44]. 
The reasons of its diffusion are essentially its good classification performance and 
computational efficiency. NB is the simplest form of Bayesian classifier, in which all the 
variables are assumed to be independent given the value of the outcome [41]. 
Given a dataset X = {X1, …, Xn}, consisting of n observations (subjects) of p attributes 
(SNPs), and a set Y of class labels, one for each observation (case/control), a Naïve Bayes 
classifier estimates, from the dataset D, a classification rule in the form: 
'I = Jf|, ⋯ , 	 = 'I = Jf	 ∙ ∏ '|I = Jf	∑ 'I = Jf	Bi ∙ ∏ 'jkI = Jil  (2.17)   
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The classification rule of equation (2.17) states that the probability of a subject being in 
class yk, given a combination of values for the attributes X1, . . ., Xp, is equal to the a priori 
probability of class yk, P(Y = yk), times the probability of each attribute given class yk, 
P(Xi|Y = yk): the implicit assumption below this classification rule is that attributes X1, . . ., 
Xp are all conditionally independent given Y. 
Given discrete-valued inputs and binary outcome, the algorithm learns the probability 
distribution of equation (2.17) estimating two sets of parameters. The first is 
mif = 'j = AikI = Jfl ≅ #p = Ai˄I = Jfq + N#PI = JfT + Nr ,s = 1, … , r (2.18)   
For each input attribute Xi, each of its possible values xij (J = 3 in case of SNPs) and each 
of the two possible values yk of Y. The #D{x} operator returns the number of elements in 
the set D that satisfy property x. The second is the prior probability over Y: 
=f = 'I = Jf	 = #PI = JfT + N|| + 2N  (2.19)   
Where |D| denotes the number of elements in the set D. 
The l term is the only tunable parameter of the Naïve Bayes algorithm and it is known in 
the Bayesian literature as Equivalent Sample Size or Dirichlet Weight [41], and 
represents a prior probability which prevents the class-conditional probabilities from 
becoming zero when training attributes are sparsely populated. 
2.5.2 Methods 
BoNB consists in an ensemble of Naïve Bayes Classifiers, trained on GWAS data with 
the procedure known as Bootstrap Aggregating or Bagging [12]. 
Given a training dataset X, the Bagging procedure starts by computing a set of Bootstrap 
replicates of X, i.e. a set {X(1), …, X(B)} of datasets, each one obtained by sampling n 
observations with replacement from the training set X [20]. A Naïve Bayes Classifier 
NBC(b) is then trained on each Bootstrap sample X(b). Classification of unseen subjects, 
drawn from an independent test set, is then obtained by majority vote or weighted average 
of the output class probabilities computed by each NBC(b) (Figure 2.10). Such an 
approach is known not only to increase the robustness of the predictions in terms of 
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classification accuracy [12], but also to improve the precision and stability in the step of 
feature selection [18]. 
 
Figure 2.10: Schematics of the BoNB algorithm: B Bootstrap samples {X(1),…, X(B)} are drawn from a 
GWAS training dataset X; B Naïve Bayes Classifiers (NBC) are trained on the Bootstrap samples, with the 
novel procedure for attribute ranking and selection; predictions of unseen subjects from a GWAS test 
dataset are carried out independently by each NBC and class probabilities are then averaged; biomarker 
selection is carried out with the novel permutation-based procedure, exploiting Out-of-Bag (OOB) samples. 
 
Given the binary nature of the case/control classification problem and the frequent 
unbalance between the number of cases and controls in a GWAS, classification 
performances are evaluated by the Matthews Correlation Coefficient (MCC, [12]). The 
MCC is defined as: 
 uvv = - ∙  − \- ∙ \w- + \-	 ∙ - + \	 ∙  + \-	 ∙  + \	 (2.20)   
where tp, tn, fp and fn stand for true positives, true negatives, false positives and false 
negatives, respectively. 
The MCC is often preferred to standard classification accuracy, i.e. to the proportion of 
correctly classified examples, because it is not sensitive to class unbalance: the MCC, in 
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fact, ranges from -1 (all examples incorrectly classified) to 1 (all correctly classified) and 
equals 0 in case of majority classification, i.e. when all labels are assigned to the most 
represented class. 
For estimating probabilities as in equation (2.17), the Naïve Bayes Classifier makes the 
assumption that the attributes {X1, …, Xn} are all conditionally independent of one 
another, given Y . Such an assumption is unlikely to hold if all the SNPs of a GWAS are 
exploited as attributes, because of genetic linkage. Moreover, computing equation (2.17) 
for the whole SNP set can be computationally heavy and can lead to numerical and 
overfitting problems. 
A procedure for selecting a good set of independent SNPs for each NBC(b) was thus 
developed. 
The procedure first ranks each SNP according to the classification performance obtained 
on the training set X(b) itself by using the SNP as a single attribute of the NBC(b). To 
account for possible class unbalance, classification performance is assessed with the MCC 
(equation (2.20)). The obtained MCC represents the score of the SNP. SNPs are then 
ranked in decreasing order of score, obtaining a ranked list for each NBC(b). 
In the second step, SNPs are iteratively added, in decreasing order of score, as attributes 
of each NBC(b) from its corresponding ranked list, computed on X(b). Each time a SNP is 
included as an attribute, all the SNPs in the ranked list that are both close to the SNP on 
the genome (distance < 1Mb) and correlated with it (r2 > θ, where r2 is the squared 
correlation coefficient and θ is a user defined threshold) are removed from the list: such 
an approach enforces attribute independence, thus coping with the problems arising from 
genetic linkage. Rather than including one SNP at a time, uncorrelated SNPs are added in 
groups of exponentially increasing size, starting from one SNP and doubling the size at 
each new addition. New SNPs are added as long as the generalization ability of NBC(b) 
increases: to estimate the generalization ability, each NBC(b) is tested on the 
corresponding Out-of-Bag sample OOB(b), consisting of all the observations left out from 
X when sampling X(b), and the MCC of the prediction is measured. The exponential 
increase in the number of added attributes allows BoNB to reach the adequate size for the 
attribute set of each NBC in a logarithmic number of steps. 
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Such an attribute selection procedure, iterated for the B bootstrap samples, results in an 
ensemble of B Naïve Bayes Classifiers, each with a possibly different set of features. 
Classification of new subjects, the first objective of GWASs, is then obtained by having 
each NBC estimate output class probabilities and by averaging the probabilities across all 
the B NBCs. Classification performance of the ensemble of NBCs can then be assessed on 
an independent GWAS test set, by measuring the MCC of the predictions. 
For the second objective of GWASs, biomarker selection, a procedure originally designed 
for the Random Forests bagged classifier [11] was adapted for BoNB: for each of the 
SNPs included as attributes by at least one NBC, the genotype of the SNP is randomly 
permuted in the OOB sets, each NBC(b) is tested on its corresponding OOB(b) and the 
relative decrease in MCC due to the permutation is recorded. Such a measure, which can 
be used as an indicator of the importance of each selected attribute given all other 
selected attributes, is defined marginal utility (MU). 
For each SNP, the permutation procedure returns a list of values of MU, one value for 
each NBC that included the SNP: MUs significantly greater than zero are tested with a 
one-tailed Wilcoxon signed rank test on the list of values, selecting as biomarkers the 
SNPs for which the p-value of the test is lower than 0.05. 
2.5.3 Results 
BoNB was tested on the WTCCC case-control study on Type 1 Diabetes [13], where 
approximately 2000 T1D cases and 3000 healthy controls were examined. Each subject 
was genotyped on the Affymetrix GeneChip 500K Mapping Array Set. A small number 
of subjects was excluded according to the sample exclusion lists provided by the WTCCC. 
In addition, a SNP was excluded if (i) it is on the SNP exclusion list provided by the 
WTCCC; (ii) it has a poor cluster plot as defined by the WTCCC. The resulting dataset 
consists of 458376 SNPs, measured for 1963 cases and 2938 controls. 
The BoNB algorithm exposes two parameters to the user: the number of Bootstrap 
replicates and Naïve Bayes Classifiers, B, and the threshold on the squared correlation 
coefficient above which two SNPs are considered correlated, θ. B and θ were set to200 
and 0.1, respectively (see section 2.5.4 for an analysis of how performance is affected by 
variations of the parameters B and θ). 
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Classification performance was estimated on independent train-test set pairs obtained by 
repeatedly sub-sampling at random 90% of the dataset for training and 10% for testing. 
The procedure was iterated 10 times and classification performance was assessed with the 
MCC of the predictions on the test sets. The list of selected biomarkers, on the other hand, 
was computed on the whole dataset. 
Since BonB is based on the Naïve Bayes classification framework and has been 
developed as a valid alternative to penalized logistic regression methods, classification 
performance was compared with the ones obtained by a standard Naïve Bayes Classifier, 
trained on all the SNPs that reached the significance threshold of 5×10-7 (as in [13]) in a 
single 2df χ2 test of association with a general genetic model, and by HyperLASSO, a 
logistic regression method representing the gold standard for the simultaneous analysis of 
all SNPs in a GWAS, described in section 2.4.1. The former algorithm was chosen to 
assess the improvement of BoNB both in terms of biomarker selection, with respect to a 
standard univariate test, and in terms of classification performance, with respect to the 
algorithm on which BoNB is based. The latter algorithm was chosen because of its best 
performance among classification and biomarker selection methods for genome-wide data, 
as reported in [54] and [4], and because of the complete availability of the source code. 
On the experimental dataset, BoNB reached an MCC of 0.55 ± 0.03 (mean ± standard 
deviation), significantly higher than the ones reached by both the standard Naïve Bayes 
Classifier (0.31 ± 0.05, Wilcoxon signedrank p-value 0.002) and by HyperLASSO (0.45 
± 0.03, p-value 0.002). Figure 2.11 (left panel) shows the boxplots of the MCC obtained 
by the three algorithms on the ten iterations of the sub-sampling procedure. For the sake 
of completeness, Figure 2.11 (right panel) shows also the boxplots of classification 
accuracy. 
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Figure 2.11: Boxplots of MCC (left panel) and classification accuracy (right panel) of the simple Naïve Bayes 
classifier, HyperLASSO and BoNB on ten random sub-samplings of the WTCCC T1D dataset. 
 
To further analyze the behavior of the three methods at different levels of the output 
function (i.e. of the output class probability for BoNB and the standard Naïve Bayes 
classifier and of the logistic regression value for HyperLASSO) in Figure 2.12 the 
Precision vs Recall curve and the Receiver Operating Characteristic, or True Positive 
Rate vs True Negative Rate curve, of the three algorithms on one of the ten random sub-
samplings are reported (the behavior on the other sub-samplings is similar). As it is clear 
from the figure, the performance of the standard Naïve Bayes classifier is completely 
dominated by the performance of both BoNB and HyperLASSO. Concerning the two 
latter algorithms, one can observe that HyperLASSO has a better performance at the two 
extremities of the curves, i.e. for subjects whose logistic regression value is closer to the 
maximum or the minimum; moving from the extremities to the middle scores, BoNB 
outperforms HyperLASSO, being indeed able to reach overall higher MCC and 
classification accuracy. 
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Figure 2.12: Precision vs Recall curve (left panel) and Receiver Operating Characteristic (right panel) of the 
standard Naïve Bayes classifier, HyperLASSO and BoNB on a random sub-sampling of the WTCCC T1D 
dataset. 
 
For biomarker selection, BoNB was run on the whole dataset and its results compred with 
the biomarkers identified by HyperLASSO and by the general 2df test (see section 2.3.1). 
The average number of attributes included by BoNB in each NBC was 3.24, 75 SNPs 
were included by at least one NBC and 9 SNPs by at least 5% of the NBCs (see Table 
2.2). Among the 9 SNPs, only 7 SNPs reached the significance level on the permutation 
test and were chosen as genetic biomarkers (marked in bold in Table 2.2). All the 7 
selected SNPs fall into regions of interest for Type 1 Diabetes according to the on-line 
database T1DBase [http://www.t1dbase.org] (cytobands p13.2 on chromosome 1 and 
p21.32 on chromosome 6, also known as the MHC region) and their association with the 
disease was confirmed in a larger meta-analysis, subsequent to the WTCCC study [7]. 
The squared correlation coefficients between all pairs of selected SNPs are all lower than 
0.155, indicating low redundancy in the information coded by the set of 7 SNPs. 
Compared to the 394 SNPs that reached the significance level on the 2df general test, both 
the list of 75 SNPs used for classification and the list of 7 biomarkers selected by BoNB 
are more compact, but this does not prevent BoNB to reach significantly higher 
classification performance. 
HyperLASSO selected 8 SNPs, all in the MHC region of chromosome 6: 4 of the SNPs 
are in the list of biomarkers selected by BoNB, thus suggesting a certain coherence 
between the two algorithms and providing further confidence on the identified biomarkers. 
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SNP Chr Gene Relation % 
NBCs 
MU 
(median) 
rs6679677 1 RSBN1 downstream 7 0.033 
rs9266774 6 MICA upstream 5.5 0.011 
rs805301 6 BAT3 intron 17.5 0.043 
rs492899 6 SKIV2L intron 8.5 0.025 
rs9273363 6 HLA-DQB1 downstream 100 0.835 
rs9275418 6 HLA-DQB1 upstream 80 0.160 
rs6936863 6 HLA-DQA2 upstream 8 0.08 
rs9784858 6 TAP2 intron 5 0.008 
rs3101942 6 LOC100294145 exon 21.5 0.045 
Table 2.2: SNPs selected as attributes for at least 5% of the Naïve Bayes Classifiers by BoNB on the WTCCC 
T1D dataset, with B = 200 Bootstrap samples and classifiers. First column: dbSNP RS ID. Second column: 
SNP chromosome. Third and fourth column: annotated gene and relation with the SNP. Fifth column: 
percentage of Naïve Bayes Classifiers that included the SNP as attribute. Sixth column: median of the 
marginal utility of the SNP. SNPs selected as genetic biomarkers by the permutation procedure are marked 
in bold. 
2.5.4 Sensitivity analysis 
As already pointed out in the results section, the BoNB algorithm exposes two parameters 
to the user: the number of Bootstrap replicates and Naïve Bayes Classifiers, B, and the 
threshold on the squared correlation coefficient above which two SNPs are considered 
correlated, θ. In this section a brief analysis to describe how performance is affected by 
variations of the parameters B and θ was carried out. 
Figure 2.13, left panel, represents the MCC obtained by BoNB on ten random sub-
samplings of the WTCCC T1D dataset, for B = 200 and θ ranging from 0.02 to 0.5. As it 
is clear from the figure, θ = 0.1 is optimal and results in a significantly higher 
classification performance (Kruskal-Wallis test p-value 3.7×10-4). 
Concerning the number of Bootstrap replicates B, on the other hand, one can observe 
from Figure 2.13, right panel, that classification performance is not much sensitive to 
variations of B (Kruskal-Wallis test p-value 0.98), though it is slightly higher for B = 50 
and 200. Analyzing the list of selected biomarkers, BoNB returns the same seven 
biomarkers reported in Table 2.2 for B = 200 and 500, adds SNP rs2856688 to the list for 
B = 100 and misses SNPs rs6679677 and rs492899 for B = 50. Given the consistency 
among the results for higher values of B, suggested values for BoNB parameters are thus 
θ = 0.1 and B = 200. 
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Figure 2.13: Box plots of the MCC obtained by BoNB on ten random sub-samplings of the WTCCC T1D 
dataset, for B = 200 and θ ranging from 0.02 to 0.5 (left panel) and for θ = 0.1 and B ranging from 50 to 
500 (right panel). 
2.5.5 Computational complexity 
For analyzing the computational complexity of BoNB, the pseudocode summarizing the 
training phase and the biomarker selection phase of the BoNB algorithm is reported in the 
following: 
// Training 
1 for b = 1 to B 
2     [X(b), OOB(b)] = bootstrap replicate from X 
3     for s = 1 to p 
4         Compute the contingency table for SNP s from X(b) 
5         Compute the Naïve Bayes attribute score of s 
6     L(b) = list of SNPs in decreasing order of score 
7     Initialize NBC(b) as a Naïve Bayes Classifier with no attributes 
8     Extract M = 1 new attributes for NBC(b) from the top of L(b), excluding from future 
additions all SNPs at distance > 1 Mb and with r2 < θ 
9     while MCC of NBC(b), tested on OOB(b) with the new attributes, increases 
10       Add the new attributes to NBC(b) 
11       Update M = 2 * M 
12       Extract M new attributes from the top of L, excluding each time from future 
additions all SNPs at distance > 1 Mb and with r2 < θ 
 
// Biomarker selection 
13 for s in all SNPs selected by at least 5% of the NBCs 
14     for b in all NBCs that selected s 
15         Permute the genotype of s in OOB(b) 
16         Record the Marginal Utility (MU) of s 
17         Select as biomarkers the SNPs with MU significantly larger than zero. 
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For each b in B, the attribute ranking step (lines 3-6) takes O(np) for computing the 
contingency tables and the scores (where n is the number of subjects and p is the number 
of SNPs in the dataset) plus O(p log p) for sorting the score list, thus has a total 
complexity of O[Bpn + Bp log p]. The attribute selection step (lines 7-12), executed for 
each b in B, has a computational complexity dominated by two operations: computation 
of the squared correlation coefficient r2 between SNPs and test of NBC(b) on OOB(b). 
Defining with M* the average number of attributes included by each NBC (which is 
problem dependent) and p*1Mb the average number of SNPs in a 1 Mb section of the DNA 
(which is dataset dependent, but is a roughly linear function of p), the first operation costs 
O(n) for each SNP pair and is executed M* · p*1Mb  times, having thus a total 
computational complexity of O(BnM*p*1Mb) . The second operation, on the other hand, is 
executed log(M* + 2) times, each time with a doubling number of features for NBC (b), 
and its computational complexity is thus expressed by the following summation: 
  xxy∗z{|}∗F	? ∙ 2 = xxy∗ ∙ j2z{|}∗F
	 − 1l ≅ u∗	 (2.21)   
where n*OOB is the average number of subjects in an OOB set, tending to (1 – 1/e) ·  n for 
large n [20]; the total complexity of the second operation is thus O(BnM*) , 
asymptotically negligible with respect to the cost of computing the squared correlation 
coefficients. The total computational complexity of the training phase of the BoNB 
algorithm is thus O[B(pn + p log p + nM*p*1Mb)] . For the complexity of the biomarker 
selection phase of BoNB, the number of SNPs selected by at least 5% of NBCs (which is 
problem dependent) is defined as p*5%. The inner loop of lines 15-16 is executed at most 
O(B p*5%) times; since the cost of the two operations in the loop is linear in n, the 
biomarker selection phase has a total computational complexity of O(Bn p*5%). 
2.5.6 Implementation 
BoNB is implemented in C++ and relies only on standard libraries, thus being fully 
portable across operating systems. On the WTCCC case-control study on Type 1 Diabetes, 
BoNB takes approximately 50 minutes for training 200 NBCs and selecting the 
biomarkers on a 3.00 GHz Intel Xeon Processor E5450. A careful allocation strategy 
makes BoNB occupy around 600 MB of RAM for the WTCCC dataset, allowing it to be 
easily run on a desktop computer. 
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2.6 Discussion 
In this chapter the problem of modeling the effect of genotype on the outcome was 
discussed. In the context of  Genome Wide Association Studies, the objective of such a 
modeling is twofold: on the one hand, GWAS aim to perform biomarker selection 
detecting correlation between one or more SNPs and a discrete trait (the presence or 
absence of a disease condition or a complication), on the other the modeling process 
allows also to learn a rule for classifying unknown subjects as cases or controls. 
For complex diseases this is not trivial, since such pathologies have an heterogeneous 
nature, and to fully capture the optimal set of genetic biomarkers, all the SNPs in a GWAS 
should be analyzed simultaneously in a multivariate framework. Moreover, linkage 
disequilibrium confounds the search for genetic biomarkers, because of the non-random 
association between the true genetic causes and the SNPs in genomic regions close to 
them, thus resulting in a lack of precision and stability of the lists of biomarkers selected. 
The standard approaches generally analyze one SNP at time, thus losing information on 
biomarkers interaction and suffering for statistical significance of the selected features. 
Multivariate approaches try to overcome these limitations, but the most widely used 
methods in the literature still suffer for the problem of robustness of the list of selected 
biomarkers. In fact, it is in principle possible to have a lack of stability due to the 
presence of many highly correlated features, even with classification accuracy equal to 
one. 
The presented algorithm, Bag of Naïve Bayes, was developed to effectively tackle this 
problem. 
BoNB is based on Naïve Bayes classification enriched by three main features to tailor the 
Naïve Bayes framework to Genome Wide SNP data analysis: (a) a bagging of Naïve 
Bayes classifiers, to improve the robustness of the predictions, (b) a novel strategy for 
ranking and selecting the attributes used by each bagged classifier, to enforce attribute 
independence, and (c) a permutation-based procedure for selecting significant biomarkers, 
based on their marginal utility in the classification process. 
Learning an ensemble of classifiers from a bootstrap sample of the original dataset 
guarantees a higher generalization ability by increasing the stability of the learning 
process [12]-[18] and, simultaneously, it allows to define a measure of the marginal 
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utility of each SNP, given all the other SNPs exploited for classification, and to select 
significant biomarkers among these SNPs in a statistically robust way. 
Two features of the Naïve Bayes Classifier, chosen as building block of the BoNB 
algorithm, make it more appealing for genome-wide data analysis than logistic regression 
approaches: on the one hand, conditional probability table analysis does not assume a pre-
specified model of genetic effect, on the other hand, missing values are seamlessly 
handled by both the learning and the classification procedure.  
BonB approach to attribute selection, consisting in a univariate ranking step followed by a 
multivariate selection step, has the advantage of favoring informative attributes, but 
without the need of pre-selecting fixed sets of attributes or of defining cut-offs on the 
strength of the association with the disease: attributes, in fact, are added to the classifiers 
as long as their combined effect on the generalization ability increases. 
The effectiveness of BoNB was demonstrated by applying it to the WTCCC case-control 
study on Type 1 Diabetes: BoNB indeed outperforms two algorithms from the state of the 
art, namely a Naïve Bayes Classifier and HyperLASSO, in terms of classification 
performance and all the genetic biomarkers identified by BoNB are meaningful for Type 
1 Diabetes, thus confirming the good performance also in terms of precision of the 
selected biomarkers. 
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Chapter 3 
 
3 Modeling the combined effect of 
phenotype and treatment on the 
progression of diabetes 
complications 
 
Referring to the multi-level scheme of Figure 1.1, this chapter will focus on the combined 
effect of phenotype and treatment on the outcome, as shown in Figure 3.1. 
 
Figure 3.1: Modeling the effect of genotype, phenotype and treatment on the outcome. 
After a brief overview describing the most interesting models already developed in the 
literature to model the progression of diabetes complications, a new in-silico model, 
based on Dynamic Bayesian Networks and accounting for phenotypic information as well 
as information on treatment, will be presented. Validation of the model on the Diabetes 
Control and Complications Trial dataset will be then reported and discussed. Finally, the 
under development web interface as a decision support tool for clinicians will be 
presented.  
PHENOTYPE
TREATMENT
GENOTYPE OUTCOME
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3.1 Introduction 
In complex disease, such as diabetes mellitus, the development of complications and their 
impact on costs are difficult to assess through  short-term studies. Since long-term clinical 
trials are costly, time-consuming, and difficult to conduct, the use of computer-simulate 
disease models has increased considerably in recent years to facilitate the simultaneous 
evaluation of long-term clinical end economic effects of treatment [87],[71]. It is now 
widely accepted that models can provide valuable information for clinical practice and are 
important tools in medical, regulatory, governmental and public health decision-making 
[82],[90]]. 
For example an in-silico model of chronic disease can be used as a tool to simulate a 
clinical trial based on the available medical literature and publicly available data sources. 
Even in situations where a clinical trial does exist, models are often used to incorporate 
the benefits and costs beyond the time horizon of the trial or to consider all the available 
options simultaneously [71]. A good example of the former statement is the cost-
effectiveness analysis alongside the Scandinavian Simvastatin Survival Study [69], where 
the authors used a previous model of Coronary Heart Disease to project beyond the five-
year horizon of the study. An example of the latter statement is the supplement that 
strategies of annual  analysis of  fecal occult blood testing (FOBT) with five-year 
sigmoidoscopy, recommended by the American Cancer Society [60], could bring to an 
analysis of a clinical trial of annual FOBT versus no testing, such a s the Minnesota 
Colon Cancer Control Study [73] 
In-silico models of complex diseases are exploited to predict the evolution (i.e. the 
appearance of events or the persistence in a state devoid of severe complications) of an 
individual (or a population), providing a probability distribution for the individual (or the 
population) to develop a certain complication. 
The aims of complication models do not limit to predict time courses. It is of interest also 
evaluating possible variations of the quality of life during the lifetime that is predicted for 
a patient and the costs that the treatments that are administered to him require, since 
multiple treatments are often possible for the same disease [90]. The choice of the best 
strategy involves the evaluation of both clinical outcomes and costs of the different 
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available strategies. The formal process for comparing available alternative strategies is 
called decision analysis. 
The final aim of an in-silico model is to support decision analysis, helping clinicians in 
taking the best choice among the available ones [90]. 
The steps of constructing, evaluating and interpreting the model are done iteratively to 
give a progressive refinement. 
A requirement for diabetes simulation models has been identified in the medical and 
healthcare policy community, and, as a result, a number of models, mainly based on the 
Markov Models, have been developed and reported in the literature [79], [63], [74]. In the 
next section, a brief introduction on Markov Models and a rapid overview on the 
available models of diabetes complications will be presented. 
 
3.2 Markov Models 
As concerns mathematical aspects, the complication models of major importance are all 
composition of Markov models, each of them representing a complication. 
A Markov Model (MM), also called state transition model, is used to represent recursive 
events [85]. Discrete MMs enumerate a finite set of mutually exclusive possible states 
such that, in any given interval of time (called a cycle or stage), an individual member of 
the Markov cohort is in only one of the states. 
A Markov model is a stochastic model that assumes the Markov property, which is the 
following memoryless property: the state of the system at time instant t depends only on 
the state of the system at time instant t-1; in other words, it does not depend on previous 
time instants.  
A set of initial probabilities is used to specify the distribution of the cohort (group of 
individuals that is homogenous for a set of demographic and clinical aspects) among the 
possible states at the beginning of the process. A matrix of transition probabilities is used 
to specify the transitions among states.  
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In the original graphical representation of a MM (Figure 3.2), sometimes called “bubble 
diagram”, each state is represented using a circle while arrows represent transitions from 
a state to another one.  
A transition arrow pointing back to the state from which it originates indicates that it is 
possible for a cohort member to remain in the same state for more than one stage. The 
numbers along the arrows indicate the transition probabilities. The probabilities of the 
transition arrows emanating from any state must sum to 1. 
Each complication is represented by a Markov model similar to that in Figure 3.2: 
 
Figure 3.2: 3-state Markov model for a generic complication. Circles represent possible states, i.e. clinical 
conditions that can characterize a person. Arrows indicate possible transitions. 
 
The model of Figure 3.2 is characterized by 3 states: “No complication” representing 
diabetic people without any severe complication; “Complication” representing the people 
that reach the considered endpoint; “Dead” represents death caused by the complication.  
Therefore, Markov models allow representing the evolution over time of a diabetic 
population that is often simulated with time step of 1 year. The Markov models allow 
simulating over time the evolution of a cohort of patients in its mean behaviour and 
performing individual-level simulations. The first one is generally called expected-value 
simulation and is based on a deterministic approach, i.e. if the probability of transition 
no complication
complication dead
0.83
0.15
0.18
0.02
0.1
0.72 1
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from state “No Complication” to state “Complication” is p=0.03, then the 3% of patients 
in the former will transfer to the latter at next 1-year step of the simulation. On the 
opposite, the second is a stochastic simulation where the single in silico individual 
transfers only if the number provided by a random number generator is smaller than 
transition probability p. That is why this kind of simulation is also named Monte-Carlo.  
Obviously, also a high number of single in silico individuals can be considered and the 
results of these multiple simulations can be averaged. Theoretically, higher is the number 
of individual-level simulations, more similar are their average results to the expected-
value predictions. 
On the other hand, a high number of individual-level simulations allows quantifying the 
variability in model outcomes resulting very helpful to establish the reliability of average 
predictions and of the expected-value simulation. 
For instance, the evolution over time of an in silico population obtained with a toy-model 
is reported in Figure 3.3: 
 
Figure 3.3: Evolution over time of a diabetic population obtained with a toy, 3-state Markov model. 
 
Automatically, a survival curve can be obtained from these simulations: 
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Figure 3.4: Survival curve obtained from the simulations of 
 
Transition probabilities are estimated from the data collected during clinical trials. Wrong 
values of these probabilities mean wrong predictions; this is why the availability of high 
quantity of data, derived from homogenous cohorts, is critical.
Simulations do not limit to the predictions of events but extend to the time course of risk 
factors. When data are available, risk factors worsening is based on them, otherwise a 
gradual worsening is usually implemented.  This latter can be slowed by treatm
whose administration can be implemented in the software. Since treatments are 
characterized by a rate of failure, also this occurrence is sometimes inserted in the model 
together with the possibility to administer multiple and subsequent, distinct tr
The most interesting diabetes 
collected by clinical trials are the Palmer 
EAGLE model [74], which will be described in the following
Figure 3.3. 
 
complication models that were developed thanks to data 
model [79], the Eastman model 
. 
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51 
 
3.2.1 The Palmer model 
One of the most known complication models is the Palmer model (also called CORE 
model), which is based on multiple interconnected sub-models: one for each of the 
considered complications [79], [80], [81]. All the sub-models are Markov models 
characterized by 2, 3 or more states depending on the specific modeled complication. The 
dependences among events are generally expressed by changes in the worsening rate of 
risk factors or in the values of transition probabilities.  
The considered complications or endpoints are: myocardial infarction, angina, heart 
failure, stroke, peripheral vascular disease, neuropathy, foot ulcer, macular edema, 
cataract, limb amputation, blindness, microvascular complications (retinopathy, vitreous 
haemorrhage, nephropathy and renal failure), hypoglycemia, ketoacidosis, and lactic 
acidosis, to which add “surrogate endpoints”, i.e. stages of disease worsening that allowed 
monitoring precisely the evolution over time of neuropathy, orthostatic hypotension, 
impotence. 
Palmer model is also one of the most appreciated models since it is based on original data 
derived from the most recent databases. However, model predictions do not base only on 
these clinical database but on treatment and economics databases. The former stores data 
on treatment pathways, treatment effects and on the change in each physiological 
parameter in the simulation, as a consequence of treatment or patient management. The 
latter is used to perform economic analysis, i.e. to evaluate the cost of patient treatment 
(with and without complication) over the considered time period. In addition, the 
economics database allows evaluating the quality-adjusted life years, which briefly 
consist in life expectancy corrected for the quality of life. 
Palmer model allows simulating both the time evolution of a cohort of patients in its 
mean behavior and the individual-level simulation. 
As regards transition probabilities, they are derived from event rates registered during the 
clinical trials. However, probabilities can depend also on some risk factors [79]. 
3.2.2 The Eastman model 
As Palmer model, also the Eastman model is based on Markov type models and exploits a 
Monte-Carlo approach to simulate possible complication events in single in silico 
individuals [62], [63]. Again, as Palmer model, multiple sub-models are present, each one 
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for a single complication. Considered endpoints are: retinopathy, nephropathy, 
neuropathy and cardiovascular disease.  
A high number of the implementation principles characterizing this model were taken up 
by Palmer and the EAGLE modelers and this highlights the importance of the Eastman 
model in the history of complication model development. In particular, a methodology to 
estimate incidence rates, to be used as transition probabilities of the Markov models, from 
the cumulative incidence observed during the survey, was detailed. The presented 
reasoning that is based on the fit of an exponential model to collected data laid the 
fundamentals for the use of more complicate models exploited by the following modelers, 
like the Cox proportional model [86]. 
3.2.3 The EAGLE model 
The most recent model among the three reported here is the EAGLE model. It 
implements an object-oriented probabilistic Monte Carlo simulation, which is based on a 
Markov process with yearly intervals. Transition probabilities are dependent on the status 
of the simulated patient, with related calculations defined internally.  
Twenty outcomes (e.g., hypoglycemia, retinopathy, macular edema, end stage renal 
disease, neuropathy, diabetic foot syndrome, MI, and stroke) are projected based on data 
from epidemiological and clinical trials.  
The EAGLE model is capable of simulating the progression of type 1 and type 2 diabetes 
and this is the major difference with respect to previous models. In fact, the reader can 
find in this description the basic principles already enunciated for the older Eastman 
model. On the other hand, the model author’s made clear that the EAGLE was not 
developed on original data, but on a subset derived from previous people's publications. 
This is the main drawback of the model. 
A systematic comparison of Palmer, EAGLE and other models is detailed in [78]. 
3.3 Objective of the work 
As resulting from the overview presented in the previous section, models able to integrate 
accumulating –omics knowledge (metabolomics, proteomics, genomics) into a clinical 
macro-level for multifactorial diseases are still missing and, so far, the most interesting 
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complication models, developed from data collected by clinical trials, are based on 
Markov Models and use only phenotypic variables as features to describe the cohort of 
interest.  
The aim of the present work is to model the progression of diabetes vascular 
complications relying on the powerful framework of Dynamic Bayesian Networks 
(DBNs). DBNs provide a more flexible structure with respect to Markov Models, and 
allows to easily enlarge the model with additional information. This is why such a model 
will represents a solid base for future developments, such as the enrichment with 
genotypic information, as it will be discussed at the end of the chapter. 
 
3.4 Methods 
3.4.1 Bayesian Networks 
Bayesian networks are now being used in a variety of applications. The interest in general 
instruments able to compute posterior probability distributions has been quite high in the 
Bioengineering and Biomedical Informatics community. As a matter of fact, DBNs allow 
dealing with a variety of crucial problems in biomedicine, ranging from classification to 
prediction, and from simulation to parameter estimation. Recently, Bayesian network 
approaches were successfully employed in the context of genome biology and in 
biomedical research [64]. One of the most common application is diagnosis problems, as 
in case of medical diagnosis. An example is PATHFINDER [67], a program to diagnose 
diseases of the lymph node by means of Bayesian network approach. 
A Bayesian Network (BN) is a probabilistic graphical model that represents conditional 
dependence over a set of random variables in a compact and human-readable form. 
Probabilistic graphical model possess two important characteristics: i) they clearly 
express the conditional independence between the variables, thus allowing an intuitive but 
sound way to describe the assumptions underlying the modeling process; ii) they 
associate to the graph a probabilistic model that can be used for performing inference, and, 
thus, estimation, simulation and prediction [68]. 
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A Bayesian Network is completely determined by a Directed Acyclic Graph (DAG), 
known also as the network structure, and by a set of conditional probability distributions: 
each node of the network corresponds to a random variable and each edge corresponds to 
a probabilistic dependence between the two nodes (the terms node and random variable 
are used as synonyms).  
More precisely, a Bayesian Network represents a joint probability distribution between its 
nodes for which the Markov condition holds: any node in a Bayesian Network is 
conditionally independent of its non-descendants, given its parents. 
The Markov condition implies that the joint probability distribution of the nodes can be 
decomposed as 
 ', … , 	 = ~ 'jk'W6l.  (3.1)   
Where PaX denotes the set of parents of X: whenever we have an edge  → i, we say 
that Xj is a child of Xi and that Xi is a parent of Xj. 
The decomposition of equation (3.1) is called chain rule for Bayesian Networks and 
allows a more compact representation of the full joint probability distribution, requiring 
fewer parameters to be completely specified: the probability distribution of each node can 
in fact be expressed simply as a function of the states of its parent nodes. 
Figure 3.5 reports an example of discrete Bayesian Network with 4 nodes, modeling the 
hypothetical probabilistic relations between the variables HighFatDiet (HFD), 
GlucoseTolerance (GT), Obesity (OB) and RiskOfCardiovascularDisease (CVD). As it is 
clear from the figure, the probability distribution of each node is expressed as a function 
of all possible combination of values of its parents, in the form of a conditional 
probability table (CPT). A natural application of this network is to use it as instrument to 
compute posterior probability distributions, i.e. the posterior probability of any of the 
problem variables given knowledge about any of the other variables of the problem. This 
theme is called inference. For example, such a network can be used to answer queries 
like: “What is the probability of being obese, if on a high fat diet?”, “What is the 
probability of having impaired glucose tolerance, if at risk of cardiovascular disease?”, “If 
obese and on a high fat diet, what is the probability of being at risk of cardiovascular 
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disease?”. Moreover, the Markov condition can be used to infer conditional independence 
relations from the network. For example, we can infer from the network structure that, 
once the values of GlucoseTolerance and Obesity are known, 
RiskOfCardiovascularDisease becomes independent of HighFatDiet. 
 
 
Figure 3.5: Example of a simple Bayesian Network with 4 discrete variables, representing the interactions 
between High Fat Diet (HFD), Glucose Tolerance (GT), Obesity (OB) and Cardio Vascular Disease (CVD). 
 
The example in Figure 3.5 is a BN with discrete variables, i.e. variables with a finite 
number of possible values. Conditional distributions in discrete variable BNs can be 
conveniently represented with probability tables and are able to model dependencies 
between variables without making any assumption on the underlying relationship (e.g. 
linearity). Many real-world variables are of a continuous nature (e.g. blood glucose 
concentration or gene expression levels). In these cases, a possible solution is to discretize 
these variables and resort to discrete BNs. In some cases, though, discretization would 
lead to a major loss of information, unless a high number of discrete states is employed, 
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which would significantly increase model complexity. The other solution is to employ 
continuous-variable BNs. The general BN framework so far presented holds for both 
discrete and continuous variables, as long as the conditional distribution '|'W	 
assigned to each node represents for each possible value -W of 'W a distribution over X. 
When all variables in the network are continuous, the most commonly employed 
distribution is a linear Gaussian distribution model. Given the continuous variable Y with 
continuous parents X1, …, Xk, the probability density of Y as a function of its parents is: 
 
'I|A, … , Af	 = >? + >A + ⋯ + >fAf; 
	 (3.2)  
This simple model can be extended to cases in which the mean of Y depends on its 
parents in a nonlinear way, or in which the variance also depends on the parent values. 
Hybrid models are also possible, which incorporate both discrete and continuous 
variables. 
Both the graphical structure of a BN and the parameters of the conditional probability 
distributions can be learned from the available data. However, learning these networks is 
often non-trivial due to the high number of variables to be taken into account in the model, 
with respect to the instances of the dataset. 
Structure learning of a BN is NP-complete problem in the general case: given a dataset , 
containing multiple samples of a set of random variables, the objective is to find the best, 
or the most probable, BN structure in the exponential space of all possible structures. 
Several scoring functions have been proposed to assess the quality of a BN structure: 
some of the most notable are the Akaike Information Criterion (AIC), the Bayesian 
Information Criterion (BIC) and the Bayesian Dirichlet equivalent (BDe) [67]. Regarding 
the learning approaches, from the vast literature, three main approaches can be identified 
to BN structure learning: greedy search, complete search and search based on 
independence tests. Briefly, greedy search attempts to construct a BN structure starting 
with a network without any edge and iteratively adding the “best” set of parents to each 
node, according to a local score; complete search, conversely, explores the entire space of 
possible networks and is guaranteed to return an optimal network, but the huge memory 
and time requirements limit its application to small sized networks; approaches based on 
independence tests start with a complete network and aim at forbidding as many edges as 
possible, by assessing conditional independence between variables with statistical tests. 
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In the present work, an approach based on independence tests evaluated by a Bayesian 
Dirichlet equivalent with uniform priors (BDeu), has been adopted, as described in 
section 3.4.5.3. 
3.4.2 Dynamic Bayesian Networks 
Being interested in modeling the history of diabetic patients, the dynamics of the disease 
will be explicitly modeled by relying on Dynamic Bayesian Networks (DBNs). 
DBNs are an extension of BNs that represent the temporal evolution of variables over 
time. Nodes in the directed acyclic graph associated with a DBN continue to represent 
random variables, while edges represent temporal dependencies. The key assumption is 
that the probability distributions describing the temporal dependencies are time invariant 
so that the overall temporal evolution of the analyzed process can be entirely 
reconstructed by knowing the temporal dependencies represented in the DBN graph [83]. 
Figure 3.6 shows an example of DBN describing the evolution of the expression values of 
three genes G1, G2, and G3. The graph shows that the expression value of each gene at 
time (t + 1) is assumed to depend on the gene’s expression at time t as well as on the 
expression of one or two of the other genes. Furthermore, the example shows that the 
temporal dimension of DBNs allows encoding feedback regulation such as the one 
occurring between G1 and G2, which is not possible in static BNs because of the required 
acyclicity of the graph. The example in the Figure is a DBN of order 1, as all temporal 
dependencies occur between consecutive time points; yet DBNs are not restrict to 
dependencies of order 1 but can represent also higher order dependencies. 
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Figure 3.6: Example of a Dynamic Bayesian Network for three genes G1, G2 and G3. 
DBNs are advantageous with respect to MMs since each variable is represented by one 
node, whereas MMs require as many nodes as the number of combinations of variable 
values [75], [92]. Thus, extending the DBN model with the addition of new variables just 
requires adding as many nodes.  
3.4.3 Model general structure 
The general scheme of a DBN for modeling the dynamics of a complex disease such as 
diabetes is represented in Figure 3.7. 
In the scheme of Figure 3.7, the input variables are called covariates (referred to as U), 
while the output variables are called outcomes (referred to as Y). In particular, the time 
depending covariates are called dynamic (referred to as Udyn), while the remaining 
covariates are called static (referred to as Ustat), since they are not time dependent. To be 
precise, static variables are either constant or time varying, but their variation across time 
is completely predictable (e.g. age, which deterministically increases of 1 year every time 
step). All the outcomes are time-dependent. 
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Figure 3.7: General scheme of a Dynamic Bayesian Network for the dynamics of a multifactorial disease 
The dependences between variables can be summarized as follows: 
• Each dynamic covariate at time t can depend on each other dynamic covariate at time 
t-1  and on each static covariate; 
• Each outcome at time t can depend on each other outcome a time t-1, on each 
dynamic covariate at time t-1 and on each static covariate. 
This network represents the a priori structure of the model. 
The specific structure of the model, i.e. the set of variables used as nodes of the network 
and edges representing their conditional probabilities, depends on the  information 
contained in the available data, and will be presented in section 3.5. 
3.4.4 Data 
3.4.4.1 Datasets 
Databases collecting data over more than ten years allow estimating the event rates that 
are basic for the development of complication models. Therefore datasets represent the 
fundamental starting point for any predictive model. Three of them, i.e. the Framingham 
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Heart Study database, the Diabetes Control and Complications Trial (DCCT) database, 
and the UK Prospective Diabetes Study (UKPDS) resulted particularly important for the 
field [61], [89] and have been used to implement predictive models described in the 
previous section.  
The Framingham Heart Study is a cornerstone of epidemiological studies and, after more 
than 50 years from its beginning, it remains the most famous and influential investigation 
in cardiovascular disease epidemiology. Nowadays, it is considered the epitome of a 
successful epidemiological research, productive of insights and applications and the 
prototype of the cohort study [77]. 
The DCCT was a multicenter, randomized clinical trial designed to compare intensive 
with conventional diabetes therapy with regard to their effects on the development and 
progression of the early vascular and neurologic complications of insulin-dependent 
diabetes mellitus [61]. 
Similarly, the UKPDS was designed to establish whether, in patients with type 2 diabetes, 
intensive blood-glucose control reduced the risk of macrovascular or microvascular 
complications, and whether any particular therapy was advantageous [89]. 
The three databases differed for many aspects, among which the pathologies of interests, 
the surveyed patients, and the duration of the study. However, all of them allowed 
establishing the importance of some clinical factors for the development of 
micro/macrovascular complications in the long period, discarding others.  In particular, 
the Framingham Study was the first one to suggest a relationship between diabetes and 
cardiovascular diseases, on the basis of statistical evaluations, laying the foundations for 
the subsequent two trials, more focused on diabetes. 
Most of all, they share the approach that is based on a survey of the population of interest 
along time, periodical measurements of factors of clinical interest (systolic blood pressure, 
plasma insulin...), which are usually called “risk factors”, and on the effort of relating 
these latter with the observed incidence of micro/macrovascular events. That is why all of 
them were followed by predictive models of complications, which were developed on 
collected data. 
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A forth database that is often used for the implementation of complication models is the 
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), which can provide 
additional  information for the specific complication retinopathy [70]. Both Type I and 
Type II diabetes were considered in the survey allowing accomplishing two parallel 
studies.  
With the objective to model the progression of diabetes complications modeling the 
combined effect of phenotype and treatment (and the future prospect of use genotypic 
information too), data needed to learn the model have to satisfy some precise 
requirements: 
- the number of patients composing the cohort has to assure a robust learning; 
- the dataset has to contain information about the main diabetic complications and the 
correlated events, as well as information on phenotypic variables and the main 
treatments; 
- data have to be collected through a longitudinal study over a period of medium-long 
duration (e.g., ten years); 
- the dataset has to contain also genetic information, in particular SNP data. 
Among the available dataset previously described, only the DCCT satisfies all these 
requirements. 
The next section provides a brief description of the DCCT dataset, mainly focused on the 
relevant characteristics for building the prediction model. 
3.4.4.2 DCCT/EDIC description 
The Diabetes Control and Complications Trial (DCCT, 1982-93) and the Epidemiology 
of Diabetes Interventions and Complications  (EDIC,  1994-2006) follow-up study have 
been ongoing for more than twenty years [61]. The clinical trial and subsequent follow-up 
have provided the scientific community with invaluable information regarding the effect 
of glycemia and glycemic control on long-term diabetes complications.  
The DCCT studied a cohort of 1,441 subjects between 13 and 39 years old which had 
suffered type 1 diabetes mellitus (T1DM) for 1-15 years at the time of recruitment. All 
participants were relatively healthy except for diabetes and were free of severe diabetes-
related complications. The Primary Prevention cohort consisted of 726 subjects with 
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T1DM for 1-5 years and no diabetes related complications (no microaneurysms on fundus 
photography and urine albumin excretion <40 mg/day). The Secondary Intervention 
Cohort consisted of 715 subjects with T1DM for 1-15 years and mild to moderate non-
proliferative retinopathy and a urinary albumin excretion rate <200 mg/day. Subjects 
were randomized to conventional (CT) or intensive diabetes therapy (IT) (Figure 3.8). 
The intent of IT was to achieve blood glucose levels of 70-120 mg/dL in the morning and 
before meals, <180 mg/dL after meals, and an HbA1c in the non-diabetic range (<6.05%). 
Although it was not feasible to achieve these glycemic targets consistently in the majority 
of the subjects assigned to the IT group (fewer than 5% maintained an average HbA1c 
<6.05%), there was a substantial difference in glycemic control between the IT and the 
CT groups. The CT group maintained an average HbA1c of about 9.0% (similar to their 
baseline value) throughout the 3-9 (mean 6.5) years of follow-up. Those in the IT group 
lowered their HbA1c to about 7.0% and maintained this for the duration of the study 
(Figure 3.9).  
Following the end of the DCCT in 1993, and a transitional period during which the 
conventional treatment group was taught intensive therapy and the clinical care of all of 
the subjects was transferred to their own health care providers, an observational study of 
the DCCT cohort, entitled Epidemiology of Diabetes Interventions and Complications, 
was launched. The goal of the EDIC follow-up was to examine the longer term effects of 
the original DCCT interventions, especially concerning complications, such as 
cardiovascular disease and more advanced stages of retinal and renal disease, that require 
a longer period of time to develop. During the transition from the DCCT clinical trial to 
the EDIC observational study, the average difference in glycemic control, measured by 
HbA1c, that had been approximately 2% during the DCCT (7.2% in the intensive 
treatment group compared with 9.1% in the conventional treatment group) narrowed 
(7.9% vs. 8.1% in IT and CT groups, respectively). The difference in mean HbA1c 
between the two original treatment groups has become statistically indistinguishable 
during the most recent six years of EDIC follow-up. (Figure 3.9) Phase 1 of the EDIC 
follow-up study spanned twelve years. The total mean follow-up of the original cohort 
was approximately 16 (range 13-20) years. Retention of the DCCT cohort remained 
outstanding: 96% of the surviving DCCT cohort joined EDIC in 1994 and 94% of the 
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original cohort (n= 1357 of 1441) remained active throughout the first phase of EDIC 
(Figure 3.9) 
 
Figure 3.8: number of patients for therapy during DCCT and EDIC studies. the notations “Conventional” and 
“Intensive” referred to EDIC, have to be meant as “EDIC patients who were treated with Conventional 
therapy during DCCT” and “EDIC patients who were treated with Intensive therapy during DCCT”. 
 
 
Figure 3.9: Glycemic Levels during DCCT/EDIC as measured by glycosylated hemoglobin (HbA1c). Medians 
with 25th to 75th percentiles shown. 
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3.4.4.3 Data analysis and preprocessing 
Data from both DCCT and EDIC studies were used, thus having the possibility to train 
the model on a longer time period. Since the 1441 patients entered the DCCT in different 
years (thus having different follow-up time periods), for each patient the number of 
DCCT-years was computed by comparing the individual date of DCCT enrolling and 
DCCT close-out. For each patient, individual EDIC data were then appended at the end of 
the last DCCT year, as shown in Figure 3.10. 
The computed mean follow-up period was 15.3 years. 
Considering the set of the measures of all the variables for a single patient on a single 
year as an instance of the dataset, that instances for which all the dynamic covariates were 
missing have been discarded, in order to reduce the missingness of the dataset and thus 
avoidind the need for massive imputation. Thus, the number of available (or valid) years 
for each patient was computed. The mean value for the number of available years was 15.  
 
Figure 3.10: For each patient, EDIC data were appended at the end of the DCCT data. The resulting mean 
follow-up period was 15.3 years. 
 
Relaying on previous literature works (see section 3.2) and on data availability in the 
DCCT/EDCI dataset, the following variables were used as covariates for the DBN model: 
Static Covariates 
This group includes both actually static variables, such as patient gender, and variables 
that vary in time but in a completely predictable way (e.g. age) or dependent by external  
decisions (e.g. treatment). 
DCCTdata1 EDICdata1
DCCTdata2 EDICdata2
DCCTdata3 EDICdata3
DCCTdatai EDICdatai
DCCTdataN EDICdataN
pat 1
pat 2
pat 3
pat i
pat N
…
…
…
…
time (years)
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1. SEX: 
Patient’s gender, assuming 2 possible discrete values: Male and Female 
2. AGE: 
Patient’s age in years 
3. DURATION: 
Number of years since diabetes was first diagnosed 
4. TREATMENT: 
Annual treatment received by the patient. This variable represents the type of 
treatment the patient received during the year ending with the current visit, and it can 
assume 3 possible discrete values: Conventional treatment, Intensive self-treatment 
(i.e. intensive treatment managed by the patient himself) or Intensive forced treatment 
(i.e. intensive treatment managed by clinicians). Treatment received during the DCCT 
period belongs to the Intensive forced treatment class, while treatment during the 
EDIC period belongs to the Intensive self-treatment class. This variable is considered 
an “intervention variable”, i.e. an independent variable that is known to influence 
Glycosylated Hemoglobin (HbA1C) value and thus is forced to contain this link in the 
DBN. 
5. THERAPY: 
Number of years of diabetes not treated with intensive therapy, either forced or self-
treatment. This variable initially represented the number of years of intensive therapy. 
Then, it was converted into a more informative variable, accounting for the total 
number of years of diabetes not treated with intensive therapy. The variable was 
computed combining information from the original variable THERPAY and the 
variable DURATION 
6. SMOKE: 
Patient’s smoking status, assuming 2 possible discrete values: Never smoked or Ever 
Smoked. The variable was initially a dynamic covariate, assuming 3 possible values 
according to the DCCT/EDIC codification: Smoker (if the patient was actually 
smoking at the visit time), Non Smoker (if the patient never smoked or quit smoking 
more than 3 months before the visit time), Former Smoker (if the patient had smoked 
but quit less than 3 months before the visit time). Since there’s little difference 
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between the states Smoker and Former Smoker from a clinical point of view, this 
latter status was incorporated by the former. Given the high missingness throughout 
the study, the variable was then converted into a static covariate, computed as the 
mode of the available values for each patient, thus giving 2 possible states: Never 
Smoked or Ever Smoked 
7. EXERCISE: 
Patient’s physical activity level, assuming 3 possible values: Sedentary, Moderate and 
Vigorous. This variable was initially a dynamic covariate, assuming 4 possible values 
according to the DCCT codification and 3 possible values according to the EDIC 
codification: Sedentary (less than 5 hours of moderate activity per week), Moderate 
(more than 5 hours of moderate activity per week), Vigorous (more than 8 hour of 
hard activity per week) and Strenuous ( more than 5 hours of very hard activity per 
week) in the DCCT dataset, and Sedentary (occasional physical activity), Moderate 
(considerable, but not constant, physical activity) and Strenuous (constant physical 
activity) in the EDIC dataset. In order to have uniform information, the third status of 
DCCT codification (Vigorous) was incorporated with the last one, thus giving the 
single state Strenuous, as in the EDIC dataset. A correspondence between 
homonymous states in the DCCT and EDIC codifications was then assumed. Given 
the high missingness throughout the study, the variable was then converted into a 
static covariate, computed as the mode of the available values for each patient. 
Dynamic Covariates 
8. WHR: 
Waist circumference to hip circumference ratio; information on WHR in the DCCT 
was available only at the screen visit, while annual measurements were available in 
the EDIC. This variable was thus imputed, for each patient, by performing a linear 
interpolation of the available values, thus obtaining the WHR time-course within the 
study. 
9. HBA1C: 
Glycosylated Hemoglobin (HbA1C) value, expressed as percentage of the total 
hemoglobin. HbA1C is strictly connected to diabetes mellitus, since it is a form of 
hemoglobin that is correlated to the average plasma glucose concentration over 
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prolonged periods of time, thus serving as a marker for average glycemic values. In 
diabetes mellitus, high levels for glycosylated hemoglobin indicate a poor control of 
blood glucose levels, and have been associated with cardiovascular disease, 
nephropathy, and retinopathy [72]; 
10. SBP: 
Systolic Blood Pressure, expressed in millimeters of mercury (mmHg); 
11. TRIG: 
Triglycerides value, expressed in mg/dl. 
12. LDL: 
Low-Density Lipoproteins value, expressed in mg/dl 
13. HDL: 
High-Density Lipoproteins value, expressed in mg/dl. 
Since measures of TRIG, LDL and HDL were available every 2 years in EDIC, we 
decided to impute isolated missing values (i.e. missing values placed between two 
valid measures at the previous and the following year) with a linear interpolation of 
the 2 adjacent measures, as reported in the example of Figure 3.11; 
14. BMI: 
Body Mass Index, given by mass/height2 and thus expressed in Kg/m2. 
 
Figure 3.11: Example of imputation for the covariate TRIG for the i-th patient. Missing values (in gray) 
placed between two valid measures (in yellow) are replaced by a linear interpolation (in green). Discarded 
measures (in black) were not used for imputation. 
TRIGi
TRIGi
EDIC year
1 2 3 4 5 6 7 8 9
measure missing discarded imputed
Before linear
interpolation
After linear
interpolation
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Table 3.1 reports the final list of the variables used as covariates for the model. 
Variable name Variable Description Covariate Type 
Variable 
Nature 
Unit of measure / 
Possible States 
SEX Patient’s gender Static Discrete M/F 
AGE Patient’s age Static Continuous years 
DURATION Patient’s duration of diabetes Static Continuous years 
TREATMENT Annual treatment Static Discrete 
CONVENTIONAL/ 
INTENSIVE-SELF/ 
INTENSIVE-FORCED 
THERAPY 
Total number of years 
of diabetes not treated 
with intensive therapy 
Static Continuous years 
SMOKE smoking status Static Discrete NEVER/EVER 
EXERCISE physical activity status Static Discrete SEDENTARY/MODERATE/STRENUOUS 
WHR Waist-Hip Ratio Dynamic Continuous Unit-less 
HBA1C Glycosylated Hemoglobin  value Dynamic Continuous % 
SBP Systolic blood Pressure value Dynamic Continuous mm Hg 
LDL Low-Density Lipoproteins value Dynamic Continuous mg/dl 
HDL High-Density Lipoproteins value Dynamic Continuous mg/dl 
TRIG Triglycerides value Dynamic Continuous mg/dl 
BMI Body-Mass Index 
value Dynamic Continuous Kg/m
2
 
Table 3.1: Variables used for the DBN model of diabetes complications. 
 
Since the DBN wants to model the transition from a year to the following, a variable is 
needed to have a valid measure both at time t and at time t+1. Thus, a variable was 
considered to have a non-missing value only if it had a valid measure both at year t and at 
year t+1. Missingness for each covariate c, for each couple of consecutive years yy, was 
computed as the rate of the number of patients with a missing measure for covariate c to 
the total number of available patients for the couple of consecutive years yy. The resulting 
percentages of missingness for the model’s covariates are reported in Table 3.2, together 
with the number of valid patient for each couple of consecutive years. Covariates with no 
missing values are not reported in the Table. 
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% missing WHR HBA1C SBP LDL HDL TRIG BMI # valid patients 
year 1-2 3.96 0.28 0.07 0.14 0.00 0.07 0.07 1439 
year 2-3 3.77 0.42 0.14 0.07 0.07 0.07 0.00 1433 
year 3-4 3.51 0.77 0.28 0.00 0.00 0.00 0.07 1426 
year 4-5 3.18 0.64 2.05 0.35 0.35 0.35 0.07 1417 
year 5-6 2.93 1.29 5.00 1.50 1.50 1.50 0.71 1400 
year 6-7 2.49 1.54 6.44 1.61 1.24 1.24 1.54 1366 
year 7-8 2.32 0.97 5.62 3.00 2.55 2.55 3.00 1335 
year 8-9 1.99 1.15 3.51 2.29 1.76 1.76 3.28 1309 
year 9-10 1.00 1.61 2.07 5.74 4.98 4.98 3.14 1306 
year 10-11 0.78 1.41 1.41 3.53 2.59 2.59 4.00 1274 
year 11-12 0.56 1.11 1.43 4.05 3.18 3.18 4.53 1259 
year 12-13 0.00 0.95 1.75 4.44 3.33 3.33 4.68 1260 
year 13-14 0.00 0.82 1.80 16.99 15.60 15.60 5.07 1224 
year 14-15 0.00 0.99 2.17 13.69 12.22 12.22 5.02 1015 
year 15-16 0.00 0.58 0.86 30.22 29.06 29.06 3.02 695 
year 16-17 0.00 1.77 0.51 15.40 13.89 13.89 2.27 396 
year 17-18 0.00 1.61 1.20 6.02 4.02 4.02 3.21 249 
year 18-19 0.00 3.36 1.68 60.92 59.66 59.66 6.72 238 
Table 3.2: Missingness throughout the DCCT-EDIC dataset. 
Analyzing Table 3.2, we decided to use the first 15 years of the data, for which the 
missingness level is always lower than 20%. 
Outcomes 
As reported in section 1.1, the main diabetic vascular complications are cardiovascular 
disease, nephropathy and retinopathy. Since there was no uniformity of information 
between retinopathy status in DCCT and retinopathy status in EDIC, only cardiovascular 
disease and nephropathy were considered as outcomes for the model. As illustrated in 
section 3.2, each complication can be modeled by a state transition model, allowing 
representing the evolution over time of the patients. 
1. CARDIOVASCULAR DISEASE (CVD): 
According to the DCCT design and protocols, the following cardiovascular episodes 
were recorded during the study: Myocardial Infarction, Angina Pectoris, Heart Failure, 
Stroke (or Cerebro-Vascular Accident) and Coronary Artery Disease. Only 64 CVD 
episodes occurred during the entire DCCT/EDIC study, involving 42 patients. Given 
this small number, the CVD status of a patient was modeled as a discrete outcome 
with 2 possible values, as reported in Table 3.3. The possible states transitions are 
reported in the scheme of Figure 3.12: once a patient suffers a CVD episode, he is 
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considered a patient at CVD risk, thus having no possibility to come back to the 
control condition. 
CVD 
STATUS Description 
1: Control no CVD episodes 
2: CVD any CVD episode 
Table 3.3: Possible values for the CVD status. 
 
 
Figure 3.12: Possible states transitions for CVD. 
2. NEPHROPATHY: 
According to the DCCT design and protocols, the nephropathy status was computed 
combining the values of 2 clinical variables, respectively Albumin Excretion Rate 
(AER) expressed in mg/day, and Creatinine Clearance (CR-CL) expressed in 
ml/min/1.73m2, and coded in 6 levels of increasing severity, as shown in Table 3.4. 
DCCT nephropathy 
severity level 
AER 
(mg/day) 
CR-CL 
(ml/min/1.73m2) 
1 < 40  
2 [40, 100)  
3 [100,200)  
4 [200, 300)  
5 ≥ 300 ≥ 70 
6 ≥ 300 < 70 
Table 3.4: Nephropathy severity levels according DCCT criteria. 
Following the guidelines for the outcomes codification defined within the SUMMIT 
project by SAIL (Sample AILability system), the nephropathy status of a patient was 
modeled as a discrete outcome with 4 possible values, combining information on the 
patient’s Albumniuria status and End-Stage Renal Disease (ESRD) status, as reported 
in Table 3.5. Both the individual Albuminuria status and ESRD status are coded 
according to the variable codification defined by SAIL and reported in Table 3.6. The 
Control CVD
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Albuminuria status is computed on the basis of the Albumin Excretion Rate value (in 
mg/day). The ESRD status is computed on the basis of estimated Glomerular 
Filtration Rate (eGFR) value (expressed in mg/min) or on the basis of episodes of 
renal insufficiency (dialysis or kidney transplantation). 
The possible states transitions are reported in the scheme of Figure 3.13: any 
transition is allowed, except for any backward step from the last status, which 
represents a clinical condition in which kidney is no longer able to perform its 
function. 
NEPHROPATY 
STATUS Description 
1: Control NormoAlbuminuria 
and no ESRD episodes 
2: microAlbuminuria microAlbuminuria 
and no ESRD episodes 
3: macroAlbuminuria macroAlbuminuria 
and no ESRD episodes 
4: ESRD any ESRD episode 
Table 3.5: Possible values for the Nephropathy status. 
 
Albuminuria status AER (mg/day) 
Control < 30 
MicroAlbuminuria [30, 300) 
MacroAlbuminuria ≥ 300 
ESRD status eGFR (mg/min) 
Control > 15 
ESRD ≤ 15, or episode of renal insufficiency (kidney transplant or dialysis) 
Table 3.6: Albuminuria and ESRD status according to the SAIL definitions. 
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Figure 3.13: Possible states transitions for Nephropathy. 
Table 3.7 lists the number of patients in each status of Diabetic Nephropathy for 
each year of the study, according to codification reported in Table 3.5. 
Nephropathy numbers 
in the DCCT/EDIC dataset 
Year # Controls # Micro # Macro # ESRD 
1 1284 157 0 0 
2 1292 140 6 0 
3 1253 173 7 0 
4 1244 165 16 0 
5 1240 157 21 1 
6 1216 157 25 1 
7 1171 166 32 0 
8 1133 171 35 1 
9 1122 166 33 3 
10 1088 194 35 4 
11 1072 171 39 6 
12 1055 176 51 5 
13 996 179 58 8 
14 946 174 62 12 
15 631 117 48 13 
16 464 87 32 12 
17 222 58 15 8 
18 173 35 18 7 
19 100 19 12 4 
Table 3.7: Number of patients for each state of Diabetic Nephropathy throughout the DCCT/EDIC study. 
 
 
 
Control micro macro ESRD
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3.4.5 Learning 
3.4.5.1 Split TRAIN/TEST 
In order to train and further test the model, the entire dataset was partitioned into 2 
subsets of subjects to be used, respectively, as training set, on which learn the model, and 
as test set, on which test the model. The split train/test was performed stratifying patients 
by the following 3 variables: age, sex and treatment. The TRAIN:TEST proportion is 9:1 
(1298 subjects in the training set and 143 in the test set). 
Missingness is uniformly distributed between the training and the test set, exhibiting 
similar percentages to the ones computed for the entire dataset (see Table 3.8 and Table 
3.9 compared to Table 3.2). 
The proportion 9:1 was respected also in the number of patients which suffered CVDs 
episodes (37 in the training set and 5 in the test set) and renal insufficiency episodes (21 
in the training set and 3 in the test set). 
 
% missing 
TRAIN 
WHR HBA1C SBP LDL HDL TRIG BMI # valid patients 
year 1-2 4.01 0.23 0.08 0.15 0.00 0.08 0.08 1296 
year 2-3 3.80 0.31 0.08 0.08 0.08 0.08 0.00 1290 
year 3-4 3.50 0.70 0.23 0.00 0.00 0.00 0.08 1284 
year 4-5 3.14 0.63 2.20 0.31 0.31 0.31 0.08 1275 
year 5-6 2.86 1.19 5.32 1.59 1.59 1.59 0.79 1259 
year 6-7 2.44 1.39 6.76 1.63 1.22 1.22 1.63 1227 
year 7-8 2.25 0.92 5.76 3.09 2.59 2.59 3.17 1198 
year 8-9 1.95 1.19 3.48 2.21 1.61 1.61 3.48 1177 
year 9-10 1.02 1.70 1.96 5.79 4.94 4.94 3.15 1175 
year 10-11 0.87 1.48 1.40 3.67 2.71 2.71 4.28 1145 
year 11-12 0.62 1.24 1.50 3.98 3.10 3.10 4.78 1130 
year 12-13 0.00 1.06 1.95 4.69 3.54 3.54 4.77 1131 
year 13-14 0.00 0.91 2.01 17.50 16.13 16.13 5.29 1097 
year 14-15 0.00 1.10 2.20 13.86 12.32 12.32 5.39 909 
year 15-16 0.00 0.49 0.81 30.26 29.13 29.13 3.24 618 
year 16-17 0.00 1.70 0.57 15.01 13.60 13.60 2.55 353 
year 17-18 0.00 1.79 1.34 6.25 4.02 4.02 2.68 224 
year 18-19 0.00 3.72 1.86 62.33 60.93 60.93 6.51 215 
Table 3.8: Missingness throughout the training set. 
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% missing 
TEST 
WHR HBA1C SBP LDL HDL TRIG BMI # valid patients 
year 1-2 3.50 0.70 0.00 0.00 0.00 0.00 0.00 143 
year 2-3 3.50 1.40 0.70 0.00 0.00 0.00 0.00 143 
year 3-4 3.52 1.41 0.70 0.00 0.00 0.00 0.00 142 
year 4-5 3.52 0.70 0.70 0.70 0.70 0.70 0.00 142 
year 5-6 3.55 2.13 2.13 0.71 0.71 0.71 0.00 141 
year 6-7 2.88 2.88 3.60 1.44 1.44 1.44 0.72 139 
year 7-8 2.92 1.46 4.38 2.19 2.19 2.19 1.46 137 
year 8-9 2.27 0.76 3.79 3.03 3.03 3.03 1.52 132 
year 9-10 0.76 0.76 3.05 5.34 5.34 5.34 3.05 131 
year 10-11 0.00 0.78 1.55 2.33 1.55 1.55 1.55 129 
year 11-12 0.00 0.00 0.78 4.65 3.88 3.88 2.33 129 
year 12-13 0.00 0.00 0.00 2.33 1.55 1.55 3.88 129 
year 13-14 0.00 0.00 0.00 12.60 11.02 11.02 3.15 127 
year 14-15 0.00 0.00 1.89 12.26 11.32 11.32 1.89 106 
year 15-16 0.00 1.30 1.30 29.87 28.57 28.57 1.30 77 
year 16-17 0.00 2.33 0.00 18.60 16.28 16.28 0.00 43 
year 17-18 0.00 0.00 0.00 4.00 4.00 4.00 8.00 25 
year 18-19 0.00 0.00 0.00 47.83 47.83 47.83 8.70 23 
Table 3.9: Missingness throughout the test set. 
 
3.4.5.2 Discretization of continuous covariates 
Dealing with both discrete and continuous variables, an hybrid DBN could appear the 
most appropriate choice. However, since modeling an hybrid DBN requires specific 
assumptions on the distribution of continuous variables, a discrete DBN was adopted. 
Thus, each continuous variable was discretized using specific cut-offs and the whole 
model was fully specified by a set of Conditional Probability Tables (CPTs). Variables 
WHR, SBP, LDL, HDL, TRIG and BMI were discretized according to literature cut-offs 
reported in Table 3.10. 
Variable Cut-offs Number of cut-
offs 
Number of 
states 
Reference 
WHR 0.9 (men) and 0.85 (women) 1 2 [76] 
SBP 120 mmHg and 140 mmHg 2 3 [59] 
LDL 100 mg/dl 1 2 [84] 
HDL 
40 mg/dl (men) and 50 mg/dl 
(women) 1 2 [84] 
TRIG 150 mg/dl 1 2 [84] 
BMI 20 Kg/m2 and 25 Kg/m2 2 3 [91] 
Table 3.10: Literature cut-offs used for continuous variables. 
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Since there are no literature guidelines concerning cut-offs for the age, the duration of the 
disease and the number of years of diabetes not treated with intensive therapy, a search 
strategy to identify the optimal cut-off values while learning the DBN structure was 
defined, and it will be described in the next section. The same cut-off search strategy was 
applied to HbA1c, being it the direct intervention target of the DCCT and EDIC studies.   
3.4.5.3 Structure and cut-offs learning 
The DBN here implemented aimed to merge the data-driven information with literature 
knowledge. Therefore, the DBN structure was learned directly from data, but 
incorporating some constraints derived from the literature both in the network structure 
(i.e. allowing only certain edges to be learned, as detailed in the following) and in 
discretization cut-offs, as explained in the previous section (see Table 3.10). 
Nodes of the DBN can be classified into four classes, each of them with specific edge 
constraints: 
• Static Nodes: 
Each static covariate (see section 3.4.4.3) is represented by a static node (St) in the 
network (except for the covariate TREATMENT, which will discussed later). Thus, the 
static nodes are: SEX, AGE, DURATION, THERAPY, SMOKE and EXERCISE. These 
nodes cannot be influenced by other nodes, i.e. they can be parent but not child nodes. 
Edges from static nodes can be directed to dynamic nodes at time t, Dynv(t), or 
outcome nodes at time t, Outv(t). 
• Dynamic Nodes: 
Each dynamic covariate (see section 3.4.4.3) results in 2 dynamic nodes in the 
network, representing the value at time t, Dynv(t), and t-1, Dynv(t-1), respectively, 
where t is a positive integer representing the year (2 < t < 15). Thus, the dynamic 
nodes are: HBA1C(t), HBA1C(t-1), SBP(t), SBP(t-1), LDL(t), LDL(t-1), HDL(t), 
HDL(t-1), TRIG(t), TRIG(t-1), WHR(t), WHR(t-1), BMI(t) and BMI(t-1). Each Dynv(t-
1) node cannot be a child node. Each Dynv(t) node is forced to be a child of its 
correspondent Dynv(t-1) node and is a candidate child of every other Dyni(t-1) node 
and St node. 
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• Outcome Nodes: 
As for dynamic covariates, each outcome (see section 3.4.4.3) results in 2 outcome 
nodes in the networks, representing the value at time t, Outv(t), and t-1, Outv(t-1), 
respectively. Thus, the outcome nodes are: CVD(t), CVD(t-1), NEPHRO(t)  and 
NEPHRO(t-1). Each Outv(t-1) node cannot have parents. Each Outv(t) node is forced 
to be a child of its correspondent Outi(t-1) node, and can be child of every other 
Dyni(t-1) node, St and Outi(t-1) node. 
• Intervention Nodes: 
The covariate TREATMENT (see section 3.4.4.3) is forced to result in 2 static 
intervention nodes, Int(t) and Int(t-1), representing the state of the treatment at time t 
and t-1 respectively, since, from a clinical point of view, it is relevant not only 
information on the current treatment but also on the recent change in treatment. Thus, 
the intervention nodes are: TREATMENT(t) and TREATMENT(t-1), for a total of 26 
nodes in the network. Since the covariate TREATMENT represents the intervention 
variable of the DCCT and EDIC studies, where the intent of the intensive treatment 
was to achieve HbA1c level in the non-diabetic range (<6.05%) [61], the nodes 
TREATMENT(t) and TREATMENT(t-1) can affect only the HBA1C(t) node. 
Table 3.11 summarizes all node types and the related candidate parent/child node types 
according to the edge constraints. 
Type 
Forced parent 
edge 
Forced child 
edge 
Possible parent 
edge 
Possible child 
edge 
St None None None Dynv(t), Outv(t) 
Dynv(t-1) None Dynv(t) None Dynv(t) 
Dynv(t) Dynv(t-1) None 
Dynv(t), St, 
Int(t)*, Int(t-1)* 
Outv(t) 
Outv(t-1) None Outv(t) None Outv(t-1) 
Outv(t) Outv(t-1) None 
Outv(t-1), 
Dynv(t), St 
None 
Int(t) None None None HBA1C(t) 
Int(t-1) None None None HBA1C(t) 
Table 3.11: Nodes type and edges constraints. * Int(t) and Int(t-1) nodes are possible parents only for the  
HBA1C(t) node. 
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The DBN structure was learned from data by searching the space of all possible network 
structures with a Tabu Search algorithm [66], identical to the Hill Climbing  step of the 
Max-Min Hill Climbing  (MMHC) algorithm for Bayesian Networks structure learning 
described by Tsamardinos et al. in [88]. Basically, the search aims to find both edges and 
discretization thresholds in order to maximize the DBN's prediction ability. 
The search shapes edges connecting Dynv(t-1), Outv(t-1), St, Int(t) and Int(t-1) nodes to 
Dynv(t) and Outv(t) ones. Considering the constraints listed above, each Dynv(t) and 
Outv(t) node has one forced parent node, and a number of candidate ones. For each node, 
the goal is to find the best parent combination, determined by the likelihood-equivalence 
Bayesian Dirichlet score with uniform priors (BDeu), with Equivalent Sample Size α = 5 
[88], [67]. The goal is reached by searching the combination of parent edges that 
maximizes BDeu for each candidate node on the training data. The forced parent is 
always included when computing the score for a combination of candidate parents. Each 
node's parents can be searched independently.  
The implemented search is stepwise. At each step the algorithm determines if an edge is 
to be added or removed from the optimal parent combination obtained at the previous step. 
Since an edge can be either present or absent, each combination of candidate n parents 
can be represented by a binary vector p with a size n (the forced parent is not considered 
in p). The initialization step assumes no candidate parent selected, i.e. the BDeu score for 
a node is computed considering only the edge of its forced parent. Then the search 
algorithm proceeds by evaluating n possible steps, each one determined by switching a 
single binary value of p. For example, the search for a node with n = 3 begins setting p 
equal to [0, 0, 0]. The very first considered steps are [1, 0, 0], [0, 1, 0] and [0, 0, 1]. The 
step associated to the highest BDeu score is then selected, and the search continues. 
Once a step is selected, its vector p is compared to the elements of a Tabu list with 
maximum size t. If p is already present in the Tabu list, its score is set as -Inf. If not, p is 
pushed into the Tabu list. Once the list is full, new vectors push out the previously 
inserted ones, following a first-in-first-out approach. If more than s steps are completed 
without a BDeu score improvement, the search stops. Values for t and s were 100 and 15 
respectively, according to the literature gold standards [66]. 
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Note that in the original MMHC algorithm the edges, at each step, could undergo three 
possible perturbations, namely addition, removal or reversal. In the present case, however, 
edge direction is fixed, so there is no need to test for edge reversal. Furthermore, the 
network is acyclic by construction. This yield two major consequences: on the one hand, 
there is no need to check for acyclicity after every step of the Tabu Search algorithm; on 
the other hand, the optimal parent set for each node can be identified independently of the 
other nodes, thus greatly reducing computational complexity. 
As reported at the end of the previous section, for some nodes discretization thresholds 
have been taken from the literature (Table 3.10), while for variables AGE, DURATION, 
THERAPY and HBA1C the thresholds have been inferred by the data. For these latter 
variables, each one was assumed to have three possible states (low = 1, medium = 2 and 
high = 3), and the thresholds could be computes as 4 possible combinations: (a) the 33th 
and 66th percentile; (b) the 25th and 50th percentile; (c) the 25th and 75th percentile; or (d) 
the 50th and 75th percentile. Thresholds combinations have been explored during the BN 
structure learning described above: in particular, the learning of the edges was performed 
for each possible threshold combination on the variables AGE, DURATION, THERAPY 
and HBA1C, for a total of 44 = 256 combination. For each combination, the whole BN 
score was computed as the sum of each individual Dynv(y) node and Outv(t) node BDeu 
score. 
Table 3.12 reports the learned thresholds for AGE, DURATION, THERAPY and HBA1C, 
thus completing information of Table 3.10. 
Variable Cut-offs Number of cut-offs Number of states 
AGE 28 years and 40 years 2 3 
DURATION 100 months and 157 months 2 3 
THERAPY 4.92 years and 10.17 years 2 3 
HBA1C 7.1 % and 9.1 % 2 3 
Table 3.12: Learned cut-offs for continuous variables 
3.4.5.4 Parameters learning 
Once the structured is fixed, the phase of learning the conditional distributions implied by 
the network consists in estimating, for each variable X, a set of parameters |_ 
describing the dependency of X over its parents PaX.  
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In the case of a discrete network, the parameters to be estimated are all the entries of the 
CPT of each variable, i.e. the values mG|B_ = '( = A|'W = -W ) for each of the 
possible values of X and of its parents 'W.    
To this aim, the Bayesian maximum a posteriori (MAP) estimates was exploited. The 
Bayesian MAP estimates consists on a maximum likelihood estimates (based on 
calculating the relative frequencies of the different events in the data), augmenting this 
observed data with prior distributions over the values of these parameters. 
The maximum likelihood estimate of mG|B_is given by: 
 mG|B_ = ( = A ∧ 'W = -W)('W = -W) , (3.3)  
where N(c) counts the number of observations in the dataset satisfying condition c. 
One of the risks of maximum likelihood is that it can sometimes return estimates equal to 
zero, in case no example satisfying the condition at the numerator is observed in the 
dataset. To avoid this situation, it is often preferred to smooth the estimate with a 
coefficient α known as Equivalent Sample Size (ESS). The smoothed estimate is given by: 
 mG|B_ = ( = A ∧ 'W = -W) + ('W = -W) + |!WN('W)| ∙  , (3.4)  
where |!WN('W)| is the number of distinct values 'W can take.  
This expression corresponds to a MAP estimate of mG|B_ , assuming a Dirichlet prior 
distribution with equal-valued hyper-parameters α. An intuitive interpretation of α is the 
number of imaginary samples, for each combination of values of X and 'W, assumed to 
have been observed before estimating mG|B_  from  the data, as already explained in 
section 2.5.1. In this context, α was set equal to 5, as already mentioned in the previous 
section. 
3.4.6 Prediction 
Once the  model was fully specified through the learning phase, it was applied on the 
cohort of subjects of the test set to predict the evolution of the patients’ state. 
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Given the initial discretized values for both covariates and outcomes, the CPTs allow 
predicting the values of all the variables for the following years and thus the probability 
of developing a certain complication. For example, in Figure 3.14 the value of discretized 
HbA1c level at time point t depends only on the values of the same variable at time t-1, 
thus the correspondent CPT is represented by a 3x3 matrix, each column representing the 
conditional probability of HbA1c at time t given the value of its parent (HbA1c at time t-
1). Assuming for the i-th patient that HbA1c has low level at time point t-1, the level at 
time t will be predicted by a roulette wheel selection method where the chance for every 
possible value is given by the conditional probability in the correspondent cells. In the 
case shown in Figure 3.14, given the trained CPT and a low level of HbA1c at time t-1 for 
the i-th patient, the probabilities for low, medium and high level at time t are 5%, 74% 
and 21%, respectively, and the simulation predicts a medium level for HbA1c at time t. 
By applying iteratively this procedure to all the covariates and outcomes, the evolution of 
each patient belonging to the cohort of interest can be predicted year by year. This 
approach permits to predict the progression of a complication also over long period of 
time. 
The described approach was applied to the cohort of patients of the test set, starting from 
the initial values and using a prediction horizon of 15 years. For each patient, 100 
simulations were performed in order to obtain a probability distribution for each variable 
and for each year. The basic idea of this stochastic simulation approach is to run a 
simulation process that, starting from the observations and following a topological order, 
samples a new value of each unobserved variable given the values of all the other 
variables sampled so far. In this way a chain of values is generated. Such chain is known 
to converge to the posterior distribution of the variables given the observations [65]. 
 Figure 3.14: Example of 
 
3.5 Results 
The final network resulting from the learning step is 
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a single variable prediction by exploiting the correspondent CPT
represented in Figure 3.
Figure 3.15: Final DBN structure 
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Analyzing Figure 3.15, 2 well-distinct blocks can be observed in the network: a sub-
network for Nephropathy (Figure 3.16), in which a clear short-term effect is played by the 
variable TREATMENT on the nephropathy state through the intermediate effect on the 
variable HBA1C, and a sub-network for the Cardiovascular Disease (Figure 3.17), in 
which a clear long-term effect is played by the variable DURATION on the CVD state 
through an intermediate effect on the variable WHR. It is interesting to note how the lipid 
variables (i.e. TRIG, LDL and HDL) as well as the anthropometric variables (WHR and 
BMI) belong to the same sub-network of CVDs, thus showing a certain consistency with 
clinical knowledge [76]. The variables THERAPY (i.e. the number of years of diabetes not 
treated with intensive therapy), SMOKE and EXERCISE were left out from the network, 
since their effect was likely overcome by the stronger influence of other variables. 
 
Figure 3.16: Nephropathy sub-network. 
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Figure 3.17: CardioVascular Disease sub-network. 
The validation step consisted in comparing results of simulations run on the initial 
population of the test set to real data. In particular, the comparison was performed at a 
population level: for each dynamic variable, the annual population distributions computed 
on simulated data were compared to the annual population distributions computed on real 
data. The annual distribution was computed considering all the 100 simulated values for 
each patient. Figure 3.18 to Figure 3.26 show real distributions (top panel) and percentage 
difference with simulated distributions (bottom panel) for all the dynamic variables in 
order to quantify prediction accuracy. Considering that only the first 15 years of the data 
were used to train the model, the population predictions for the first 15 years fit very well 
real data, exhibiting percentage differences not greater than 10% for all the dynamic 
variables. In particular for the outcomes, the differences are lower than 5% for all the 15 
years. These results are similar to the ones obtained by [74], where the authors defined a 
valid model as one in which the mean simulate event rates correspond to the mean 
published event rates within a range of ±10%. 
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Figure 3.18: Real population distribution of WHR and percentage difference with predicted one for each 
year. 
 
Figure 3.19: Real population distribution of HBA1C and percentage difference with predicted one for each 
year. 
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Figure 3.20: Real population distribution of SBP and percentage difference with predicted one for each 
year. 
 
Figure 3.21: Real population distribution of LDL and percentage difference with predicted one for each 
year. 
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Figure 3.22: Real population distribution of HDL and percentage difference with predicted one for each 
year. 
 
Figure 3.23: Real population distribution of TRIG and percentage difference with predicted one for each 
year. 
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Figure 3.24: Real population distribution of BMI and percentage difference with predicted one for each 
year. 
 
Figure 3.25: Real population distribution of CVD and percentage difference with predicted one for each 
year. 
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Figure 3.26: Real population distribution of NEPHRO and percentage difference with predicted one for each 
year. 
 
3.6 Software tool for diabetes care professionals 
As already pointed out in the Introduction of the current Chapter, the final aim of an in-
silico model is to provide clinicians with a tool for supporting decision analysis, in order 
to predict the risk for long-term complications, thus optimizing clinical trials and 
avoiding invasive and expensive tests.  In this context, the final step of the present work is 
representing by the development of a web application to simulate the progression of 
diabetes long-term complications. In particular, here we developed a standalone Java 
application that implements stochastic simulation based on Bayesian network structure 
and parameters learned from the DCCT and EDIC datasets. The main goal of the 
application is to provide a tool to simulate single patient or population evolution 
dynamics, toward nephropathy and cardiovascular disease.  The tool will allow 
professionals involved in diabetes care to analyze and predict the onset of pathologies 
such as coronary heart disease, stroke and nephropathy with a certain belief, based on 
patients or population anamnestic evidence.  
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In order to reach the highest compatibility with existing operative systems and an easy to 
install and run deployment strategy, we employed Java Standard Edition (Java SE) 
technology to develop this application. Indeed, Java SE Platform lets you develop and 
deploy Java applications on desktops and servers, offering rich user interface, 
performances and portability that today application require. Having as objective the 
distribution of the software over the internet, Java Web Start technology has been selected. 
This technology is being developed as Java Network Launching Protocol & API (JNLP), 
which provides a browser-independent architecture for deploying Java technology-based 
applications to the client desktop. 
3.6.1 Methods 
3.6.1.1 Packages 
Classes and methods are grouped in four Java packages. The package dbn is the main 
package. It provides initialization of the main classes and the application layer control. 
The package libDBN contains all the classes and methods developed to simulate single 
patient or population evolution dynamics and all storage data structures. The package 
dbnGUI has been developed to provide a graphical user interface (GUI) employing Java 
AWT and SWING libraries. Implementing the interfaces ActionListener and ItemListener 
provided by these libraries, it makes possible the interaction with user and events. The 
package visualDBN provides the facilities for visualization of network structure and 
outputs analysis graphs. 
3.6.1.2 Data structures 
The structure and parameters of the Bayesian network learned are stored in an object, 
instance of the class NetStructure. It stores the conditional probability tables (CPTs) 
values and adjacency matrix in matrices and variable names, nodes arity (i.e. number of 
possible states) and discretization levels for each variable in arrays. The object can be 
serialized, indeed the class implements the interface Serializable, and saved to disk. This 
allows loading the entire network structure in a single step, making faster the application 
start up process. In case of network modification due to subsequent learning processes it 
is possible to re-load the structure and all parameters into the NetStructure object and 
save it again to disk. Access to CPTs values is allowed by means of a function that maps 
a combination of indexes given the topological order of a variable to the linear index of 
the CPTs matrix.  
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The data employed for and obtained from the simulation process are stored in a data 
structure implemented with the class evolutionMatrix. Each year of simulation is stored in 
a generic list container, an ArrayList<T> container of the Java Generics library. Several 
auxiliary and temporary data structures are employed to perform internal computation. 
 
3.6.2 Simulations 
Inference in Bayesian network can be accomplished in several ways, such as exact 
inference by enumeration or by variable elimination, message passing algorithms and 
stochastic simulation.  Exact inferences need to rewrite a query P(X|e) in terms of CPT 
entries product. Given any subset of Xi setting them to certain values due to evidence, we 
can calculate the probability distribution of some other subset of Xi by marginalizing over 
the joint. This is costly due to calculating an exponential number of joint probability 
combinations. In this application, we implemented a Markov Chain Monte Carlo 
stochastic simulation, as described in section 3.4.6. Briefly, for each variable the 
distribution of possible values is obtained from the CPT tables. Inserting the covariates 
initial values for the single patient or for the population, distribution probabilities may be 
generated according with the observed data. The new value of the considered variable is 
obtained from a random sampling among possible values according to its conditional 
probability distribution. A stochastically selected value is assigned to current variable. 
This procedure is repeated for each variable to generate a complete dataset for the 
selected number of patients. By this way, users can insert initial values and simulate the 
entire dynamic evolution process of the cohort of patients. 
3.6.3 Visualization 
Simulation results may be visualized in the main windows of the application where a 
table reports the distribution per year of each variable. Incidence of nephropathy and 
cardiovascular disease over the year may be visualized as a graph. We are currently 
finalizing the implementation of the DAG visualization and the exporting functions for 
graph and tables. A preliminary mock-up of the interface is shown in Figure 3.27. 
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Figure 3.27: Preliminary mock-up for the user interface of the software tool. 
 
3.7 Discussion 
In this chapter the problem of modeling the combined effect of phenotype and treatment 
on the outcome was discussed. 
In-silico models of complex diseases are essential to predict the risk for long-term 
complications, thus optimizing clinical trials and avoiding invasive and expensive tests.  
A requirement for diabetes simulation models has been identified in the medical and 
healthcare policy community, and, as a result, a number of models, have been developed 
and reported in the literature. However, these models are mainly based on Markov 
Models, thus requiring as many nodes as the number of combinations of variable values. 
In the present work, the progression of two vascular diabetes complications, 
Cardiovascular disease and Nephropathy, was modeled using Dynamic Bayesian 
Networks and integrating in the model phenotypic information as well as information on 
treatment. A Bayesian Network is a probabilistic graphical model that represents a set of 
random variables and their conditional dependencies via a directed acyclic graph. DBNs 
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are a special class of BNs that model the stochastic evolution of a group of random 
variables over time. DBNs are advantageous with respect to Markov Models since each 
variable is represented by one node, thus, extending a DBN model with the addition of 
new variables just requires adding as many nodes.  
The DBN model was developed on the data collected from the DCCT (Diabetes Control 
and Complication Trial),  a randomized clinical trial which involved 1441 type 1 diabetic 
volunteers between 1982 and 1993, with the aim of comparing the effects of standard 
control of blood glucose versus intensive control on the complications of diabetes. 
In particular, relying on an a-priori information on the network general structure, the 
model was learn directly from a subset of real data, and validated on the subset left out 
during the learning phase.  
Results regarding the network structure show a good consistency with clinical knowledge, 
exhibiting 2 well-distinct blocks of effects: a first block with a stronger short-term effect 
for Nephropathy, regulated by the indirect effect of treatment on HbA1c, and a second 
block with a stronger long-term effect for Cardiovascular Disease, regulated by the 
indirect effect of the duration of diabetes on Waist-Hip Ratio, and involving also all the 
lipid variables. 
Results regarding the simulated progression of complications show very good 
performances, exhibiting a prediction accuracy greater than 90 % for all the dynamic 
covariates and greater than 95 % for the outcomes, Nephropathy and Cardiovascular 
Disease, thus proving the effectiveness of the model. 
The good prediction performances of the model make it rather suitable to be use as a tool 
for support clinical decision analysis. To such an aim, a web Java application that 
implements stochastic simulation based on the structure and parameters learned from the 
DCCT and EDIC datasets is currently under development. The web application 
development is still ongoing, but the current version represents a good starting point for 
future extensions and improvements. 
Future developments, in particular, can regard the extension of the DBN model and the 
refinement of the web application based on it. 
The flexible structure of the DBN will in fact allow the easy introduction of other 
variables: the most interesting variables to be exploited are diabetic Retinopathy, as an 
93 
 
additional outcome of the model, and the genotypic information as a potential mean to 
improve predictions. 
A cost-effectiveness analysis to evaluate costs and consequences of possible treatments, 
as well as a cost-utility analysis to quantify eventual improvements in the patients’ quality 
of life, will be implemented, in order to better address the supporting function of the web 
application in the decision analysis process. 
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Chapter 4 
 
4 Modeling the effect of treatment on 
diabetes phenotype: a 
compartmental model of aspirin 
action 
 
Referring to the multi-level scheme presented in Figure 1.1, this chapter will focus on the 
effect of treatment on phenotype, as shown in Figure 4.1. 
 
Figure 4.1: Modeling the effect of treatment on phenotype. 
Aspirin represents an important component of cardiovascular prevention in diabetic 
patients. The biological background regarding the physiological mechanisms of action of 
aspirin as antiplatelet agent will be firstly introduced, then the most relevant results from 
clinical trials and epidemiological studies of aspirin as a therapy for patients at high 
cardiovascular risk will be shown. A compartmental model of aspirin action developed to 
qualitatively explain experimental evidence will be finally presented and its performance 
evaluated by a sensitivity analysis approach.  
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4.1 Introduction 
4.1.1 Atherothrombosis 
Atherosclerosis is a chronic inflammatory disorder in which immune mechanisms interact 
with metabolic risk factors to initiate, propagate, and activate vascular lesions, and 
represents the major cause of ischemic coronary artery disease and cerebrovascular 
disease [104]. 
Arterial thrombosis, an acute complication that develops on the surface of a ruptured 
atheromatous plaque or as a consequence of endothelial erosion, may cause myocardial 
infarction or ischemic stroke. Platelets are key cellular components of arterial occlusive 
thrombi and may participate in the development and progression of atheromatous plaques 
[131]. 
Platelets originate from megakaryocytes in bone marrow and are vital components of 
hemostasis, the physiologic process that arrests hemorrhage after tissue trauma and 
vascular injury. Although the adhesion and activation of platelets can be viewed as a 
repair-oriented response to sudden fissuring or rupture of an atheromatous plaque, 
uncontrolled progression of such a process through a series of self-sustaining 
amplification loops may lead to the intraluminal formation of thrombus, vascular 
occlusion, and transient ischemia or infarction. The ability of platelets to participate in 
both normal hemostasis and atherothrombosis depends on their adhesive properties and 
their capacity to become activated very quickly in response to various stimuli [131]. 
Currently available antiplatelet drugs, such as aspirin, interfere with certain steps in the 
activation process by selectively blocking key platelet enzymes or receptors, reducing the 
risk of arterial thrombosis through mechanisms that cannot be dissociated from an 
increased risk of bleeding complications [121]. 
In particular, randomized trials indicate that low-dose aspirin can prevent arterial 
thrombosis under various circumstances, including first vascular events among low-risk, 
healthy subjects and recurrent vascular events among patients with known acute or 
chronic occlusive vascular disease [121]. However, a diminished responsiveness has been 
reported in patient with type 2 diabetes [127], [100], [101], with the suggestion that this 
 might explain the apparent failure of the drug to reduce the risk of atherothrombotic 
events in individual trials and meta
A more comprehensive picture of the main results from clinical trials will be presented in 
section 4.2. 
4.1.2 Aspirin as antiplatelet agent
Aspirin, also known as acetylsalicylic acid
group of medications called nonsteroidal anti
synthesized by Felix Hoffman, a chemist with the German company Bayer, in 1897
if the active metabolite of aspirin, 
willow in 1763 by Edward Stone of Wadham College, Oxford University. 
is one of the most widely used medications in the world
aches and pains, as an antipyretic to reduce fever, and as an anti
with an estimated 40,000 tones of it being consumed each year
The best-characterized mechanism of action of aspirin is 
dependent platelet function, through permanent inactivation of the cyclooxygenase 
(COX) activity of prostaglandin H synthase 1 (also referred to as COX
shown in Figure 4.3, prostaglandin
hydroperoxidase (HOX) activity
involved in cellular signaling and inflammatory process, to a complex set of derivatives 
which are collectively known as the ‘arachidonic acid cascade’.
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coagulation factors  as well as increasing platelet aggregation (the enzyme is in fact 
named for its role in clot formation, i.e. thrombosis). 
 
Figure 4.3: Mechanism of action of aspirin on the arachidonic acid cascade. Figure from [122]. 
 
The synthases are colloquially termed cyclooxygenases and exist in two forms, 
cyclooxygenase-1 (COX-1), which is the constitutive form of the enzyme, and 
cyclooxygenase-2 (COX-2), which is an inducible form. Low-dose aspirin mostly inhibits 
COX-1, whereas high-dose aspirin inhibits both COX-1 and COX-2 [122]. In particular, 
by diffusing through cell membranes, aspirin enters the COX channel, a narrow 
hydrophobic channel connecting the cell membrane to the catalytic pocket of the enzyme. 
Aspirin acts on COX-1 permanently inactivating it, trough an irreversible acetylation 
process: a single molecule of aspirin reacts with a single molecule of COX-1 producing a 
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single molecule of salicylic acid and a single molecule of acetylated COX-1 (Figure 4.4), 
thus preventing AA to bind the catalytic site of the enzyme to start the AA cascade [140].  
 
Figure 4.4: Reaction between aspirin and COX-1: aspirin acetylates the hydroxyl group of a serine residue 
at position 529 (Ser529) in the polypeptide chain of platelet prostaglandin G/H synthase, thus inactivating 
the cyclooxygenase catalytic activity of the enzyme which leads to formation of prostaglandin G2 from 
arachidonic acyd.  Figure from [140]. 
 
This process is irreversible and its effect is long-lasting for the entire single platelet 
lifespan, since platelets are not able to synthesize de novo COX-1 and, thus, only new 
platelet generation from megakaryocytes in bone marrow can recover pre-aspirin COX-1 
levels [140]. 
In the next section, exemplifying results from clinical trials of aspirin in cardiovascular 
prevention will be briefly presented. 
 
4.2 Results from clinical trials 
In the context of the multi-level analysis adopted in this thesis, the main clinical trials of 
aspirin can be separated in 2 classes, on the basis of the final end-points considered: 
1. Trials focusing on the outcome (Figure 4.5.A), in which the goal of the study is to 
analyze the effect of aspirin on cardiovascular events; 
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2. Trials focusing on the phenotype (Figure 4.5.B), in which the goal of the study is to 
characterize the effect of aspirin on COX-dependent platelet activity. 
 
Figure 4.5: Scheme for trials focusing on the outcome (A) and for trials focusing on the phenotype (B). 
 
4.2.1 Trials focusing on the outcome 
The efficacy and safety of aspirin on non diabetic patients are document from analysis of 
many randomized clinical trials that included patients at variable risk of thrombotic 
complications of atherosclerosis [120]. Aspirin has been tested in patient demonstrating 
the whole spectrum of atherosclerosis, from apparently healthy low-risk individuals to 
patients presenting acute vascular events. Among patients with occlusive vascular disease, 
both individual studies and meta-analysis of trials of antiplatelet therapy indicate that 
aspirin significantly reduces the risk of a serious vascular event (nonfatal myocardial, 
infarction, nonfatal stroke, or death from  vascular causes) [122]. For example, in [137] a 
meta-analysis of 287 studies involving 135 000 patients in comparisons of aspirin therapy 
PHENOTYPE
TREATMENT
GENOTYPE OUTCOMEA)
B)
PHENOTYPE
TREATMENT
GENOTYPE OUTCOME
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versus control, showed that among a wide range of patients with vascular disease, for 
which the annual risk of a serious vascular event ranges from 4 to 8 percent, aspirin 
significantly prevented at least 10 to 20 fatal and nonfatal vascular events for every 1000 
patients treated for one year (Figure 4.6).  
 
Figure 4.6: Absolute effects of antiplatelet therapy with aspirin on the risk of vasculareEvents 
(nonfatal myocardial infarction, nonfatal stroke, or death from vascular causes) in five groups of high-
risk non diabetic patients. Figure from [122]. 
 
The inhibition of thromboxane-dependent platelet function by aspirin may lead to the 
prevention of thrombosis as well as to excess bleeding, thus assessing the net effect 
requires an estimation of the absolute thrombotic risk versus the hemorrhagic risk of the 
individual patient. In [121], aspirin has been evaluated in six primary prevention trials of 
aspirin versus placebo (the Primary Prevention Project trial on high-risk men and women 
[99], the Hypertension Optimal Treatment trial on hypertensive patients [105], the 
Thrombosis Prevention Trial on high-risk men [136], the Swedish Angina Pectoris 
Aspirin Trial on stable angina patients [112], the Physicians’ Health Study trial on healthy 
men [110] and the United Kingdom Doctors trial on healthy men [124]) for a total of 
approximately 58000 patients who were at variable cardiovascular risk. Results show that 
as the risk of experiencing a major vascular event increases, so does the absolute benefit 
of antiplatelet prophylaxis with aspirin for a number of clinical conditions, including 
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stable and unstable angina pectoris and patients who suffered a myocardial infarction 
(Figure 4.7). 
 
 
Figure 4.7: For each category of patients, the abscissa denotes the absolute risk of experiencing a major 
vascular event. The absolute benefit of antiplatelet treatment is reported on the ordinate as the number of 
subjects in whom an important vascular event is actually prevented by treating 1,000 subjects with aspirin 
for 1 year. Figure from [121]. 
 
In contrast to non-diabetic subjects, for which aspirin has been proofed to have a 
significant effect, a clear benefit of aspirin in the prevention of major cardiovascular 
events in people with diabetes remains unproved [98]. 
For example, in order to examine the efficacy of aspirin for the primary prevention of 
atherosclerotic events in patients with type 2 diabetes, Ogawa and Nakayama studied 
results from the Japanese Primary Prevention of Atherosclerosis With Aspirin for 
Diabetes (JPAD) trial [115], a randomized controlled trial in which patients were 
randomly assigned to assume low-dose aspirin (81 or 100 mg per day) or not. End-points 
were atherosclerotic events, including fatal or nonfatal ischemic heart disease, fatal or 
nonfatal stroke, and peripheral arterial disease as well as death from any cause. The 
incidence of the primary end point of any atherosclerotic event was not significantly 
different in the aspirin group than in the non-aspirin group (log-rank test, p-value = 0.16), 
as shown in  Figure 4.8, thus the authors concluded that aspirin as primary prevention did 
not reduce the risk of cardiovascular events [115]. 
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Figure 4.8: Total percentage of atherosclerotic events according to treatment group in the JPAD trial. CI 
indicates confidence interval; HR, hazard ratio. Figure from [115]. 
 
Similar results were obtained by Belch from the analysis of results from the Prevention of 
Progression of Arterial Disease and Diabetes (POPADAD) trial [94], a multicentre, 
randomized, placebo controlled trial conducted to determine whether aspirin was more 
effective than placebo in reducing the development of cardiovascular events in patients 
with diabetes mellitus and asymptomatic peripheral arterial disease. Two hierarchical 
composite primary end points of death from coronary heart disease or stroke, non-fatal 
myocardial infarction or stroke, or amputation above the ankle for critical limb ischemia, 
and death from coronary heart disease or stroke were the main outcomes measured. 
Overall, the authors concluded that specific adverse events were not significantly 
different between the aspirin and no-aspirin groups [94]. 
Pignone and Alberts performed a meta-analysis that added data from three trials 
performed specifically in patients with diabetes (the already mentioned JPAD [115] and 
POPADAD [94], and the Early Treatment of Diabetic Retinopathy Study [113]) to the 
data from subgroups of patients with diabetes from  the six large trials of aspirin for 
primary prevention in the general population  investigated also in [121], as already 
described. Using a random-effect model, the authors found that aspirin was associated 
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with a 9% decrease in risk of coronary heart disease events (non fatal and fatal 
myocardial infarction) and with a 15% decrease in the risk of stroke, both decreases not 
being statistically significant (Figure 4.9). The authors concluded that aspirin likely 
produces a modest reduction in CVD risk in patients with diabetes, but not statistically 
significant compared to diabetic patients not treated with aspirin [125]. 
 
Figure 4.9: Effect of aspirin on coronary heart disease events, tests for heterogeneity: P =0.367 (A). Effect 
of aspirin on risk of stroke in patients with diabetes, tests for heterogeneity: P =0.131 (B). CI stands for 
confidence interval. BMD indicates British Medical Doctors; ETDRS, Early Treatment of Diabetic 
Retinopathy Study; HOT, Hypertension Optimal Treatment; JPAD, Japanese Primary Prevention of 
Atherosclerosis with aspirin for Diabetes; PHS, Physicians’ Health Study; POPADAD, Prevention of 
Progression of Arterial Disease and Diabetes; PPP, Primary Prevention Project; TPT, Thrombosis Prevention 
Trial; and WHS, Women’s Health Study. Figure from [125]. 
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In the medical literature, the interindividual variability in response to aspirin, which 
brings to treatment failure, has been indicated with the term ‘aspirin resistance’ [118]. To 
be precise, today scientists argue about the term to be used, since the term ‘resistance’ 
implies that something can be measured that has a direct bearing on clinical efficacy of 
aspirin and that may lead to a change in the therapy. Since, so far, a such a relationship 
has not been discovered yet, the term ‘treatment failure’ may be more correct [102]. In 
this thesis, for simplicity, the term ‘aspirin resistance’ will be used  henceforth. 
4.2.2 Trials focusing on the phenotype 
Moving from black box approach adopted by clinical trials focusing on the outcomes, in 
this sub-section the main results from clinical trials focusing on the phenotype will be 
presented. In particular, 2 trials conducted by Rocca and Santilli will be described; the 
former conducted on healthy subjects, and the latter on diabetic ones. 
In both trials, the effect of aspirin on the activity of platelet COX-1 (referred to as simply 
COX henceforth) have been characterized through measurements of serum thromboxane 
B2 (TxB2), which is an indirect measure of the COX activity in serum [133]. More 
precisely, particular attention was paid to the recovery of serum TxB2 during and after 
aspirin therapy. 
4.2.2.1 Healthy subjects 
In the first trial, the authors randomized 48 healthy Caucasian subjects to 1 to 8 groups, 
according to treatment duration, ranging from 1 to 8 weeks [133]. Each patient received 
enteric-coated aspirin 100 mg once a day and was instructed to take tablets at the same 
time of the day. Serum TxB2 (in ng/ml) was measured (together with other blood and 
urine samples) at the end of each week of aspirin, and at days 1, 2, 3 and 7 after 
withdrawal. The authors found that: 
• serum TxB2 was steadily suppressed over 8 weeks, the average percent inhibition 
being constantly above 99% of the baseline, without significant intergroup 
differences: 1-week treatment caused  99.3% ±0.7% inhibition, and 8-weeks treatment 
produced 99.6 ± 0.3% inhibition (Figure 4.10).  
• initial recovery of serumTxB2 levels seem to differ among groups: at days 1 and 2 
following aspirin withdrawal, TxB2 values were similar in the subjects treated for 1 
and 2 weeks and significantly higher than the corresponding values of longer 
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treatment groups (2-factor repeated measurements analysis of variance with the post 
hoc Holm-Sidak test for pairwise comparison, p-value < 0.05). Exposure to aspirin for 
at least 3 weeks showed a 2-day delay before detectable recovery (Figure 4.11); 
• the overall kinetics of TxB2 recovery showed a complex sigmoidal pattern, not 
appropriately described by a simple first-order kinetics (Figure 4.11). 
 
Figure 4.10: Absolute values of TxB2 (mean ± sd) of baseline (week 0) and for each week of treatment. 
Figure from [133]. 
 
Figure 4.11: TxB2 data pooled from 1 to 2 weeks versus 3 to 8 weeks of treatment for the whole post-
treatment period.* indicates significant difference. Figure from [133]. 
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These findings made the authors conclude that: 
• to suppress COX recovery for 2 days after aspirin withdrawal, at least 3 weeks of 
treatment 100 mg once daily are needed; 
• the 2-days delay, exhibited by COX recovery after more than 2 weeks of treatment 
100 mg daily, is interpreted as the evidence that aspirin acetylates COX in 
megakaryocytes, thus leading to generation of inactivated platelets within the first 2 
days after aspirin withdrawal; 
4.2.2.2 Diabetic subjects 
In the second trial, the authors characterized the kinetics of platelet COX recovery in 
aspirin-treated diabetic (and non diabetic) patients [128]. In the first phase of the trial, one 
hundred type 2 diabetic patients on chronic aspirin 100 mg daily were studied and serum 
TxB2 measured every 3 hours, between 12 and 24 hours after a witnessed aspirin intake. 
The linear slope of serum TxB2 recovery between 12 and 24 hours was computed for each 
patient (Figure 4.13). Patients with the fastest TxB2 recovery (i.e. the ones in the upper 
tertile of the slope distribution) underwent phase 2: they were randomized to aspirin 100 
mg once a day, 200 mg once a day or 100 mg twice a day, for 28 days and TxB2 was 
reassessed. The protocol scheme is represented in Figure 4.12. Results from the first 
versus second phase of the study are presented in Figure 4.14. The authors found that: 
• the median serum TxB2 concentration measured at 12 hours after aspirin dosing in the 
100 diabetic patients was comparable to the median value reported in the first clinical 
trial on healthy subjects, treated with the same dose and formulation of aspirin; 
• about one third of the 100 diabetic patients showed a COX recovery significantly 
higher than healthy subjects in the 12-24 interval after aspirin intake; 
• a twice-daily regimen with 100 mg aspirin is significantly more effectiveness with 
respect to a once-daily regimen and a 200 mg once-daily regimen (Figure 4.14). 
The authors, thus, concluded that: 
• aspirin maximal effectiveness in the suppression of COX-dependent platelet function 
is not different between healthy and diabetic patients; 
• the main difference between healthy subjects and a fraction of diabetic patients is 
represented by a faster COX recovery during the 12-24 hours dosing interval; 
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daily administration in patients with type 2 diabetes
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12: Protocol of the study. Figure from [128]. 
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Figure 4.14: Serum TxB2 recovery slope between 12 and 24 hours after aspirin dosing in diabetic patients in 
the upper tertile, before (left panels) and after (right panels) the randomized phase of the study. (A-D) 
patients randomized to 100 mg once a day; (B-E) patients randomized to 200 mg once a day; (C-F) patients 
randomized to 100 mg twice a day. Figure from [128]. 
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4.2.2.3 Conclusions: potential mechanisms 
Combining results from the 2 clinical trials described above, the authors concluded that 
the main difference between healthy and diabetic patients is represented by a faster COX 
recovery between 12 and 24 hours after aspirin intake and that this is likely the cause of 
the so-called ‘aspirin resistance’ leading to treatment failure in most diabetic patients 
treated with aspirin [128]. The authors hypothesize that this mechanism may be caused by 
an enhanced  thromboxane biosynthesis in type 2 diabetics with macrovascular disease 
(as indicated by other literature works [97]), most likely reflecting variable platelet 
turnover. Moreover, they also hypothesize that a reduced systemic bioavailability of 
enteric-coated aspirin can limit the extent of COX acetylation in megakaryocytes [128]. 
 
4.3 Objective of the work 
If, on one hand, a possible approach to the analysis of the ‘aspirin resistence’ problem is 
the same dynamic statistical analysis used for the in silico model of diabetes 
complications adopted in Chapter 3, on the other hand it is interesting to study the 
problem from a physiological point of view as well, searching for the biological 
mechanisms responsible for the different responses to drug, observed in experimental 
data.  
Since, due to limited access to bone marrow megakaryocytes, it is difficult to clinically 
investigate both the causes of experimental evidence as well as the adequacy of different 
aspirin regimens, an in silico model of aspirin responsiveness can be useful to simulate 
interaction between aspirin and COX, and  might help designing personalized antiplatelet 
regimens in T2DM. 
Though some works have tried to explain this process from a mathematical point of view  
[119], [111], a detailed and complete characterization is still missing. 
The object of the work presented in this chapter is, thus, to develop an in silico model of 
aspirin action, able to: 
• explain data in healthy subjects; 
• test hypothesis for faster recovery in diabetic patients; 
• predict correct response to different aspirin regiments. 
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4.4 Methods 
A compartmental model to describe and simulate the processes of COX inhibition and  
reappearance in serum in response to an aspirin therapy has been developed. 
The model consists of four key-elements: 
1. Thrombopoiesis mechanism 
2. COX kinetics 
3. Aspirin pharmacodynamics (PD) 
4. Aspirin pharmacokinetics 
The following section will describe, for each key-element, the hypotheses and assumption 
used to build the model. 
4.4.1 Thrombopoiesis mechanism 
The term thrombopoiesis refers to the process of thrombocyte generation, i.e. generation 
of platelets from megakaryocytes in bone marrow. The developed model of 
thrombopoiesis is based on available literature, in particular on the most recent work by 
Patel [116], [117] and Thon [135], [134]. 
According to most recent findings, platelets (PLTs) are generated from megakaryocytes 
(MKs) by fragmentation: each MK  is generated in bone marrow by a precursor cell, and, 
after a megakaryocyte-maturation-period (MK_matur) during which each MK increases 
its dimension and  becomes proliferative, i.e. able to generate PLTs. Each MK generates a 
certain number of ProPLTs (N_ProPLTs_per_MK), an intermediate form of platelet, over 
a subsequent time interval called megakaryocyte-proliferation-period (MK_prolif). The 
generation of ProPLTs takes place during the entire MK_prolif, until the complete 
fragmentation of the MK. Each ProPLT, although physically connected to the MK, is 
functionally disconnected, and, after a short period during which it stretches and 
elongates its structure, it detaches from the MK. The detached ProPlLT is a barbell cell, 
which, after a ProPlatelet-life-period (PrePLT_life),  finally generates 2 Platelets (PLTs).  
While megakaryocytes and proplatelets are in bone marrow, platelets are released in 
systemic circulation. 
A MK is supposed to reach its mature state when it starts generating ProPLTs, and to die 
when the last ProPLT is generated. So, the Megakaryocyte life is given by the sum of the 
MK_matur and the MK_prolif. 
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For simplicity, ProPLTs are supposed to form consecutively over the MK_prolif, i.e., the 
number of ProPLTs generated by the MK in the time unit is a constant. 
A ProPLT is supposed to form when it starts protruding from the MK and to die when it 
is divided into 2 Platelets.  
A Platelet simply dies after the Platelet-life-period (PLT_life). 
Figure 4.15 represents the chronologic order of the events for a single MK. 
The population of MKs at the generic time t is supposed to be, with respect to the stage of 
maturation, without any privileged stage, as shown in Figure 4.16. 
 
Figure 4.15: timeline of the process of platelets generation from a single megakaryocyte. The different 
stages of the process, with representative literature  values, are represented with different colors: 
megakaryocyte-maturation-period (yellow), megakaryocyte-proliferation-period (light orange), 
proplatelets-life-period (dark orange), and platelet-life-period (magenta). 
 
Figure 4.16: Whole population of Megakaryocytes uniformly distributed over the interval 0 ÷ MK_life 
Table 4.1 lists the physiological parameters of the thrombopoiesis mechanism with 
literature ranges. 
MK maturation (~ 2 d) ProPLT life
(~ 12-24 h)
PLT life (~ 7 d)
time
MK proliferation
(~ 4-10 h)
MK life
t time
. .
MK life
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Parameter Description Literature value 
N_MKs_per_Kg 
Number of Megakaryocytes per 
kilogram of subject weight ~ 6.1e
6
 [106] 
MK_matur Maturation period of Megakaryocytes ~ 2-4 days [117] 
MK_prolif Proliferation period of Megakaryocytes ~ 4-10 hours [106]-
[116] 
ProPLT_life Lifespan of ProPlatelets ~ 12-24 hours [117] 
PLT_life Lifespan of Platelets ~ 7-10 days [135] 
N_ProPLTs_per_MK 
Number of ProPlatelets generated from 
each Megakaryocyte 
~ 1000 ÷ 1500 [116] 
N_PLTs_per_ProPLT 
Number of Platelets generated from each 
ProPlatelet 
2 [116] 
Table 4.1: Literature values for the parameters of thrombopoiesis. 
 
4.4.2 COX kinetics 
Since PLTs are not able to synthesize de novo COX [140], the enzyme is supposed to be 
constantly produced only within MKs during their maturation period. When the MK 
terminates its maturation and enters the proliferation period, COX synthesis is supposed 
to stop. Each ProPLT is supposed to inherit a certain amount of COX from its MK father. 
The total amount of COX within the MK is supposed to be equally distributed to all the 
ProPLTs generated from the MK, so that COX amount received by each ProPLT is the 
same. COX inherited from the MK remains inside the ProPLT throughout its life period, 
during which the ProPLT stretches and detaches from the MK, without any de-novo 
synthesis occurring. Then, when the ProPLT divides into 2 PLTs, COX is simply 
supposed to be equally divided between the 2 new-forming PLTs. COX degradation is 
supposed to be negligible in MKs and ProPLTs, since COX is a housekeeping enzyme 
(i.e. an enzyme present in all the cells to perform essential metabolic functions), while a 
nonzero degradation is supposed to take place in PLTs, representing enzyme utilization 
and elimination thought platelet death. 
To model the processes of synthesis and transfer of COX from megakaryocytes in bone 
marrow to platelets in blood, accounting also for the temporal dimension of the processes 
involved in thrombopoiesis (see previous section), the compartmental distributed model 
of Figure 4.17 has been developed. 
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Figure 4.17: The compartmental model for COX kinetics. Each compartment represent COX total amount in 
a different cell population: maturing megakaryocytes (yellow), proliferating megakaryocytes (light 
orange), proplatelets (dark orange) and Platelets (magenta). Solid arrows denote fluxes of COX: P 
represent COX synthesis, while k denote its degradation rate. 
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The model is described by the following partial differential equations: 
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Where: 
• t and s are the 2 independent variables, representing ‘time’ and ‘cell maturation state’ 
respectively. The unit of measure is [time] for both the variables, since ‘cell 
maturation state’ represents the age of the cell. 
• Q1, Q2, Q3, and Q4 represent active-COX (i.e. non acetylated COX) distribution over s 
in, all the maturing megakaryocytes, all the proliferating megakaryocytes, all the 
proplatelets and all the platelets, respectively. The unit of measure for COX is [mass]. 
The Q1, Q2, Q3, and Q4 are time-dependent distributions, i.e. function of the 2 
independent variables, and this is why the model is not lumped (i.e. dependent on one 
variable only) but distributed. 
• Q10, Q20, Q30, and Q40 represent the initial distribution over s of, all the maturing 
megakaryocytes, all the proliferating megakaryocytes, all the proplatelets and all the 
platelets, respectively. 
• COX1, COX 2, COX 3, and COX 4 represent active-COX total amount in, all the 
maturing megakaryocytes, all the proliferating megakaryocytes, all the proplatelets 
and all the platelets, respectively, and are function of time only, simply given by the 
integral over s of their respective distributions. 
• COX10, COX20, COX30, and COX40 represent the initial total amount of active-COX in, 
all the maturing megakaryocytes, all the proliferating megakaryocytes, all the 
proplatelets and all the platelets, respectively. 
• P(s) represents the overall synthesis of new COX (which is supposed to take place 
within maturing megakaryocytes only) as a function of the maturation state s. P is 
considered to be constant over time. The unit of measure for P is [mass/time]. 
• f  is a function expressing the partial derivative of the active-COX distribution in all 
the proliferating megakaryocytes (Q2) with respect to the maturation state of the 
proliferating megakaryocytes s. 
• the fi (i = 1,2,3) are functions expressing the dependency of the initial value of the 
distribution over s (where ‘initial’ stands for ‘in the initial maturation state’, i.e. for s 
= 0) of compartment i on the previous variable state Qi-1. 
• k represents the degradation rate coefficient of COX. COX degradation is supposed to 
be a linear process taking place only in the platelets compartment, i.e. the degradation 
flux is proportional to COX amount in the compartment via a rate coefficient k, which 
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is supposed to be  a constant. The unit of measure for k is [time-1]. Information from 
[103] support an indicative value for COX half-life t½  of about 0.8÷1 day, i.e. a 
value for k equal to ln(2) / t½ ~ 4.8e-4÷6.0e-4 min-1.  
• y represents the output of the model, i.e. the measure, which is the time-course of 
active-COX total amount in blood (i.e. in all the circulating platelets). The unit of 
measure for y is [mass]. 
Analytical expression for the P(s), Qio, COXi0, f and fi are derived from the physiological 
parameters of thrombopoiesis mechanism, shown in Table 4.1, and from the COX 
degradation rate coefficient k and the rate of new COX synthesis in the single 
megakaryocyte pMK, following the rationale detailed in the following section 
4.4.2.1 Mathematical formulation 
To derive the mathematical formulation of the model, the steady-states of COX 
distributions separately for each cell type (i.e. maturing megakaryocytes, proliferating 
megakaryocytes, proplatelets and platelets) need to be considered and described. 
Analytical expression for the P(s), Qio, COXi0, f and fi will be highlighted in bold. 
 Maturing megakaryocytes 
COX kinetics within the single maturing MK  is simply given by the constant production 
of COX taking place in the single MK (pMK). Thus, the differential equation describing 
the COX time-course of the single maturing MK (qMKm(t)) is given by: 
 
¤}/ = -} , ¤}/(0) = 0 (4.14)  
Since in the initial maturation state (s = 0) COX = 0, the analytical solution for qMKm(t) is 
algebraically described by a linear equation (see Figure 4.18): 
 ¤}/() = -} ·   = 0 ÷ u¦_-X¨Nb\ (4.15)   
Assuming the population of MKs at the generic time t to be distributed, with respect to 
the state of maturation, without any privileged state (see Figure 4.16), we can state that 
the number of MKs in the single maturation state (N_MKs_per_s) is a constant given by: 
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_u¦_-CX_ = _u¦u¦_Nb\C (4.16)   
where N_MKs is the total number of MKs in bone marrow. 
Given the hypothesis of uniform distribution, we can also state that, in steady-state, COX 
distribution of maturing MKs over the maturation state s at the generic instant t (Q10) 
coincides with the time-course of qMKm (equation (4.15)) multiplied by the number of 
MKs in each maturation state: 
 
©ª« = _u¦u¦_Nb\C · -} · ,  = 0 ÷ u¦_Nb\C (4.17)   
COX total amount in all the maturing MKs is given by the sum of COX of each single 
maturing MK, thus is computed integrating equation (4.17) over s, and, in steady-state, is 
given by:  
 
¬­®ª« =  _u¦u¦_Nb\C · -} ·  
}_/_¯°
?
 =
= 12 · _u¦u¦_Nb\C · -} · u¦_±W²X
 
(4.18)   
The overall synthesis of new COX in the generic state s is a flux given by the single MK 
production pMK multiplied by the number of MKs in the maturation state s: 
 
³(´) = _u¦u¦_Nb\C · -}  = 0 ÷ u¦_±W²X (4.19)  
P(s) is a constant function defined in the interval 0 ÷ MK_matur, since production is 
supposed to take place in maturing MKs only. 
 Proliferating megakaryocytes 
In the single proliferating MK, a simple constant flux takes place, this flux representing 
COX amount transferred to ProPLTs in the unit time, until the MK is completely devoid 
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of COX. Thus the COX time-course in the single proliferating MK (qMKp(t)) is a linear 
function (see Figure 4.18): 
¤}B() = -} · u¦_±W²Xu¦_-X¨Nb\ ˙(u¦_-X¨Nb\ − ),  = 0 ÷ u¦_-X¨Nb\ (4.20)   
 
Figure 4.18: COX time-course within the single megakaryocyte. 
 
Given the usual hypothesis of uniform distribution, we can state that, in steady-state, the 
distribution of proliferating MKs over the maturation state s at the generic time t (Q20) is 
represented by the same linear function of the COX time-course in the single proliferating 
MK (equation (4.20)) multiplied by the number of MKs in each maturation state: 
©¶« = -} · u¦_±W²Xu¦_-X¨Nb\ ˙(u¦_-X¨Nb\ − ) · _u¦u¦_Nb\C,  = 0 ÷ u¦_-X¨Nb\ (4.21) 
Since the COX distribution of the single MK over its maturation state is a continuous 
function, denoting with s1 the maturation state of the maturing MK and with s2 the 
maturation state of the proliferating MK, for each generic time t it necessarily will be: 
 ( = u¦_±W²X, ) = 
(
 = 0, ) (4.22)   
that is, the initial condition for Q2 it is a function of Q1, and, in particular, coincides with 
the final value of the Q1 distribution: 
time
COX time-course within single MK
0 MK_matur MK_prolif
MK_life
pMK ·MK_matur
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 
(0, ) = ·¶Q©ª(´, ¸)S = ( = u¦_±W²X, ) (4.23)   
 COX total amount in all the proliferating MKs is given by the sum of COX of each 
single proliferating MK, thus is computed integrating equation (4.21) over s, and, in 
steady-state, is given by: 
¬­®¶« =  _u¦u¦_Nb\C · -} · u¦_±W²Xu¦_-X¨Nb\ ˙(u¦_-X¨Nb\ − ) 
}_B{z¹
?
 =
= 12 · _u¦u¦_Nb\C · -} · u¦_±W²X · u¦_-X¨Nb\ 
(4.24)   
COX total amount in all the MKs (maturing and proliferating), can be computed as the 
sum of equation (4.18) and equation (4.24): 
 v}º = v? + v
? = 12 · _u¦ · -} · u¦_±W²X (4.25)  
To derive the differential equation expressing the evolution of COX distribution in the 
proliferating MKs (Q2(s,t)) in function of the maturation state s, the following 
assumptions were made: 
- ProPLTs are constantly generated during the proliferation period of a MK, thus, the 
number of ProPLTs generating in each maturation state of the proliferating MK 
(N_new_ProPLTs_per_s) is supposed to be constant and equal to: 
 
_C»_'X¨'Z_-CX_ = _'X¨'Z_-CX_u¦u¦_-X¨Nb\  (4.26)   
- COX within the single proliferating MK is considered as a whole amount which, at 
each maturation state s, will be uniformly distributed among the ProPLTs “to be 
generated yet” at sate s. 
From equation (4.26), the number of ProPLTs “to be generated yet” (N_ProPLTs_tbg) is 
given by: 
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_'X¨'Z_¼Y() = ju¦B{z¹ − lu¦B{z¹ · _'X¨'Z_-CX_u¦ (4.27)  
Given the usual hypothesis of uniform distribution for the MKs population, the 
distribution over the maturation state s coincides with the time-course within the single 
MK multiplied by the number of MKs per state, thus, at the generic state s, the COX 
amount leaving the proliferating MK is given by the COX total amount in s, divided by 
the number of ProPLTs “to be generated yet” in s, multiplied by the number of new 
ProPLTs generating in s: 

(, )_'X¨'Z_¼Y() · _C»_'X¨'Z_-CX_ = 
(, )u¦_-X¨Nb\ −  
and the differential equation expressing the dependency of Q2(s,t) on the maturation state 
s, is given by: 
 
d
(, )d = ·Q©¶(´, ¸), ´S = 
(, )u¦_-X¨Nb\ −  (4.28)   
In steady-state, Q2(s,t) is given by equation (4.21), and equation (4.28) becomes: 
 
d
(, )d = -} · _u¦u¦_Nb\C · u¦_±W²Xu¦_-X¨Nb\ (4.29)   
which yields to a linear equation for Q2(s,t) over the maturation state s, as confirmed by 
equation (4.21). 
In figure Figure 4.19, 2 examples are shown: in the left column, active-COX time-course 
within the single proliferating MK in steady-state; in the right column, active-COX time-
course within the single proliferating MK in the case of an instant and partial inactivation 
of COX at t = t*. For each column, top panel represents active-COX time-course within 
the single proliferating MK, middle panel the number of ProPLTs to be generated as a 
function of the time, bottom panel active-COX amount leaving the proliferating MK. 
While in steady-state, active-COX amount transferred to ProPLTs is a constant amount 
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(panel C), in the other case, one can see how active-COX amount transferred to ProPLTs 
decreases after the inactivation at t = t* (panel F). 
 
Figure 4.19: Example of time-course of COX amount leaving the proliferating MK, in steady-state (left 
column), and in the case of an instant inactivation of COX at t = t* (right column). For each column, top 
panel represents active-COX time-course within the single proliferating MK, middle panel the number of 
ProPLTs to be generated as a function of the time, bottom panel active-COX amount leaving the 
proliferating MK.  
 Proplatelets 
The single ProPLT inherits a certain amount of COX when it is generated by its father 
MK, and then stores that COX amount for all its life (ProPLT_life), until it splits into 2 
PLTs. 
At the generic time t, the single newborn ProPLT inherits a COX amount (qProPLT(t)) 
given by the total COX amount in its father proliferating MK at time t (qMKp(t)) divided 
by the number of ProPLTs “to be generated yet” at time t: 
COX time-course within the single prolif MK
time0
MK_prolif
time0
time0
# ProPLTs to be generated
COX amount leaving the prolif MK
COX time-course within the single prolif MK
time0
MK_prolif
time0
time0
# ProPLTs to be generated
COX amount leaving the prolif MK
t *
A)
B)
C)
D)
E)
F)
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 ¤{() = ¤}B()_'X¨'Z_¼Y() (4.30)   
The newborn ProPLTs are the ProPLTs whose state of maturation is s = 0. 
The total number of newborn ProPLTs at each instant t (N_new_ProPLTs_s0) is a 
constant given by the number of proliferating MKs at time t multiplied by the number of 
ProPLTs generated in the unit time (which is the constant given by equation (4.26)):  
 
_C»_'X¨'Z_0 = }ºu¦z¹½ · _'X¨'Z_-CX_u¦ (4.31)   
Since the ProPLTs population is uniformly distributed, equation (4.31) represents also the 
constant number of ProPLTs in each maturation state. 
The COX amount in all the newborn ProPLTs (Q3(0,t)) is given by the COX-amount 
inherited by the single ProPLT (equation (4.30)) multiplied by the total number of 
newborn ProPLTs (equation (4.31)), which yields to: 
 (0, ) = ¤}B(, )u¦_-X¨Nb\ −  · _u¦ · u¦_-X¨Nb\u¦_Nb\C  (4.32)  
where qMKp(s) is the COX amount in the single proliferating MK, and it is simply given 
by the distribution of COX amount in the proliferating MKs over the maturation state s 
(Q2(s,t)), divided by the number of MKs in each maturation state (equation (4.16)), which 
yields to the following expression: 
 (0, ) = ·¾Q©¶(´, ¸)S = 
(, ) · u¦_-X¨Nb\u¦_-X¨Nb\ −  (4.33)   
In steady-state, Q2(s,t) is Q20. Considering that ProPLTs population is uniformly 
distributed and that the distribution of COX in ProPLTs over the maturation state (Q3(s,t)) 
is constant (see equation (4.7)), Q3(s,t) in steady-state (Q30) is obtained by using the 
expression for Q20, given by equation (4.21), in equation (4.33): 
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©¾« = _u¦u¦_Nb\C ∙ -} ∙ u¦_±W²X,  = 0 ÷ 'X¨'Z_Nb\C (4.34)   
COX total amount in all the ProPLTs is given by the sum of COX of each single ProPLT, 
and, in steady-state, is computed integrating equation (4.34) over s: 
¬­®¾« =  _u¦u¦_Nb\C · -} · u¦_±W²X 
{_z¹½
?
 =
= _u¦u¦_Nb\C · -} · u¦_±W²X · 'X¨'Z_Nb\C 
(4.35)   
 Platelets 
The single PLTs inherits half of the COX amount of its mother ProPLT. COX within 
PLTs is supposed to undergo a degradation process regulated by the degradation rate 
coefficient k. As for MKs and ProPLTs, also the total population of PLTs is uniformly 
distributed over the maturation state, meaning that the number of PLTs in each state of 
maturation is the same. Considering that the whole COX amount stored in all the 
ProPLTs at the end of their life (i.e. for s = ProPLT_life) is transferred to newborn PLTs 
(i.e. the set of all PLTs whose maturation state is s = 0), it is easy to compute the initial 
condition for the distribution of COX in PLTs over s (Q4(s,t)) as a function of the 
distribution of the previous compartment: 
 ¡(0, ) = ·¿Q©¾(´, ¸)S = ( = 'X¨'Z_Nb\C, ) (4.36)  
The differential equation expressing the kinetics of Q4(s,t) over s is the partial differential 
equation (4.10), whose solution yields to the expression for the distribution of COX in 
PLTs over the maturation state s: 
¡(, ) = ¡(0, ) ∙ CMf∙º  = 0 ÷ 'Z_Nb\C (4.37)  
Using equation (4.34), the expression for Q4(s,t) in steady-state is: 
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©¿« = _u¦u¦_Nb\C ∙ -} ∙ u¦_±W²X ∙ CMf∙º  = 0 ÷ 'Z_Nb\C (4.38)   
COX total amount in all the PLTs is given by the sum of COX of each single ProPLT, 
and, in steady-state, is computed integrating equation (4.38) over s: 
¬­®¿« =  _u¦u¦_Nb\C · -} · u¦_±W²X ∙ CMf∙º 
_z¹½
?
 =
= _u¦u¦_Nb\C · -} · u¦_±W²X · 'Z_Nb\C ∙ 1 − C
Mf∙_z¹½
(  
(4.39)   
Figure 4.20 shows a summary picture of COX kinetics within each single cell type: in the 
upper panel, COX kinetics within the single MK; in the middle panel, COX kinetics 
within the single ProPLT; in the bottom panel, COX kinetics within the single PLT. 
 
Figure 4.20: COX kinetics within the single MK (top), the single ProPLT (middle) and the single PLT (bottom) 
time
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4.4.2.2 Why a distributed model? 
The model is distributed meaning that the state variables, i.e. COX amounts, depend not 
only on the time but also on the state of maturation of the cells in which COX is stored: 
the state variables are, in fact, time-dependent distributions. 
The reason why a distributed model was implemented is that a lumped compartmental 
linear model misses the information on how COX is distributed among cells at different 
maturation states, thus not properly describing the timing of COX kinetics. For example, 
a lumped model is not able to explain a pure delay in the time-course recovery of active-
COX in the case of a complete shooting-down of the COX in platelets precursors: in fact, 
if all the COX in the platelets and proplatelets is inactivated, there won’t be any COX re-
appearance in platelets before a ∆t = ProPLT_life, because new active COX, produced in 
megakaryocytes, needs to be transferred from megakaryocytes to proplatelets, and then 
has to wait a period equal to the life of a proplatelet before moving to platelets. A lumped 
model cannot reproduce these behavior. In Figure 4.22, an example in which COX is 
completely and instantly inactivated in proplatelets and platelets at t = 1 day is shown for 
the distributed model (blue curve) and for a lumped version of the model (red curve) 
developed on the same literature knowledge (Figure 4.21) and described by equations 
(4.40)-(4.43). In the example of Figure 4.22, ProPLT_life is set to 1 day. 
 
Figure 4.21: Lumped version of the model for COX kinetics. 
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Figure 4.22: comparison between a lumped model and a distributed one for a complete inactivation of COX 
in both ProPLTs and PLTs. 
 
4.4.3 Aspirin PD 
Aspirin acts on COX permanently inactivating it, trough an irreversible acetylation 
process: a single molecule of Aspirin (ASA) reacts with a single molecule of COX 
producing a single molecule of salicylic acid (SA) and a single molecule of acetylated 
COX (COXA) [140]. The reaction follows a first order kinetics [130] and it is regulated 
by the constant λ (equation (4.44)). λ’s unit of measure is [mass-1time-1]. 
 ÀÁÀ + v Â ÁÀ + vÃ (4.44)   
Reaction (4.44) can be described by the mass-action law, which states that the speed of a 
reaction is proportional on the product of the molar concentrations of the reagents: 
 




QÀÁÀ()S = −λ ∙ QÀÁÀ()S ∙ Qv()SQv()S = −λ ∙ QÀÁÀ()S ∙ Qv()SQÁÀ()S = λ ∙ ÀQÁÀ()S ∙ Qv()SQvÃ()S = λ ∙ QÀÁÀ()S ∙ Qv()S
c
 
(4.45)   
(4.46)   
(4.47)   
(4.48)   
In the model of COX kinetics (Figure 4.17), a new flux appears from each compartment, 
representing COX acetylation by aspirin, as shown in Figure 4.23. 
The model is still described by the old equations (4.1)-(4.13), with the only difference 
that, now, in the derivative of COX with respect to time in each compartment (equations 
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(4.2), (4.5), (4.8) and (4.11), respectively) a new term appears, representing degradation 
by aspirin, modeled as in equation (4.46). Equations (4.2), (4.5), (4.8) and (4.11) are then 
replaced by the followings: 





c
 
d(, )d = −[ · QÀÁÀ()Sy} · (, ), 1(, 0) = 10 (4.49)   d
(, )d = −[ · QÀÁÀ()Sy} · 
(, ), 2(, 0) = 20 (4.50)   d(, )d = −[ · QÀÁÀ()Sy} · (, ), 3(, 0) = 30 (4.51)   
d¡(, )d = −[ · QÀÁÀ()Syz · ¡(, ), 4(, 0) = 40 (4.52)   
where [ASA(t)]BM and [ASA(t)]Bl represent the time-course of aspirin molar concentration 
in bone marrow and blood, respectively. 
According to equations (4.49)-(4.52), aspirin is supposed to act uniformly on COX, i.e. 
aspirin in blood will uniformly acetylate COX in all the PLTs, and aspirin in bone 
marrow will uniformly acetylate COX in all the MKs and the ProPLTs. 
 
Figure 4.23: Aspirin effect on COX kinetics: Aspirin contributes to COX elimination with a rate coefficient 
equal to λ·ASA(t). Aspirin concentration time-course in bone marrow acts on the compartments of 
maturing megakaryocytes, proliferating megakaryocytes and proplatelets; aspirin concentration time-
course in blood acts on the compartment of platelets. The regulation is represented by dashed red arrows. 
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4.4.4 Aspirin PK 
Aspirin represents the intervention input of the model. As for the thrombopoiesis 
mechanism, information on the time-course of aspirin was derived from the literature. 
A first issue to be faced when approaching aspirin PK is that aspirin can present 2 
different formulations: simple compressed tablets or enteric-coated tablets. Enteric-
coating of drug tablets is achieved by covering tablets with a polymer layer (usually a 
polyacid soluble in aqueous media), and is used to prevent the release of drugs in the 
stomach, either to reduce the risk of gastrointestinal side effects or/and to maintain the 
stability of drugs which are subject to degradation in the gastric environment [126]. 
Aspirin is enteric coated to protect gastric mucosa from corrosion, and this is particularly 
important for patients on chronic aspirin therapy. 
These 2 different formulation of aspirin (to which we will refer as ASA for the non-coated 
formulation and ecASA for the coated one) lead to different kinetics. One of the first work 
conducted with the objective  to compare different aspirin formulation is the one of Ali 
and others [93], where the authors enrolled six healthy subjects and measured, for each 
subject, ASA levels in plasma following a first ingestion of compressed tablets 650 mg 
aspirin, and a second ingestion, after a wash-out interval of 5 weeks, of enteric-coated 
tablets 650 mg aspirin. Figure 4.24 shows the mean time-course of the 2 different 
formulations: as one can see, ASA concentration (in µg/ml) reached its peak in plasma 
about 45 minutes after compressed tablet administration (upper left panel), and about 4 
hours after enteric-coated administration (upper right panel), thus exhibiting a very 
delayed and slower kinetics in the enteric-coated formulation compared to the non-coated 
one. Moreover, the authors observed that both aspirin formulations resulted in widely 
variable ASA levels (as one can see by the error bars of Figure 4.24) and, most notably, 
ASA was undetectable in plasma during 3 experiments involving enteric-coated 
formulation [126]. These results are relevant since they highlight the issue of the 
interindividual variability in response to aspirin. The work provides more complete 
information, since the authors measured also platelets COX activity, as presented in 
Figure 4.24, where the mean COX time-course is shown for the enteric coated 
formulation (bottom right panel) and for the non-coated one (bottom left panel). The 
delayed kinetics of enteric-coated formulation is reflected in COX kinetics too, since 
COX recovery is delayed in response to the enteric-coated administration, even if, apart 
from the delay, COX time-courses appears similar after 24 hours in both cases. 
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Figure 4.24: time-course (mean ± SEM) of ASA (left column) and COX (right column) after ingestion of 
aspirin 650 mg of compressed tablets (upper panels) and enteric-coated tablets (bottom panels) in six 
healthy volunteers. Figure from [126]. 
 
Similar results regarding the kinetics of different formulation of aspirin were obtained by 
Sai and others [132], who enrolled twelve healthy volunteers to receive four separated 
100 mg oral aspirin administration: intact and chewed non-coated tablets, and intact and 
chewed enteric-coated tablets. Figure shows the four resulting time-courses of plasma 
ASA concentration. ASA was detectable in serum within 20 minutes after the ingestion of 
intact non-coated aspirin, although the authors pointed out how significant variability was 
observed. After ingestion of intact coated aspirin, ASA was not detectable in serum until 
4 hours, while, when coated aspirin was chewed, ASA was detectable within 20 minutes 
after ingestion. Moreover, levels of ecASA were significantly lower than the others (even 
if the peak of ecASA concentration could not be determined since there were not 
measurements after 8 hours and ecASA appeared to keep on rising after 8 hours). From 
the experiment, the authors concluded that enteric-coated formulation results in a slower 
kinetics of aspirin and emphasized that a significant interindividual variability was 
observed [132]. 
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Figure 4.25: Serum ASA concentration after ingestion of intact (open) and chewed (closed) non-coated 
(circle) and coated (triangle) tablets was measured for 8 h. Each point represents the mean ± SEM of 10–12 
patients. Figure from [132]. 
This wide variability was confirmed by many other studies, and extreme results were 
obtained by Ross-Lee and others [129], who studied fourteen healthy volunteers 
randomized to receive 1200 mg of ASA or 1300 mg of ecASA. For all the volunteers 
administered with ecASA, ASA levels in serum were below the detection limit of the 
assay (< 0.5 mg/l) at all times of measurements. Only repeating the experiment with 650 
mg and measuring ASA levels with a more sensitive technique, peak concentrations were 
observed (mean 0.24 mg/l ± 11) 4 hours after dosing (mean 0.24 mg/l ± 11) in 3 subjects, 
and at 6 hours in one subject. 
This brief overview on the current literature knowledge on aspirin PK, makes it rather 
clear that: 
- aspirin PK strongly depends on tablet formulation: enteric-coating results in a delayed 
and slower kinetics with respect to the non-coated preparation; 
- interindividual variability plays a major role in the appearance of ASA in serum. 
An in silico model, which aims to investigate the adequacy of different aspirin regimens, 
necessarily needs to mathematically model not only COX but also aspirin kinetics. 
Moreover, as it’s clear from section 4.4.3, not only ASA time-course in blood is needed 
but in bone marrow too, and, due to limited access to bone marrow megakaryocytes, only 
a model allows to simulate this kinetics without invasive and expensive test. 
Thus, a compartmental model of ASA PK was developed (Figure 4.26): 
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Figure 4.26: The compartmental model for ASA kinetics. 
 
The model is described by the following linear differential equations: 


 c
 
Å =  ∙ j\()l − (_ ∙ , ? = 0 (4.53)  

Å = (_ ∙  − j(_ + (BÆl ∙ 
 + (ÆB ∙ , 
? = 0 (4.54)   
Å = (BÆ ∙ 
 − (ÆB ∙ , ? = 0 (4.55)   
 
where: 
• X1, X2 and X3 represent ASA amounts in gastro-intestinal tract, systemic compartment 
(i.e. systemic circulation) and bone marrow compartment (peripheral compartment), 
respectively. The unit of measure for X1, X2 and X3 is [mass]; 
• ka represents the rate of appearance of ASA from gastro-intestinal compartment to 
systemic compartment; kel represents the rate ASA elimination from systemic 
compartment and ASA distribution to the whole body; kps and ksp represent the rates 
of exchange from systemic to peripheral compartments and vice versa, respectively. 
The unit of measure for ka, kel, kps and ksp is [time-1]; 
• the input of the model is given by the product of the oral dose D (unit of measure: 
[mass]) and the derivative of a suitable function h(t), used to simulated different 
kinetics of ASA, depending on the formulation. h(t) is given by the following 
equation of Hill: 
ℎ() = /¦ + / (4.56)  
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where K is given by: 
¦ = ± + 1± − 1 ∙ _\NCA/ (4.57)  
and t_flex is the time in which h(t) has its point of inflection (Figure 4.27). 
 
Figure 4.27:  Example of h(t) used to simulate different kinetics of release of ASA. 
 
 h(t) represents the drug availability, thus: 
lim¯É ℎ() = 1 (4.58)  
meaning that all the initial dose is released in the systemic compartment. The 
derivative of h(t) is given by: 
ℎ() = ± ∙ 
/M ∙ ¦(¦ + /)
  (4.59)  
and it simulates the release of the oral dose D. 
Figure 4.28 shows the effect on h(t) (left column) and on the consequent flux of 
appearance in the systemic compartment ka·X1(t) (right column) caused by a variation 
of the parameter t_flex (upper row) and m (bottom row), following an ingestion of 
100 mg aspirin (the parameter ka was set to a nominal value of 0.1 min-1 in the 
example). As one can see, t_flex is responsible for the delay in the release of the drug 
and for the speed of the kinetics (the grater t_flex the grater the delay and the slower 
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1
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tflex
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the kinetics), while m mainly controls the speed of the release (the grater m, the faster 
the kinetics). Both the parameters have a direct effect on the peak of the flux of 
appearance, since the faster and earlier is the release, the grater is the peak. 
 
Figure 4.28: Variation of h(t) (left panels) and ka·X1(t) (right panels), for different values of t_flex (upper 
panels) and m (bottom panels), following a dose of 100 mg ASA. Values used for t_flex are 20, 60 and 120 
minutes, values used for m are 2, 3 and 4. ka is set to 0.1 min
-1
. 
 
While COX is physically contained into the cells and its kinetics is dependent on the 
different steps of the thrombopoiesis process, aspirin is free to move through cell 
membranes by diffusion, not depending on the processes of cell maturation. This is why 
aspirin kinetics is described by a traditional lumped model, i.e. the only independent 
variable is time. 
Given mutual interaction between aspirin and COX (see ASA PD in section 4.4.3), the 
model of aspirin PK cannot be modeled separately from the model of COX kinetics, thus 
a unique aggregated model is needed. In the following section the final model will be then 
presented. 
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4.4.5 Final model 
The connection of the 2 sub-models for COX kinetics (section 4.4.2) and for aspirin 
kinetics (section 4.4.4), combined by aspirin pharmacodynamics described in section 
4.4.3, results in the final model of Figure 4.29, described by equations (4.60)-(4.75).  
 
Figure 4.29: final model, partially lumped and partially distributed, of aspirin action. Red dashed lines 
represents interaction between aspirin and COX. 
 
In summary, the input is given by the oral dose of aspirin multiplied by the derivative of 
the hill function h(t) used to simulated enteric-coated formulation. Aspirin enters the 
gastro-intestinal compartment X1 and then appears, with a constant rate ka, in the 
systemic compartment. Aspirin in the systemic compartment is partially eliminated and 
utilized by all the other tissues, with a constant rate kel, and partially transferred to the 
bone marrow compartment X3 with a constant rate kps. Aspirin in bone marrow can move 
back to the systemic compartment with a constant rate ksp. Aspirin in the systemic 
compartment acts on COX in the compartment of circulating platelets Q4, while aspirin in 
bone marrow acts on COX in bone marrow, i.e. on the compartments of maturing and 
proliferating megakaryocytes (Q1 and Q2 respectively) and on the compartment of 
proplatelets Q3. The measure is represented by COX in circulating platelets. 
X2
Asp
Syst
X1
Asp
GI
D·
COX Bone Marrow
ka
kPS
kSP
kel
Q1
COX
MKs matur
Q2
COX
MKs prolif
Q3
COX
ProPLTs
Q4
COX
PLTs
P
X3
Asp
Perif
k
y
dt
dh
136 
 


























 Å =  − (_ ∙ , ? = 0 (4.60)   

Å = (_ ∙  − Ê(½z + (Bº + [ ∙ ¡!Ë¡Ì ∙ 
 + (ºB∙ , 
? = 0 (4.61)   
Å = (Bº ∙ 
 − Ê(Bº + [ ∙  + 
 + !Ëy} Ì ∙ , ? = 0 (4.62)   
d(, )d = '(), 1(0, ) = 0 (4.63)   
d(, )d = −[ · ! · (, ), 1(, 0) = 10 (4.64)   
v() =  (, )}_/_¯°? , v1(0) = v10 (4.65)   
d
(, )d = \Q
(, ), S, 2(0, ) = \21(, ) (4.66)   
d
(, )d = −[ · ! · 
(, ), 2(, 0) = 20 (4.67)   
v
() =  
(, )}_B{z¹? , v2(0) = v20 (4.68)   
d(, )d = 0, 3(0, ) = \32(, ) (4.69)   
d(, )d = −[ · ! · (, ), 3(, 0) = 30 (4.70)   
v() =  (, ){_z¹½? , v3(0) = v30 (4.71)   
d¡(, )d = −( · ¡(, ), 4(0, ) = \43(, ) (4.72)   
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Since modeling aspirin PD by the mass-action law needs the concentrations of the 
reagents, the volumes of the different compartments have now to be accounted for. 
The volumes appearing now in the equations are: VQBM, VQ4, VX2 and VX3, representing the 
total volume of megakaryocytes and proplatelets together, the total volume of circulating 
platelets, the total volume of the systemic circulation compartment and the total volume 
of bone marrow, respectively. Indicative values for VX2 and VX3 were taken directly from 
[108]. Value for VQBM was derived combining information on megakaryocyte dimensions, 
from [114], and on megakaryocytes numerosity, from [106]. Value for VQ4 was derived 
from [109], as product between the mean number of platelets per liter of blood and the 
mean platelet volume. 
4.4.6 Model Parameters 
Given the final model of Figure 4.29, described by equations (4.60)-(4.75), the complete 
list of parameters of the model, together with the respective literature ranges or nominal 
values, is reported in Table 4.2. 
The total number of parameters is 20, of which:  
• 13 parameters (N_MKs_per_Kg, MK_matur, MK_prolif, ProPLT_life, PLT_life, 
N_ProPLTs_per_MK, N_PLTs_per_MK, k, VQBM, VQ4, ka, VX2, VX3) can be considered 
known directly or derived from the literature. It is important to make clear that 
nominal values of the parameters are to be meant for healthy subjects. 
• 7 parameters (pMK, t_flex, m, kps, ksp, kel and λ) are unknown. 
An a-priori identifiability analysis was performed, using the DAISY (Differential Algebra 
for Identifiability of SYstems) software by Bellu and others [95], which  implements a 
differential algebra algorithm to perform parameter identifiability analysis for linear and 
nonlinear dynamic models described by polynomial or rational equations. The model 
turned out to be neither globally nor locally identifiable.  
However, since the model has an explorative aim and its main objective is to qualitatively 
describe experimental evidence, unknown parameter estimation by fitting real data did 
not appear to be the more suitable strategy, especially considering that: i) only one output 
was available (i.e. measurements in one compartment only) ii) data are characterized by a 
high variability, which inevitably leads to inaccurate parameters estimates. 
Thus, the model was not simplified and no data fitting was performed.  
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Unknown parameters setting is described in the following section. 
 
Parameter Description Literature value 
TH
RO
M
BO
PO
IE
SI
S 
N_MKs_per_Kg 
number of megakaryocytes per 
kilogram of subject weight ~ 6.1e
6
 [106] 
MK_matur maturation period of megakaryocytes ~ 2-4 days [117] 
MK_prolif proliferation period of megakaryocytes ~ 4-10 hours [106]-
[116] 
ProPLT_life lifespan of proplatelets ~ 12-24 hours [117] 
PLT_life lifespan of platelets ~ 7-10 days [135] 
N_ProPLTs_per_MK 
number of proplatelets generated from 
each megakaryocyte 
~ 1000 ÷ 1500 [116] 
N_PLTs_per_ProPLT 
number of platelets generated from 
each proplatelet 
2 [116] 
CO
X 
KI
N
ET
IC
S pMK 
COX new synthesis within the single 
maturing megakaryocyte 
? 
k COX degradation rate in platelets ~ 4.8e-4 min-1 [103] 
VQBM 
volume of all megakaryocytes and all 
proplatelets together 
~ 1000 ml [114] 
VQ4 volume of all circulating platelets ~ 15 ml [109] 
AS
A 
PK
 
t_flex time of inflection of the hill function ? 
m degree of the hill function ? 
ka 
rate of ASA appearance from gastro-
intestinal tract 
~ 0.1875 min-1 [123] 
kel 
rate of ASA elimination and 
distribution to all tissues from systemic 
circulation 
? 
kps 
rate of ASA exchange from systemic 
circulation to bone marrow 
? 
ksp 
rate of ASA exchange from bone 
marrow to systemic circulation 
? 
VX2 volume of systemic circulation ~ 5600 ml [108] 
VX3 volume of bone marrow tissue ~ 1177 ml [108] 
AS
A 
PD
 
λ 
rate constant of the reaction between 
ASA and COX 
? 
Table 4.2: Parameters of the final model, with literature ranges and nominal values. 
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4.5 Parameters setting 
With the objective of setting unknown parameters to reasonable values, a set of 
simulations was performed,  where, for each parameter, different values from a search 
interval have been tested, fixing all the others to nominal values. The known parameters 
were set to the mean value of the respective range or to the nominal value reported in 
Table 4.2. For each unknown parameter, Table 4.3 reports the nominal value used and the 
search interval.  
Parameter nominal value used in simulations Search interval 
pMK 1e-15 g/min 1e-18 ÷ 1e-11 
λ 2e3 mol-1min-1 102 ÷ 105 
t_flex 180 mins 20 ÷ 480 
m 4 2 ÷ 8 
kel 0.2 min-1 0.01 ÷ 1 
kps 0.01 min-1 0.001 ÷ 1 
ksp 0.01 min-1 0.001 ÷ 1 
Table 4.3:  Nominal values and search intervals for the unknown parameters. 
A sensitivity analysis was carried out by computing the sensitivity of two main output 
variables to each unknown parameter, performing a simulation of one week therapy 100 
mg ecASA once a day. 
The two output variables are: 
- lag-time: the delay in the recovery of platelets COX, formally defined as the time 
required to reach 10% of steady-state. 
- rise-time: the time required for platelets COX to go from 10% to 90% of its steady-
state level. 
The sensitivity of the output variable out to the parameter p was computed as: 
Á(-) = ¨²(-)- ∙ -¨²(-) (4.76)  
In the following, the variation of each single parameter is discussed and, in section 4.5.1.8, 
the mean sensitivities are summarized in Table 4.4. 
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4.5.1.1 COX production within the single MK: pMK 
There’s no direct information on pMK in the literature. However, since TxB2 is supposed 
to be proportional to COX activity [133], an indicative value for pMK can be computed 
with the hypothesis of a proportion 1:1 between TXb2 and COX. Using the expression for 
platelets COX at steady-state (equation (4.39)) and the baseline value for serum TxB2 in 
healthy subjects (retrieved from [133]), a value of 1.5e-15 g/min cab be computed for pMK. 
Rather than the absolute value of pMK, the amplification effect on pMK has been 
investigated: since the proportion 1:1 between TxB2 and COX is not confirmed in the 
literature, the real production within the single MK is supposed to be N times pMK, and the 
effect of a variation of N has been studied. In particular, an increase of N results in an 
increase of COX levels in each compartment (equations (4.18), (4.24), (4.35) and (4.39)). 
Considering equations (4.45) and (4.46), which describe the interaction between COX 
and ASA, one can see that, if COX increases by N times, COX kinetics (equation (4.45)) 
does not change, while ASA kinetics (equation (4.46)) changes and the effect of COX on 
ASA is amplified by N times. Thus, ASA is consumed much faster if COX increases, and 
this indirectly affects COX too, since if ASA decreases very fast, the effect on COX is 
lower. This is confirmed by simulations, in particular, by simulating a single 100 mg 
aspirin intake, one can see that, as N increases, ASA concentration peak in serum 
decreases (Figure 4.30.A) and, consequently, COX maximal acetylation in PLTs 
decreases too (Figure 4.30.B).  
Figure 4.31 shows the output variables lag-time (panel A) and rise-time (panel B) as 
functions of N, for a simulation of one week therapy 100 mg ecASA once a day. 
 
Figure 4.30: ASA concentration in serum (A) and COX time-course in PLTs (B), increasing the parameter N 
(0.01, 0.1, 10, 100, 1000). Single aspirin intake at t = 0. 
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Figure 4.31: lag-time (A) and rise-time (B) as function of the parameter N. 
The output lag-time is more influenced than the rise-time by a variation of the parameter 
N. It is interest to note how values greater than ~ 102 result in lag-time equal to zero and 
an absence of rise-time. This is because the maximal acetylation reached is too small, as 
one can see in Figure 4.30.B. Values smaller than ~ 102 seem to result in quite constant 
values of both lag-time and rise-time. In particular, the lag-time has a value of about 2 
days for N values between 10-3 and 102. A good choice for N is likely to be within this 
interval. 
4.5.1.2 Reaction constant: λ 
Considering again equations (4.45) and (4.46), which describe the interaction between 
COX and ASA, one can see that a variation on the value of λ affects both COX and ASA 
kinetics. In particular, the grater is λ, the greater is the mutual effect between COX and 
ASA, thus the maximal acetylation of PLTs COX is grater and the acetylation reaction is 
faster (Figure 4.32.A shows this behavior for a simulation of a single intake of 100 mg 
aspirin). This is particular relevant in the case of repeated doses: Figure 4.32.B reports the 
results of a simulation of one week 100 mg ecASA once a day; one can see that, a small 
value of λ allows to obtain an effect of the duration of the therapy, i.e. we need more than 
one intake to achieve the maximal effect. However, a small value for λ does not result in a 
complete acetylation of COX in PLTs, thus not reflecting reality. 
To observe a sensible effect of λ on ASA concentrations, COX levels have to be increased 
(by increasing pMK as explain in the previous section), otherwise no effect of λ can be 
detected (Figure 4.33.A). This is because COX concentration is much smaller than ASA 
concentration, thus, to observe an effect on ASA, COX concentration needs to be grater 
(equation (4.46)). Amplifying pMK for example by 1000 times, an effect of λ on ASA 
A) B)
10-4 10-2 100 102 104
0
0.5
1
1.5
2
2.5
lag-time vs N
N (unitless)
la
g-
tim
e
(da
ys
)
10-4 10-2 100 102 104
3.54
3.545
3.55
3.555
3.56
3.565
3.57
3.575
3.58
3.585
3.59
lrise-time vs N
N (unitless)
ris
e-
tim
e
(da
ys
)
142 
 
concentration can be observed (Figure 4.33.B): as λ increases, ASA peak decreases, 
meaning that the effect of COX on ASA in greater. 
 
Figure 4.32: COX time-course in PLTs after a single dose (A) and after one week treatment with 24 hours 
intakes (B), increasing the parameter λ (100, 500, 3000, 15000, 10000). Aspirin last intake at t = 0. 
 
 
Figure 4.33: ASA concentration in serum varying λ (100, 500, 3000, 15000 and 10000) with no 
amplification of COX production (N=1, panel A) and with a one thousands amplification of COX production 
(N = 1000, panel B). Single aspirin intake at t = 0. 
Figure 4.34 shows the output variables lag-time (panel A) and rise-time (panel B) as 
functions of λ, for a simulation of one week therapy 100 mg ecASA once a day. 
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Figure 4.34: lag-time (A) and rise-time (B) as function of the parameter λ. 
It is interesting to note how small values of λ result in lag-time equal to zero, meaning 
that there is not enough acetylation of COX in PLTs (see in Figure 4.32). As a 
consequence, no rise-time can be computed for small λ values. For greater values, one can 
see that, as λ increases, the lag-time increases, while the rise-time decreases, becoming 
quite constant for λ values greater than ~ 103, even if the rise-time appears to exhibits a 
minimum for λ values between 103 and 104. A lag-time of about 2 days is obtained for λ 
values between 102 and 104, thus a good choice for N is likely to be within this interval.  
 
4.5.1.3 Time of inflection of h(t): t_flex 
As already described in section 4.4.4, t_flex is the parameter representing the time at 
which the hill function, used o simulate the enteric-coated formulation of aspirin, has its 
point of inflection.  The parameter is responsible for the delay in the release of the drug 
and for the speed of ASA kinetics. Figure 4.35 shows results of a simulation of a single 
100 mg aspirin intake: as one can see, the grater t_flex the grater the delay and the slower 
the kinetics of ASA (panel A). COX kinetics is affected in the same way even if the 
overall effect is not so strong (panel B). 
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Figure 4.35: ASA concentration in serum (A) and COX time-course in PLTs (B), increasing the parameter 
t_flex (20, 60, 120, 240 and 480 minutes). Single aspirin intake at t = 0. 
Figure 4.36 shows the output variables lag-time (panel A) and rise-time (panel B) as 
functions of t_flex, for a simulation of one week therapy 100 mg ecASA once a day. 
 
Figure 4.36: lag-time (A) and rise-time (B) as function of the parameter t_flex. 
The parameter t_flex mainly affects the lag-time: as it increases, the lag-time increases 
too. t_flex exhibits the same effect on the rise-time, even if much weaker. In particular, a 
lag-time of about 2 days is obtained for t_flex values around 200 minutes, thus a good 
choice for t_flex is likely to be near this value. 
4.5.1.4 Degree of h(t): m 
As already described in section 4.4.4, m is the degree of the hill function h(t) and it 
mainly controls the speed of ASA kinetics. Figure 4.37 shows results of a simulation of a 
single 100 mg aspirin intake: as one can see, the grater m, the faster the kinetics and the 
higher the peak of ASA (panel A). The kinetics of COX recovery is affected too, but with 
definitely smaller effect (panel B). 
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Figure 4.37: ASA concentration in serum (A) and COX time-course in PLTs (B), increasing the parameter m 
(2, 3, 4, 5 and 6). Aspirin intake at t = 0. 
Figure 4.38 shows the output variables lag-time (panel A) and rise-time (panel B) as 
functions of m, for a simulation of one week therapy 100 mg ecASA once a day. 
 
Figure 4.38: lag-time (A) and rise-time (B) as function of the parameter m. 
Both the lag-time and the rise-time are decreasing function of m, even if the effect of this 
parameter is not so great. m ~ 4 appears a good choice to obtain a lag-time of about 2 
days. 
4.5.1.5 Elimination rate from the systemic compartment: kel 
kel represents the overall ASA elimination from the central compartment, sum of several 
mechanisms: pre-systemic uptake from the liver, elimination with urine, and utilization 
by other tissues. All these mechanisms have been modeled as a single flux, which is 
supposed to be proportional to ASA concentration in the systemic compartment, via the 
rate coefficient kel. Thus, it is clear how kel plays a major role in the kinetics of ASA in 
the systemic compartment, and, as a consequence, on all the other compartments. Figure 
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4.39 shows results of a simulation of a single 100 mg aspirin intake: as kel increases, ASA 
elimination from the central compartment is faster, thus the peak of ASA concentration 
decreases and the kinetics if faster (panel A); consequently, COX acetylation decreases 
(panel B). 
 
Figure 4.39: ASA concentration in serum (A) and COX time-course in PLTs (B), increasing the parameter kel 
(0.001, 0.01, 0.1, 0.5 and 1 min
-1
). Aspirin intake at t = 0. 
Figure 4.40 shows the output variables lag-time (panel A) and rise-time (panel B) as 
functions of kel, for a simulation of one week therapy 100 mg ecASA once a day. 
As one can see, as kel increases the lag-time decreases, since ASA elimination is greater. 
For kel near to 1, the lag-time becomes almost null, meaning that ASA elimination is so 
great that COX acetylation is too small. The rise-time is quite constant for small values of 
kel, (even if there seems to be a minimum for kel values around 10-1) then it increases as kel 
increases. For kel near to 1, no rise-time can be computed, since COX acetylation is too 
small. Since kel models several mechanism, including uptake from the liver which is 
known to be relevant [123], reasonable values could be in the range of 0.1÷0.5 min-1. This 
appears to be confirmed by Figure 4.40.A, since a correct lag-time of about 2 days is 
obtained for kel values near to 10-1. 
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Figure 4.40: lag-time (A) and rise-time (B) as function of the parameter m. 
 
4.5.1.6 Transfer rate from systemic to peripheral compartment: kps 
This parameters represents the flux of ASA from the central compartment to the bone 
marrow compartment. Figure 4.41 to Figure 4.43 show results of a simulation of a single 
100 mg aspirin intake: as kps increases, a greater amount of ASA is transferred from the 
central compartment to the peripheral one, thus, the peak of ASA concentration in the 
systemic compartment decreases (Figure 4.41.A) and the one in the peripheral 
compartment increases (Figure 4.41.B). This results in a greater acetylation of COX in 
MKs, both maturing and proliferating (Figure 4.42) and ProPLTs (Figure 4.43.A) which 
produces a more delayed recovery of COX in PLTs, as shown in Figure 4.43.B. 
 
Figure 4.41: ASA concentration in serum (A) and in bone marrow (B), increasing the parameter kps (0.001, 
0.005, 0.03, 0.15 and 1 min
-1
). Single aspirin intake at t = 0. 
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Figure 4.42: COX time-course in maturing (A) and proliferating (B) MKs, increasing the parameter kps 
(0.001, 0.005, 0.03, 0.15 and 1 min
-1
). Single aspirin intake at t = 0. 
 
Figure 4.43: COX time-course in ProPLTs (A) and PLTs (B), increasing the parameter kps (0.001, 0.005, 0.03, 
0.15 and 1 min
-1
). Single aspirin intake at t = 0 
Figure 4.44 shows the output variables lag-time (panel A) and rise-time (panel B) as 
functions of kps, for a simulation of one week therapy 100 mg ecASA once a day. 
 
Figure 4.44: lag-time (A) and rise-time (B) as function of the parameter kps. 
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As one can see, small values of kps result in a small lag-time, while great values of kps 
result in a too high lag-time. This is because great values of kps cause ASA to accumulate 
in bone marrow, requiring several days before a complete elimination. This causes a 
slower COX recovery in PLTs. The rise-time seems to exhibits a minimum for a kps 
values of about 10-2. A lag-time of about 2 days is obtained for kps values between 10-2 
and 10-1, thus a good choice for kps is likely to be within this interval. 
 
4.5.1.7 Transfer rate from systemic to peripheral compartment: ksp 
This parameters represents the flux of ASA from the bone marrow compartment to the 
systemic one. Figure 4.45 to Figure 4.47 show results of a simulation of a single 100 mg 
aspirin intake: as ksp decreases, the kinetics of ASA in bone marrow is slower and the 
peak increases, as shown in Figure 4.45.B. ASA in systemic compartment is not 
sensitively affected by ksp (Figure 4.45.A). This is because the flux from the peripheral 
compartment is dominated by the flux from the gastro-intestinal compartment (which is 
grater), thus the overall appearance of ASA in the systemic compartment is little 
influenced by the former flux. As a consequence, as ksp decreases, the acetylation of COX 
in MKs, both maturing and proliferating (Figure 4.46), and ProPLTs (Figure 4.47.A) 
increase, resulting in a more delayed recovery of COX in the PLTs compartment, as 
shown in Figure 4.47.B. 
 
Figure 4.45: ASA concentration in serum (A) and in bone marrow (B), increasing the parameter ksp (0.001, 
0.005, 0.03, 0.15 and 1 min
-1
). Single aspirin intake at t = 0. 
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Figure 4.46: COX time-course in maturing (A) and proliferating (B) MKs, increasing the parameter ksp 
(0.001, 0.005, 0.03, 0.15 and 1 min
-1
). single aspirin intake at t = 0. 
 
Figure 4.47: COX time-course in ProPLTs (A) and PLTs (B), increasing the parameter ksp (0.001, 0.005, 0.03, 
0.15 and 1 min
-1
). Single aspirin intake at t = 0. 
Figure 4.48 shows the output variables lag-time (panel A) and rise-time (panel B) as 
functions of ksp, for a simulation of one week therapy 100 mg ecASA once a day. 
 
Figure 4.48: lag-time (A) and rise-time (B) as function of the parameter ksp. 
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In the opposite way respect to kps, small values of ksp result in a too high lag-time, while 
great values of ksp result in no lag-time (i.e. no sufficient acetylation in bone marrow). 
This is because small values of ksp cause ASA to accumulate in bone marrow, requiring 
several days before a complete elimination. As one can see, for ksp values greater than ~ 
10-1 the lag-time becomes null and, as a consequence, the rise-time cannot be computed 
since the maximal ecetylation of COX in PLTs is too small. The rise-time exhibits a 
minimum for a ksp values of about 10-2. A lag-time of about 2 days is obtained for ksp 
values of about 10-2 results in a lag-time of about 2 days, thus a good choice for ksp is 
likely to be near this value. 
 
4.5.1.8 Sensitivity results 
Table 4.4 reports the mean sensitivity of each output variable to each unknown parameter. 
Output 
variable 
Parameter 
pMK λ t_flex m kel kps ksp 
lag-time -0.005 0.360 0.129 -0.085 -0.274 0.503 -0.516 
rise-time 0.001 -0.035 0.018 0.083 0.044 -0.032 -0.011 
Table 4.4: mean sensitivities of lag-time and rise-time to each unknown parameter. 
The parameters regulating aspirin exchanges between systemic and peripheral 
compartment, i.e. kps and ksp, have a major effect on the output variable lag-time. λ and 
t_flex have a non-negligible effect on lag-time too, even if lower, and the weakest effect 
is the one of pMK. On the other hand, m is the parameter exhibiting the greater effect on 
the output variable rise-time, followed by kel and by λ and kps. Even for the rise-time pMK 
is the parameter with the weakest effect. 
 
4.5.1.9 Final parameter values 
Given the indicative results of simulations performed to investigate the effect of each 
unknown parameter on the output, the final list of values for all the parameters is reported 
in Table 4.5. Each known parameter has been set to its mean literature value (see Table 
4.2), while for each unknown parameter a reasonable value has been set on the basis of 
indications described in the previous sections. 
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 Parameter final value 
TH
RO
M
BO
PI
ES
IS
 
M_MKs_per_Kg 1.6e6 
N_ProPLTs_per_MK 1000 
N_PLTs_per_ProPLT 2 
MK_matur 3 days 
MK_prolif 7 hours 
ProPLT_life 18 hours 
PLT_life 8.5 days 
CO
X 
KI
N
ET
IC
S VQBM 1000 ml 
VQ4 15 ml 
k  4.8e-4 min-1 
pMK 1e-15 g/min 
AS
A 
PK
 
t_flex 180 mins 
m 4 
ka 0.1875 min-1 
kps 0.01 min-1 
ksp 0.01 min-1 
kel 0.2 min-1 
VX2 5600 ml 
VX3 1177 ml 
AS
A 
PD
 
λ 2e3 mol-1min-1 
Table 4.5: Final parameter values. 
 
4.6 Data 
Data available to evaluate the model performances come from the clinical trial performed 
on healthy subjects described in section 4.2.2.1. Data are relative to 48 healthy Caucasian 
subjects randomized to 1 to 8 groups, according to treatment duration, ranging from 1 to 8 
weeks. Each patient received enteric-coated aspirin 100 mg once a day and was instructed 
to take tablets at the same time of the day. Serum TxB2 (in ng/ml) was measured at the 
end of each week of aspirin, and at days 1, 2, 3 and 7 after withdrawal [133].  
In Figure 4.49 the mean curves (as percentage of baseline) for each group are presented, 
where also the steady-state value of TxB2 during aspirin treatment was added as initial 
value at time t = 0. 
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Figure 4.49: Mean curves of TxB2 baseline and recovery after aspirin therapy for each group of treatment. 
 
Authors observed that the overall kinetics of TxB2 recovery showed a complex sigmoidal 
pattern and that initial recovery of serumTxB2 levels seem to differ among groups. Since, 
by visual inspection of the data, it is difficult to observe differences among groups, the 
mean curve of all the data was computed (Figure 4.50) and the model was tested on it. 
 
Figure 4.50: Mean curve (± SD) over all the 48 subjects of TxB2 recovery (as percentage of baseline) after 
aspirin therapy. 
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4.7 Simulations 
4.7.1 Healthy subjects 
A qualitative description of the data presented in the previous section was performed, 
running a simulation of one week reproducing the same aspirin regimen of experimental 
data (100 mg ecASA every 24 hours), using parameters values reported in Table 4.5. 
Figure 4.51 shows the results of the simulation against real data. 
 
Figure 4.51: Serum active-COX time-course prediction (in percentage of baseline value) against real data, 
after a week of 100 mg ASA every 24 hours. First aspirin intake is at t = -6 days. Last intake is at t = 0. 
 
As one can see, the prediction is quite good, since the COX time-course in serum exhibits 
the ~2 days delay after aspirin withdrawal and the sigmoidal shape with a complete 
recovery about one week after withdrawal. 
Moreover, it can be seen how 3-4 intakes are needed in order to obtain the maximal effect. 
In particular, the curve of Figure 4.51 is characterized by the following output 
parameters: 
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Simulation on healthy subjects 
maximal acetylation of serum COX 99.2 % of baseline 
lag-time of COX recovery 1.9 days 
rise-time of COX recovery 3.6 days 
COX recovery at 7 days 95 % of baseline 
slope of COX recovery between 12 and 24 hours 0.042 %/h 
Table 4.6: Output parameters of the simulated COX recovery for healthy subjects. 
 
4.7.2 Diabetic subjects 
The model can be used also as a mean to test potential mechanisms for the diminished 
response to aspirin in diabetic patients, leading to treatment failure in most cases (the so-
called ‘aspirin resistance’). In the literature it has been hypothesized that the faster TxB2 
recovery after an aspirin intake characterizing diabetic patients may be caused by an 
enhanced  COX biosynthesis due to faster platelet turnover. 
In order to investigate how variations in the parameters of thrombopoiesis and COX 
kinetics affect the output, a sensitivity analysis, similar to the one conducted for the 
unknown parameter in section 4.5, has been performed. The tested parameters, together 
with nominal values and search intervals, are reported in Table 4.7. 
Parameter nominal value  Search interval 
MK_matur 3 days 0.25 ÷ 4 
MK_prolif 7 hours 1 ÷ 48 
ProPLT_life 18 hours 1 ÷ 48 
PLT_life 8.5 days 2 ÷ 14 
k 4.8e-4 min-1 6.8e-5 ÷ 4.8e-3 
Table 4.7:  Nominal values and search intervals for the parameters of thrombopoiesis and COX kinetics. 
The mean sensitivities of the lag-time and rise-time to each tested parameter are reported 
in Table 4.8. 
Output variable Parameter 
MK_matur MK_prolif ProPLT_life PLT_life k 
lag-time 0.212 0.159 0.388 0.012 -0.152 
rise-time 0.201 0.053 -0.001 0.077 -0.292 
Table 4.8: mean sensitivities of lag-time and rise-time to each tested parameter. 
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As one can see, the parameter which most affect the lag-time is the life of the proplatelets 
(ProPLT_life), in particular, as ProPLT_life increases the lag-time increases. This result 
confirms the hypothesis made in section 4.4.2.2 about the major role of ProPLT_life in 
determining the delay in platelets COX recovery, thus it is quite encouraging. On the 
other hand, ProPLT_life minimally affects the rise-time, meaning that this parameter is 
responsible only for the delay  but not for the slope in the recovery of platelets COX after 
aspirin intakes. The rise-time is most influenced by the rate of COX degradation (k): as k 
decreases the overall COX kinetics becomes slower, thus the rise-time increases. It is 
interesting to note how the parameter MK_matur, representing the maturation period of 
megakaryocytes, has a strong effect on both the lag-time and the rise-time. This means 
that a longer maturation period of megakaryocyte results in a slower recovery of platelets 
COX, producing both a longer delay and a lower slope of the recovery. 
The main difference between healthy and diabetic subjects, depicted in results from 
clinical trials described in section 4.2.2, is the speed of COX recovery after aspirin 
intakes. From Table 4.8, the parameters which most affect the recovery of COX after an 
aspirin intake are the maturation time of megakaryocytes (MK_matur) and the COX 
degradation rate (k). The parameter ProPLT_life instead simply results in a shift of COX 
recovery, but not in a faster recovery. Thus, a possible mechanism to explain the faster 
COX recovery in diabetic patients can be represented by an enhanced megakaryocyte 
turnover (in particular a faster maturation) and an increased utilization of COX by 
platelets. For example, using all the values reported in Table 4.5, except for MK_matur 
and k which were decreased from 3 days to 1 day and from 4.8e-5 min-1 to 1e-5 min-1 
respectively, the recovery of serum COX in a diabetic patient was simulated, in response 
to the same therapy of one week 100 mg ecASA once a day undergone by healthy 
subjects. Results are shown in Figure 4.52, where the simulated time-course of serum 
COX for the diabetic patient (green curve) is compared to the one for healthy subjects 
(blue curve). By visual inspection, COX recovery results markedly faster in case of 
diabetes, though the maximal acetylation is comparable to the one of healthy subjects, as 
confirmed by results from clinical trials (see section 4.2.2.2). Table 4.9 reports the output 
parameters of the diabetic curve, compared to the healthy ones. As one can see, maximal 
acetylation of serum COX is almost complete in both cases, and the main difference is 
represented by the speed of the recovery, in particular both the lag-time and the rise-time 
are smaller and the slope of the recovery between 12 and 24 hours is doubled. 
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Simulation on  subjects: healthy diabetic 
maximal acetylation 99.2 % of baseline 98 % of baseline 
lag-time 1.9 days 1.2 days 
rise-time 3.6 days 2.5 days 
recovery at 7 days 95 % of baseline 100 % of baseline 
slope of COX recovery between 12 and 24 hours 0.042 %/h 0.098 %/h 
Table 4.9: Output parameters of the simulated COX recovery for a diabetic subject, compared to healthy 
subjects 
 
Figure 4.52: Simulation of COX time-course in diabetic patients (green curve) versus healthy patients (blue 
curve) after a week of aspirin therapy 100 mg once a day. Last aspirin intake is at t = 0. 
 
4.7.3 Different aspirin regimens 
The model was also tested to explain the effect of different aspirin regimens. Following 
the experimental protocol of [128], the slope of COX recovery between 12 and 24 hours 
after aspirin intake was computed for three different aspirin therapies: i) one week of 100 
mg ecASA once a day every 24 hours (100od), ii) one week of 200 mg ecASA once a day 
every 24 hours (200od), iii) one week of 100mg ecASA twice a day every 12 hours 
(100bd). Results are reported in and in Figure 4.53 and Table 4.10. The model predicted a 
stronger effect for both the 200od and the 100bd therapy, compared to the 100od therapy, 
but was not able to correctly predict a stronger effect of the 100bd therapy with respect to 
the 200od therapy. The most probable explanation is that, the stronger effect of the 100bd 
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therapy is due to some non-linearity in the kinetics of aspirin, which the model is not able 
to reproduce. 
 
Figure 4.53: Serum COX recovery between 12 and 24 hours after intake (at t = 0) for different aspirin 
regimens: 100 mg once a day (blue), 200 mg once a day (red) and 100 mg twice a day (green). 
 
aspirin regimen slope of COX recovery between 12 and 24 hours 
100od 0.042 %/h 
200od 0.011 %/h 
100bd 0.015 %/h 
Table 4.10: Slope of COX recovery between 12 and 24 hours (as percentage of baseline per hour) for 
different aspirin regimens: 100 mg once a day (100od), 200 mg once a day (200od) and 100 mg twice a day 
(100bd). 
 
4.8 Discussion 
In this chapter the problem of modeling the effect of the treatment on the phenotype was 
discussed, focusing on the preventive effect of aspirin against atherothrombosis and 
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has been proofed to have a significant effect, a clear benefit of aspirin in the prevention of 
major cardiovascular events in people with diabetes remains unproved. 
From a biological point of view, the best-characterized mechanism of action of aspirin is 
the inhibition of thromboxane-dependent platelet function, through permanent 
inactivation of the COX-1, an enzyme which leads to the final formation of thromboxane 
TxB2, the major promoter of platelets activation and aggregation. 
Although widely studied in many clinical trials, a characterization of this mechanisms 
from a modeling point of view is still missing in the literature. 
A compartmental model of COX kinetics and aspirin pharmacokinetics-
pharmacodynamics has been developed with the objective of qualitatively describing and 
simulating the process of COX inhibition and reappearance in platelets in response to 
aspirin exposure. 
The model consists of four key-elements (interconnected each other), describing: i) the 
timing of the thrombopoiesis mechanism, ii) COX kinetics, iii) aspirin PK and iv) aspirin 
PD, respectively. 
The two main innovative features of the work are represented by: i) the distributed 
description adopted for COX kinetics, which makes the model capable to correctly 
simulate COX time-course in the different compartments according to the timing of the 
thrombopoiesis mechanism, ii) the interconnection between the aspirin PK model and the 
COX kinetics model (which differs from the classical approach of using the drug 
concentration as a forcing input of the model), which allows to correctly model the not 
separable interaction between aspirin and COX.  
The model has been tested on data of serum thromboxane TxB2 (which is proportional to 
platelets COX activity) recovery levels after aspirin withdrawal in 48 healthy subjects, 
treated with aspirin 100 mg daily for 1 to 8 weeks. Data are taken from [133]. Given the 
explorative aim of the model and the available data, the evaluation of the model was 
performed from a qualitative point of view, obtaining a good prediction for the time-
course of COX recovering in serum. 
The model, however, predicts the need for 3-4 aspirin intakes only before reaching the 
maximal effect of the treatment, while the authors concluded from [133] that at least 1-2 
weeks of treatment are required to achieve maximal effect. The authors in fact observed 
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that initial recovery of serumTxB2 levels seem to differ among groups: they performed a 
2-factor repeated measurements analysis of variance with the post hoc Holm-Sidak test 
for pairwise comparison, and found that at days 1 and 2 following aspirin withdrawal, 
TxB2 values were similar in the subjects treated for 1 and 2 weeks and significantly 
higher than the corresponding values of longer treatment groups (p-value < 0.05). Since, 
by visual inspection of the data (see Figure 4.49), it is difficult to observe differences 
among groups (also because of the high interindividual variability), a complete statistical 
analysis was performed, in order to confirm or reject the hypothesis of significant 
differences. 
In particular, a one-side t-test for each sample time t and on each couple of consecutive 
groups (i,i+1) was performed, in order to test whether TxB2 levels of group i were 
significantly higher than TxB2 levels of group i+1 at the same times: TxB2i(t) > TxB2i+1(t), 
i.e. whether treating one more week with aspirin had a significant effect in the decrease of 
TxB2 recovery. Also clustering group 1 and 2 vs other groups was tested. Results are 
shown in Table 4.11. 
one-sided t-test: group i > group i+1 
 
p-value 
test 0 d 1 d 2 d 3 d 7 d 
1 > 2 ? 0.428 0.373 0.067 0.361 0.065 
2 > 3 ? 0.284 0.057 0.214 0.428 0.001 
3 > 4 ? 0.329 0.152 0.123 0.256 0.146 
4 > 5 ? 0.140 0.471 0.408 0.454 0.305 
5 > 6 ? 0.400 0.246 0.068 0.447 0.447 
6 > 7 ? 0.226 0.277 0.480 0.437 0.366 
7 > 8 ? 0.187 0.040 0.061 0.378 0.416 
(1,2) > (3,4,5,6,7,8) ? 0.083 0.048 0.051 0.210 0.015 
Table 4.11: one-sided t-test for each groups couple for each time. 
From Table 4.11, we observe only one p-value < 0.05, coming from testing group 7 (7 
weeks treatment) versus group 8 (8 weeks treatment) at time t = 1 day, all the other tests 
being not significant. Testing group 1 and 2 together (1-2 weeks treatment) versus all the 
other groups (3 to 8 week treatment) resulted in only one weak significant difference at 
time t = 1 day. 
Then, a test for trend was performed, in order to test whether a trend of TxB2 levels exists 
along groups, i.e. whether increasing the duration of aspirin treatment induced a 
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significant decrease of TxB2 levels. A COX-Stuart test for trend for continuous data was 
performed, for each sample time t. All the six p-values were greater than the significant 
threshold 0.05, thus no significant effect of the treatment duration on the decrease of 
TxB2 levels could be found. 
Finally, the same analysis carried out by the authors was re-implemented. A 2-factor 
mixed ANOVA with the post hoc Holm-Sidak test for pairwise comparison was 
performed. The overall ANOVA found a weak significant difference among groups (p-
value = 0.046), but the post hoc Holm-Sidak test was not able to significantly cluster the 
groups (all the p-value were greater than the significant threshold). 
From this statistical analysis it is difficult to conclude about significant differences among 
groups and the effect of therapy duration on platelets COX recovery probably needs 
future insights. 
The model was also tested for a potential mechanism to explain the diminished response 
to aspirin in diabetic patients and for explaining the effect of different aspirin regimens. 
By modifying two key parameters, describing the maturation period of megakaryocytes 
and the COX degradation rate constant respectively, the model was able to simulate a 
faster COX recovery in the 12-24 hours interval after aspirin intake for diabetic subjects, 
thus reproducing literature findings. 
The model, however, was not able to explain the greater effect (resulting in a slower COX 
recovery) of a therapy with intakes of 100 mg ecASA every 12 hours, compared to a 
therapy with intakes of 200 mg ecASA every 24 hours, thus underlining the need for 
future refinements in particular regarding aspirin pharmacokinetics. 
In conclusion, though future improvements are needed, the actual model represents a 
good starting point for further refinements and investigations. Future experiments with 
multiple measurements (i.e. simultaneous measurements in different compartments) could 
help to obtain a deeper understanding of the involved phenomena, providing the model 
with additional information, which could help designing personalized antiplatelet 
regimens in diabetes mellitus. 
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5 Conclusions 
 
In this thesis, the problem of investigating long-term complications of diabetes mellitus 
has been faced with a multi-level approach. Given the complex-nature of such a disease, 
the multi-level approach allows to characterize the phenomena of interest at different 
levels of detail, according to data availability. In the present work of thesis, three main 
levels of study have been discussed and, for each one, novel investigation methodologies 
have been proposed. 
The context of investigation of the first level of study is the one of  Genome Wide 
Association Studies, in which the objective is, on one hand, to detect correlation between 
one or more SNPs and a discrete trait (diabetes, in this case) and, on the other, to learn a 
rule to perform subject classification. The multivariate analysis approaches, developed so 
far, still suffer for the lack of precision and stability of the lists of biomarkers selected, 
mainly due to linkage disequilibrium, i.e. the non-random association between the true 
genetic causes and the SNPs in genomic regions close to them, which confounds the 
search for genetic biomarkers. A new algorithm, Bag of Naïve Bayes, was developed to 
effectively tackle this problem. BoNB is based on Naïve Bayes classification enriched by 
three main features to tailor the Naïve Bayes framework to Genome Wide SNP data 
analysis: (a) a bagging of Naïve Bayes classifiers, to improve the robustness of the 
predictions, (b) a novel strategy for ranking and selecting the attributes used by each 
bagged classifier, to enforce attribute independence, and (c) a permutation-based 
procedure for selecting significant biomarkers, based on their marginal utility in the 
classification process. The effectiveness of BoNB was demonstrated by applying it to the 
WTCCC case-control study on Type 1 Diabetes: BoNB outperforms two algorithms from 
the state of the art (a Naïve Bayes Classifier and HyperLASSO) in terms of classification 
performance, and all the genetic biomarkers identified by BoNB are meaningful for Type 
1 Diabetes, thus confirming the good performance also in terms of precision of the 
selected biomarkers. 
The second level of study deals with the in-silico modeling of complex diseases. Recently, 
due to alarming increasing of world’s diabetic  incidence, a requirement for diabetes 
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simulation models has been identified in the medical and healthcare policy community to 
facilitate the simultaneous evaluation of long-term clinical end economic effects of 
treatment, and, as a result, a number of models have been developed, mainly based on 
Markov Models. In this thesis, the progression of two vascular diabetes complications 
(Cardiovascular disease and Nephropathy) was modeled using Dynamic Bayesian 
Networks, which, differently from Markov Models, are more powerful since they allow a 
more easy handle of information. The model was developed on the DCCT dataset, 
integrating both phenotypic information and information on treatment. Results regarding 
the simulated progression of complications show very good performances, exhibiting a 
prediction accuracy greater than 95 % for the considered outcomes, , thus proving the 
effectiveness of the model. Moreover, the flexible structure of the DBN makes the model 
suitable for future developments, such as the introduction of diabetic Retinopathy, as an 
additional outcome, and the genotypic information, as a potential mean to improve 
predictions. Based on the DBN model, a web Java application, which will implement also 
cost-effectiveness and cost-utility analyses, is currently under development. 
The last level of study focuses on the in-silico modeling of drug action, in particular 
regarding the effect of aspirin against atherothrombosis and cardiovascular episodes. A 
compartmental model of aspirin PKPD was developed from literature information, in 
order to simulate the inhibition of COX enzyme (the major promoter of platelets 
activation and aggregation, which leads to the formation of thrombi) by aspirin. The 
model was built on four interconnected key-elements, describing thrombopoiesis 
mechanism, COX kinetics, aspirin pharmacokinetics and aspirin pharmacodynamics, 
respectively. Innovative features of the work are represented by the distributed 
description adopted for COX kinetics and by the not separable interconnection between 
aspirin PK and COX kinetics, which allow to potentially simulate response to any drug 
exposure, without using any forcing input. Given the explorative aim of the work, the 
model was used to qualitatively describe data of healthy subjects, as well to test potential 
mechanisms for the diminished response, exhibited by diabetic patients, to aspirin therapy 
(the so-called ‘aspirin resistance’). Although representing a good starting point, the model 
needs further refinements and investigations: future experiments and additional data will 
make the model suitable to help designing personalized antiplatelet regimens in diabetes 
mellitus. 
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